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SIM SUMO-interacting motifs  
STAT1 Signal transducer and activator of transcription 1  
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Multiple isoforms of promyelocytic leukaemia protein (PML) participate in 
various cellular activities including innate immune responses, gene transcription 
and cell apoptosis. Recent work in our laboratory demonstrated PML isoform II 
(PML-II) was required for type I interferon (IFN) and IFN-stimulated gene (ISG) 
transcription by regulating transcription factor recruitment at gene 
enhancers/promoters. This thesis examines the mechanistic role of PML-II in this 
process. 
Considering that the different C-terminal fragments of PML isoforms play 
distinct roles in PML function, the function of the PML-II C-terminal domain 
was investigated. A C-terminal region 615-758, defined by deletions 1 and 2, 
was essential for its function in the IFN response, while the N-terminal RBCC 
structure was dispensable. Removal of residues 615-758 greatly impaired PML-
II binding with transcription factors NF-κB and STAT1, coactivator (CBP) and 
SWI/SNF chromatin remodeling complex component Brg-1. These binding sites 
were further refined using smaller deletions to show that residues 645-665 were 
critical for PML-II binding with these transcription-related factors.  
The effect of PML-II on chromatin remodeling and histone modification at target 
promoters was investigated. Both PML-II and Brg-1 regulated the recruitment of 
transcription factor (STAT1) and the enrichment/disposition of H3K9me3 histone 
marks at ISG promoters but had no effect on H3K4me3 at these promoters. 
Depletion of PML-II also impaired ISG promoter binding by SWI/SNF core 
subunits Brg-1 and BAF155. Recruitment of activators, coactivators, and other 
regulators/mediators to ISG promoters occurred sequentially and was interrupted 
by PML-II depletion. This suggested that PML-II is required for forming and 
stabilizing the whole transcriptional complex which contains various factors 
including STAT1, CBP, Brg-1 and BAF155.  
Finally, the role of PML-II in IFNα-induced cell apoptosis was studied. 
Knockdown of PML-II enhanced ERK and AKT signaling, suggesting activation 
of both pro-survival pathways. Moreover, depletion of PML-II greatly decreased 
expression of IFNα-induced pro-apoptotic proteins including ISG15/54, OAS1, 
PUMA and TRAIL. It also impaired IFNα-mediated inhibition of AKT signaling 
and consequently increased cell resistance to IFNα -induced cell apoptosis.  
Collectively, in this study we have shown the specific involvement of the PML-II 
C-terminal domain in IFN responses, and mapped the sequences within this 
domain that are necessary for its interaction with relevant transcription factors. I 
have also examined in detail the physical and functional interaction of PML-II 
with the SWI/SNF complex and shown the points in the transcription activation 
pathway at which PML-II acts. Finally, we have shown how impaired PML-II 
activity reduces the pro-apoptotic signaling that normally occurs downstream of 





































1.1 PML and isoforms 
1.1.1 PML and PML-NB 
 
Promyelocytic leukaemia protein (PML), was initially identified from patients 
with acute promyelocytic leukemia (APL) in which PML and retinoic acid 
receptor alpha (RARα) genes form a fusion protein due to a t(15,17) 
chromosome translocation (de Thé et al, 1991; Goddard et al, 1991; Kakizuka et 
al, 1991). In normal cells, PML proteins form nuclear multiprotein complexes 
known as PML nuclear bodies (NBs). PML-NBs are heterogeneous and dynamic 
structures, which contain various components proteins such as SUMO-1 (Zhong 
et al, 2000a), Sp100, CREB-binding protein (CBP) (Doucas et al, 1999; LaMorte 
et al, 1998), Daxx (Zhong et al, 2000c), pRB and p53 (Fogal et al, 2000; 
Hofmann & Will, 2003). PML protein is the essential component of PML-NB. 
The formation of PML-NBs relies primarily on the self-association property of 
PML protein via its RBCC structure (Lang et al, 2010). PML SUMO binding 
motif and RING domain are necessary for PML-NB formation (Brand et al, 
2010). The sumoylation of PML facilitates the recruitment of SUMOylated 
partner proteins and/or proteins containing binding motifs into the inner core of 
PML-NBs, which finally promotes the maturation of these spherical bodies 
(Brand et al, 2010; Lang et al, 2010; Shen et al, 2006). Therefore PML may 
function as the scaffold of this structure, allowing other proteins to shuttle in and 
out. 
 
PML is known to have multiple isoforms due to mRNA alternative splicing, and 
the expression and function of those splicing variants is not yet fully understood 
(Condemine et al, 2006; Fagioli et al, 1992; Jensen et al, 2001). These PML 
isoforms and components move between NBs dynamically, thus suggesting that 
the PML-NB composition might be heterogeneous and functionally different 
(Weidtkamp-Peters et al, 2008). PML-NBs are dynamic macromolecular 
structures altering their number, size, and content in response to diverse stimuli 







PML are classified into seven principle isoforms and designated PMLI-PMLVIIb 
(Jensen et al, 2001) (Figure 1.1). Each of PML I-V may also have several 
variants depending on the differential splicing pattern of exons 4-6 (Jensen et al, 
2001). PML VII is a cytoplasmic variant of PML because it lacks exon 6 that 
contains the nuclear localization signal (NLS) and thus cannot move into nucleus 
(Reymond et al, 2001a). All PML isoforms include exons 1-3 and thus share an 
identical N-terminal region known as an RBCC motif that comprises a RING 
finger domain, two B-boxes, and a coiled-coil domain; they are distinguished by 
their unique C-terminal regions (Jensen et al, 2001). The RBCC domain is 
thought to play an important role in PML protein biological function (Jensen et 
al, 2001): it mediates a strong homo/hetero dimerization activity to interact with 
another identical partner protein (homo), or a distinct partner protein (hetero), 
which is essential for the assembly of PML-NBs (Geng et al, 2012) 
 
 
Figure 1.1 Structure of PML protein isoforms.  All six nuclear PML isoforms contain 
three cysteine-rich zinc-binding domains: a RING-finger, two B-boxes (B1 and B2) and 
a predicted α-helical Coiled-Coil domain; three SUMOylation sites (S) and a nuclear 
localization signal (N). Only PMLI-V have SUMO-interacting motifs (SIM) (Wright, 






1.1.3 PML protein C terminal domains 
 
To date, several motifs have been identified in the C-termini of PML isoforms. 
The principal nuclear localization signal (NLS) is found at exon 6 among PMLI 
to PMLVI isoforms. However, a secondary NLS was demonstrated in the PML II 
C-terminus (Jul-Larsen et al, 2010). There is also a nuclear export signal (NES) 
(amino acids 704–713/exon 9), found only in PMLI, that is consistent with the 
partial nuclear and cytoplasmic distribution of this isoform. The SUMO-
interacting motifs (SIM) is present only in PMLI to PMLV (Nisole et al, 2013).  
 
Although PML-NBs assembly is always considered to depend on the RBCC 
motif in the N-terminal of all PML isoforms and a SUMO-SIM interaction 
network, the observation that PML-II and PML-V can form nuclear bodies and 
target to PML NBs independent of their N-terminal region indicated that the C-
terminal domain of PML also contributed to assembly, maintenance, and 
structure stability of PML-NBs (Geng et al, 2012). Most recently, C-terminal 
motifs in PML isoforms have been demonstrated to have a critical role in the 
regulation of PML-NBs formation. The mutation of the SIM distinctively 
influences the structure of NBs formed by each individual PML isoform, with 
that of PMLI and PMLIV dramatically impaired. Several C-terminal elements 
that are also important in regulating NB structure, for example the 8b region in 
PML-IV, which function as a SIM thus possesses a strong ability to interact with 
SUMO-1 and SUMO-2, and critically participates in NB formation (Li et al, 
2017).  
 
It is becoming increasingly clear that different PML isoforms are functionally 
distinct (Bernardi & Pandolfi, 2007). The C-terminal of PML is thought to be 
associated with the specific biological properties of each isoform. Studies have 
shown that the difference between the C-terminal parts of PML isoforms is 
important for the recruitment of different interacting partners and therefore for 





1.1.4 Cytoplasmic PML (cPML) 
 
Although PML is localized in the nucleus predominantly, there is a small portion 
of PML present in the cytoplasm (Carracedo et al, 2011; Giorgi et al, 2010; Lin 
et al, 2004). Alternative splicing is one of the major reasons for this localization. 
PML I to PML VI contains the NLS sequence in exon 6, leading to their nuclear 
localization. PMLI contain NLS and NES which allows it shuttle between 
nucleus and cytoplasm. However, alternative splicing may produce isoforms 
lacking exon 6, thus resulting in their cytoplasmic retention. PML VIIb is an 
isoform that is devoid of NLS and localizes in the cytoplasm. However, PML 
VIIb is not the only isoform without NLS motif. Other PML isoforms identified 
include PML Ib and PML VIb are also found in cytoplasm (Lin et al, 2004; 
McNally et al, 2008; Reymond et al, 2001b). Essentially, all groups of PML 
isoforms may exist in three variants because of the possible omission of exons 4, 
5 and/or 6. Among them, the variants lacking exon 6 are devoid of the NLS motif 
(Fagioli et al, 1992; Jensen et al, 2001). This suggests that there may be many 
alternative splicing cPML isoforms that distribute in the cytoplasm.  In addition 
to the alternative splicing-generated cPML isoforms, cPML can also derive from 
the redistribution of nuclear PML. In the mitosis phase of the cell cycle, PML is 
redistributed from PML-NBs to the cytoplasm where it forms a specific complex 
termed mitotic accumulation of PML proteins (MAPPs) (Dellaire et al, 2006). 
The MAPPs may contribute to PML protein recycle to form new PML NBs in 
daughter nuclei. Moreover, viral infection may also redistribute nuclear PML to 
the cytoplasm (Borden et al, 1998; Kentsis et al, 2001).  
 
Increasing evidence has demonstrated that cPML plays an important role in 
various cellular activities including antiviral responses, apoptosis, metabolism, 
tumorigenesis and cell cycle regulation (Jin et al, 2013). This finding has 
attracted lots of attention on the regulation and biological significance of cPML. 
However, how cPML regulates numerous cellular processes remains largely 
unknown. It is proposed that cPML may form multiprotein complexes similar to 
PML-NB, where it participate in various cellular processes. Consistent with this 
notion, the formation of cPML complexes with TβRI/TβRII/SARA/SMAD1/2 in 
early endosomes have been observed. This complex is required for inducing 
22 
 
TGF-β signaling activation (Lin 2004). Sequestration of cPML by TG-interacting 
factor (TGIF) dissociates this complex and thus negatively regulates TGF-β 
signaling (Seo et al, 2006). Inhibition of TGIF promotes complex formation and 
TGF-β signaling activation (Faresse et al, 2008). cPML was also observed to 
form a large complex in the endoplasmic reticulum (ER) and the mitochondria-
associated membranes (MAMs) where cPML interacts with proteins such as 
phosphatase PP2A and kinase AKT and IP3 receptor regulates ER calcium 
release and apoptosis (Giorgi et al, 2010).  
 
Recent studies revealed cPML interacts with the M2 isoform of pyruvate kinase 
(PKM2) and regulates its activity and glycolysis; this suggests an involvement of 
cPML in the regulation of cell metabolism (Shimada et al, 2008). However, due 
to the contrary effect of PKM2 on tumorigenesis, the exact functions of cPML on 
tumor suppression or tumor promotion remains unclear, this possibly is 
dependent on tumor types or distinct microenvironment (Cortés-Cros et al, 2013; 
Goldberg & Sharp, 2012). Although numerous biological functions have been 
attributed to cPML, little is known about how individual cPML isoforms are 
involved in distinct cellular processes, and the mechanism by which cPML itself 
is regulated remains poorly understood. It remains to be determined whether 
cPML is regulated by posttranslational modifications in a similar way to its 
counterpart in PML-NBs, which is regulated by modifications including 
SUMOylation, phosphorylation and ubiquitination (Carracedo et al, 2011; Cheng 
& Kao, 2012).  
 
1.1.5 PML and post-translational modification 
 
PML-NBs are a factory for protein modifications. It has been shown that PML 
regulates protein SUMOylation, phosphorylation, ubiquitination and acetylation 
(Carracedo et al, 2011; Guan & Kao, 2015). On the other hand, PML can also be 
extensively post-translationally modified itself by these same mechanisms 
(Cheng & Kao, 2012; Nichol et al, 2009). These modifications of PML add a 
complex layer of regulation to the physiological function of PML. Here, the 
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focus is on a brief review of the regulation function of PML on other protein 
modifications, on which there is very extensive literature.     
 
PML-NBs host all kinds of enzymes capable of protein modification, such as 
acetyltransferases, deacetylases, ubiquitin and SUMO E3 ligases, deubiquitinases, 
phosphatases and kinases (Carracedo et al, 2011). The action of such enzymes 
creates a regulatory network that is of critical importance for cell homeostasis. 
Consequently, loss of PML results in deregulated modulation of protein function 
(Guan & Kao, 2015).   
 
The predominant role of PML-NBs/PML in the regulation of protein acetylation 
has been widely demonstrated. For example, PML activates p53-dependent gene 
expression by promoting its acetylation by CBP in the PML-NBs (Pearson et al, 
2000). The regulation of p53 by PML is a balance between the acetylation by 
CBP and the deacetylation by SIRT1, overexpression of which tilts the 
equilibrium towards p53 deacetylation and transcriptional repression (Langley et 
al, 2002). Interestingly, inactivation of PML, such as by formation of a PML-
RARα fusion protein, exerts the opposite effect on p53 activity, by promoting its 
deacetylation by a different family of HDACs deacetylases (Insinga et al, 2004). 
 
Regulating the activity of E3-ligases and deubiquitinases (DUBs) is essential for 
PML protein stability and function. As an example, PML was found to inhibit 
KLHL2 activity by recruiting this enzyme to PML-NBs and this physically 
separates KLHL2 from its target (Lee et al, 2010). PML has also been shown to 
recruit MDM2 to a distinct subnuclear structure, the nucleolus, hence preventing 
p53 ubiquitination and consequent proteosomal degradation (Bernardi et al, 
2004).  Lastly, PML was found to modulate the activity of protein phosphatases, 
tuning the function of the protein phosphatases 1A and 2A (PP1A and PP2A). 
Loss of PML delocalizes PP1A and reduces its activity towards pRb, resulting in 
increased proliferation and reduced differentiation of neural progenitors (Regad 
et al, 2009). PML also positively regulates the activity of PP2A towards AKT in 
PML-NBs, and, as a result, losing PML leads to a more aggressive form of 
cancer (Trotman et al, 2006). The activity of several kinases to promote protein 
phosphorylation is also regulated by PML. For example, PML promotes the 
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phosphorylation of p53 by homeodomain-interacting protein kinase-2 (HIPK2) 
kinase, which increases the rate of acetylation of p53 and consequently its 
transcriptional activation (Hofmann et al, 2002). Together, many of the 
numerous functions attributed to PML are the result of its regulation of post-
translational modification of target proteins.  
1.2 PML tumor suppressor function and apoptosis 
 
Numerous studies have shown that PML and PML NBs actively participate in 
many aspects of cellular processes such as oncogenesis, DNA damage responses 
and subsequent repair processes, stress responses (Lallemand-Breitenbach et al, 
2001), apoptosis (Giorgi et al, 2010), senescence (Bischof et al, 2002), antiviral 
activity (Everett & Chelbi-Alix, 2007), interferon responses (El Bougrini et al, 
2011) and transcription regulation (Chen et al, 2015). 
 
The tumour suppressive function of PML was first suggested by the 
identification of PML-RARα fusion protein in APL (de Thé et al, 1990; de Thé 
et al, 1991). Soon after, the tumour suppressive activity of PML was extrapolated 
to various solid tumours. Increasing number of studies have revealed that many 
cellular activities, such as growth inhibition, apoptosis, senescence, suppression 
of oncogenic transformation, and inhibition of tumour cell migration and 
angiogenesis, are related to PML (Chen et al, 2012). The inactivation or 
downregulation of PML would provide an advantage for tumour development 
and progression. Indeed, the expression level of PML protein is frequently 
reduced in diverse types of human tumours and this downregulation often 
correlates with tumour progression (Gurrieri et al, 2004; Trotman et al, 2006). 
Many lines of evidence indicate a role for PML in modulating apoptosis. For 
example, lymphocytes, thymocytes and embryonic fibroblasts derived from 
PML-null mice are more resistant to apoptosis induced by stimuli that activate 
either intrinsic or extrinsic apoptotic pathways when compared with their wild 
type counterparts (Guo et al, 2000a; Wang et al, 1998).  
 
PML mediates pro-apoptotic functions by activating p53 through multiple 
mechanisms including by promoting p53 phosphorylation and acetylation by 
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recruiting it into PML-NBs and by binding and inhibiting the p53 negative 
regulator MDM2 (Bernardi & Pandolfi, 2003; Takahashi et al, 2004). Besides 
p53, several other factors such as Daxx which are implicated in the pro-apoptotic 
function of PML are recruited to PML-NBs and interact with sumoylated PML 
(Lin et al, 2006). Daxx is reported to repress the expression of several anti-
apoptotic genes when localized in PML-NBs, thereby eliciting pro-apoptotic 
functions (Croxton et al, 2006). PML also regulates expression of IFNα-induced 
pro-apoptotic protein TRAIL in hepatocellular carcinoma cells (Chawla-Sarkar 
et al, 2001) while the inhibition effect of IFNα on myeloma cell growth 
correlated with PML induction (Crowder et al, 2005). Cytoplasmic PML was 
also found to exert proapoptotic activity through the regulation of a formation of 
a large complex, involving PP2A, AKT, and the inositol triphosphate receptor 
(IP3R), in mitochondria-associated membranes (MAMs). The MAMs connect 
the endoplasmic reticulum (ER) and mitochondria, and play a central role in 
apoptosis through the regulation of calcium influx from the ER to the 
mitochondria. PML-deficient cells exhibited impaired calcium influx to the 
mitochondria and resistance to ER-stress-induced cell death (Giorgi et al, 2010; 
Pinton et al, 2011).  
 
1.3 PML function in gene transcription  
 
PML-NBs host a huge number of functional proteins. Many of these proteins can 
be physically and/or functionally linked to PML protein. Strikingly, many of 
these proteins are involved in transcriptional regulation, for example, 
transcriptional factors IRF3, NF-κB, STATs (Chen et al, 2015), AP-1 and p53 
(Guo et al, 2000a), coactivator CREB-binding protein (CBP) (Doucas et al, 
1999), transactivator CIIAT and corepressors HDAC and N-CoR (Shiio et al, 
2006; Zhong et al, 2000b). Many transcription factors transiently associate with 
PML and PML-NB, in which their activity is modulated by posttranslational 
modification. This may result in either activation or repression of specific genes.  
 
Also supporting a role for PML-NBs in transcription, they have been shown to 
move to localize adjacent to chromatin regions when they become 
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transcriptionally active, for example Major Histocompatibility Class 1 (MHC1) 
(Kumar et al, 2007; Shiels et al, 2001) and p53 loci (Shiels et al, 2001; Sun et al, 
2003). Furthermore, PML colocalizes and binds with the histone 
acetyltransferase CBP, and colocalizes with RNA Pol II in a cell cycle-dependent 
manner (Chen et al, 2015; Kiesslich et al, 2002). It was reported recently that 
PML-II also interacts with Ad E1A-13S, and thus enhances E1A-mediated 
transcriptional activation (Berscheminski et al, 2013).  
 
On the other hand, PML can repress transcription through its interaction with 
histone deacetylases and heterochromatin protein 1 (HP1) (Seeler et al, 1998; 
Wu et al, 2001) and through the regulation of heterochromatin recondensation in 
satellite DNA (Luciani et al, 2006). The transcriptional regulation and 
heterochromatin  remodeling induced by PML have highlighted the  importance 
of this tumour suppressor in the induction of cellular senescence (Bischof et al, 
2002; Luciani et al, 2006; Ye et al, 2007), with recent evidence pointing at a role 
for PML in regulating this process through the Rb-E2F pathway (Vernier et al, 
2011).  Together, the fact that PML associates with a wide variety of 
transcriptional activators, transcriptional repressors and histone modifiers 
suggests an important role of PML in gene transcription. 
 
1.4 Interferon (IFN)  
 
In 1957, interferon was discovered as a secreted factor responsible for inhibition 
of viral growth (Isaacs & Lindenmann, 1957). Since then a large number of IFNs 
have been identified. Generally, IFNs can be classified into three main types, 
type I, type II and type III IFNs. The type I IFN family consists of multiple 
subtypes including 12 IFNα subtypes, IFNβ, IFNε, IFNκ and IFNω (Pestka et al, 
2004). By contrast, the type II IFN family only has only one member, IFNγ, a 
cytokine. The third type of IFNs is composed of IFNλ1 (also known as IL-29), 
IFNλ2 (also known as IL-28A) and IFNλ3 (also known as IL-28B) (Sheppard et 
al, 2003). All three IFN types possess strong antiviral and immunomodulatory 




Type I IFNs can be produced by almost every cell type, including leukocytes, 
fibroblasts and endothelial cells. The induction of type I IFNs differs depending 
on the stimulus and the responding cell type. Type I IFN is often considered to 
be induced specifically by viruses, but actually they can also be induced in 
response to various pathogen-associated molecular patterns (PAMP)s such as 
viral glycoproteins, viral RNA, bacterial endotoxin (lipopolysaccharide), 
bacterial flagella and DNA CpG motifs (Randall & Goodbourn, 2008; Trinchieri, 
2010). These PAMPs are recognized by different PAMPs recognized receptor 
(PRR)s, leading to the activation of transcription factors including IFN 
regulatory factor 3 (IRF3),  IRF7 and nuclear factor-κB (NF-κB) (Akira et al, 
2006; Kawai & Akira, 2008; Yoneyama & Fujita, 2009). The activated TFs, 
together with coactivator CBP, form a transcriptional complex (enhancersome) 
that binds to the IFNΒ  promoter/enhancer to initiate the transcription of IFNβ 





Figure 1.2 Signaling pathway of IFNβ induction 






1.5 Type I IFN-mediated JAK-STAT signaling pathway  
 
Following secretion from cells, type 1 IFNs mediate their effects by binding to 
heterodimeric cell surface receptors known as the IFNα/β receptors, IFNΑR1 and 
IFNΑR2. During IFNα or IFNβ stimulation, IFNΑR become associated with and 
activate Janus kinase 1 (JAK1) and non-receptor tyrosine kinase 2 (TYK2) 
(Darnell et al, 1994). Activated JAK1 and Tyk2 are auto-phosphorylated on 
tyrosine residues and this tyrosine phosphorylation activates the cytoplasmic 
latent STAT1 and STAT2. Activated STATs form STAT1/STAT2 heterodimers 
complexes that translocate to the nucleus, where they bind with IRF9 (p48) to 
form the interferon-stimulated gene factor-3 (ISGF3), STAT1-STAT2-IRF9 
trimeric complex. The resulting ISGF3 complex recognizes and binds to the 
specific interferon-stimulated response element (ISRE) sequence in the promoter 
of interferon-stimulated genes (ISGs) (Figure 1.3) (Darnell, 1997; Darnell et al, 
1994). ISGs products regulated by type 1 IFNs are the primary effectors of IFN-
mediated biological functions. 
 
 
Figure 1.3 IFNα/β activated JAK-STAT signaling pathway  
(Randall & Goodbourn, 2008) 
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1.6 IFN-stimulated genes  
1.6.1 ISG56 
 
IFN-stimulated gene 56 (ISG56), also known as IFIT1, is the defining member of 
the ISG56 gene family. ISG56 is not expressed in most untreated cells, however 
viral infection or type I IFN stimulates rapid induction of the ISG56 gene. Like 
its homologue, ISG54, ISG56 contains multiple tetratricopeptide (TPR) motifs 
and has two ISRE in its promoter so its transcription can be activated by ISGF3; 
it is also directly activated by IRF3. ISG56 is an important suppressor of viral 
replication, and is reported to be active against hepatitis C virus, West Nile virus, 
and lymphocytic choriomeningitis virus (Wacher et al, 2007; Wang et al, 2003). 
The C-terminal of ISG56 is essential for an interaction with the translation factor 
eIF-3e, which inhibits eIF-3 induced translation initiation and hence affects 
protein synthesis (Guo et al, 2000b; Hui et al, 2003). A recent study revealed 
virus-induced ISG56 also negatively regulated the activation of IRF3 and NF-κB 
through a specific association with stimulator of interferon genes (STING/also 
known as MITA) that disrupted the interaction of STING/MITA with VISA or 
TBK1; ISG56 thus also plays a negative-feedback role in the IFN antiviral 
response (Li et al, 2009).  
1.6.2 ISG54 
 
The ISG54 gene, also known as IFIT2, encodes a protein of 54 kDa (Reich, 
2013). ISG54 protein is another member of the ISG56/IFIT1 family which is 
comprised of  ISG54, ISG56/IFIT1, ISG58/IFIT5, and ISG60/IFIT3 in humans 
(Fensterl & Sen, 2011). ISG54 can be induced by type I and III IFNs, virus 
infection, and by molecular patterns such as double-stranded RNA or 
lipopolysaccharide.  ISG54 gene has two ISRE elements in its promoter which 
can be recognized and bound by the ISGF3 under various stimuli, thus activating 
its transcription (Reich, 2013). Like ISG56, the activation of IRF3 also directly 
activates ISG54 expression: HCMV-induced activation of ISG54 has been 
reported to be mediated by a transcriptional complex that contains IRF3 
(Grandvaux et al, 2002; Navarro et al, 1998).  In addition to its function as 
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antivirus protein, ISG54 is also reported to work as a mediator of apoptosis and 
to promote cell apoptosis via a mitochondrial pathway (Reich, 2013; 
Stawowczyk et al, 2011). ISG54 normally does not exist as a monomer, but 
instead is present as ISG54/ISG54 homodimers and/or as heterodimers with 
ISG56 or ISG60. The binding partner of ISG54 affects ISG54 apoptosis function: 
for example, co-expression of ISG60 with ISG54 inhibits the effect of ISG54 on 
cell apoptosis (Stawowczyk et al, 2011).  
 
1.7 PML function in IFN response  
 
Several studies have demonstrated the functions of PML protein and PML-NBs 
in innate immunity (Geoffroy & Chelbi-Alix, 2011). For example, ectopic over-
expression of PML inhibits the growth of IFN-sensitive viruses, influenza A 
virus replication is significantly repressed by over-expression of some PML 
isoforms, and correspondingly, depletion of PML leads to an enhancement in 
viral propagation (Iki et al, 2005; Tavalai & Stamminger, 2008). In addition, 
various viruses encode proteins that disrupt PML and/or PML-NB, including E4 
Orf3 of human adenovirus type 5 (HAdVC-5, Ad5) (Ullman & Hearing, 2008; 
Ullman et al, 2007) and ICP0 of herpes simplex virus type 1 (HSV1) (Leib et al, 
1999; Mossman et al, 2000) and viruses lacking these functions are unable to 
overcome IFN responses. 
 
Within the type 1 IFN response, PML-IV was reported to regulate the cellular 
distribution of Pin1 (peptidyl-prolyl cis/transisomerase) and to prevent IRF3 
degradation thus enhancing the synthesis of IFNβ in response to virus infection 
(El Asmi et al, 2014). Recent work in our laboratory demonstrated that PML-II 
positively regulates IFNβ transcription and IFN-mediated response. Knockdown 
of PML-II substantially inhibits the expression of IFNβ and IFN-stimulated 
genes (ISGs) such as ISG15, ISG20, ISG54, ISG56, IRF7, PKR and IP-10 (Chen 
et al, 2015). 
 
PML protein has also been shown to serve as a regulator in IFNγ signaling, by 
affecting STAT1 DNA binding and transcription activity (Choi et al, 2006; El 
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Bougrini et al, 2011). In addition, the presence of PML was found to enhance 
IFNγ-induced MHC Class II expression: PML-II in particular bound to the key 
transcription factor CIITA and stabilized it, causing it and the MHCII gene loci 
to associate with PML-NBs (Ulbricht et al, 2012).  
1.8 Type I IFN anti-tumour function  
 
The most important function of type I IFNs was initially considered to be an 
antiviral immune response, however, increasing evidence has shown that these 
cytokines are also involved in other cellular activities including anti-proliferative 




Figure 1.4 IFN-activated intrinsic and extrinsic apoptosis mechanisms  
(Bekisz et al, 2010) 
IFNs were the first human proteins to be effective in cancer therapy and were 
among the first recombinant DNA products to be used clinically. Type I IFNs 
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have been extensively used for the treatment of several types of cancer, including 
haematological malignancies (for example, hairy cell leukaemia and some B or T 
cell lymphomas) and solid tumours (for example, melanoma, renal cell 
carcinoma and Kaposi’s sarcoma) (Ferrantini et al, 2007; Rizza et al, 2010). 
There are some studies suggesting that type I IFNs could act as an adjuvant in 
antitumour cancer vaccines (Di Pucchio et al, 2006; González-Navajas et al, 
2012; Kirou et al, 2005). IFNα has also been used as a chemotherapeutic agent in 
combination with other anti-cancer drugs against hepatocellular carcinoma 
(HCC), and these clinical trials have demonstrated the considerable effectiveness 
of IFN in patients with HCC (Kaneko et al, 2002; Leung et al, 2002; Shaaban et 
al, 2014). 
1.9 IFNα-regulated ERK signaling pathway  
 
Regulating other (non-JAK-STATs) signaling pathways is also important for 
type I IFNs to mediate their pleiotropic biological effects (Inamura et al, 2005; 
Stancato et al, 1997; Uddin et al, 1997). For example, IFNα stimulation 
transiently activated the extracellular signal-regulated kinase 1 (ERK1) or ERK2 
signaling pathway (Arora et al, 1999). The activated ERK pathway participates 
in the response of IFN to viral infection. ERK2 was reported to regulate IFN 
activation of early response ISGs by modifying the JAK/STAT signaling cascade 
(Arthur & Ley, 2013; González-Navajas et al, 2012). Moreover, type I IFNs also 
stimulated ERK and Raf-1 enzyme activity in a RAS-independent pattern (David 
et al, 1995; Stancato et al, 1997).  
 
However, some controversial results have also reported that IFNα treatment 
reduces the phosphorylation of MEK1 and ERK1/2 in transformed human 
hepatocellular carcinoma (HCC) cell lines and hence reduces rather than 
increases ERK signaling. IFNα diminished phosphorylation of ERK after 24-48 
hours stimulation and this was paralleled by reduced enzymatic activity and but 
this was independent of upstream RAS/and RAF-1 activation (Inamura et al, 
2005; Romerio et al, 2000). Also, knockdown of STAT1 or JAK1 suppressed the 
reduction of phosphorylation both of ERK and MEK and thus diminished the 
growth inhibition by IFNα. These results suggest that IFNα induces anti-
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proliferative signaling via the JAK/STAT pathway and may reduce growth 
stimulation signaling by cross-talk with the MEK/ERK pathway.  
 
Taken together, the data are clear that type I IFNs can regulate multiple signaling 
pathways, activating or suppressing them in different target cells, and that this 
regulation is essential for IFNs wide spectrum of biological activities such as 
antiviral activity, immunomodulatory and growth inhibitory effects.  
 
1.10 IFNα-regulated PI3K/AKT signaling pathway  
 
In addition to its effects on Jak/STATs and ERK signaling, type I IFN can also 
induce the activation of the serine kinase phosphatidyl-inositol (PI) 3'-kinase 
(PI3K)/AKT/mTOR signaling pathway in a STAT-independent manner (Kaur et 
al, 2008a; Kaur et al, 2008b; Uddin et al, 1997). Activation of the PI3K signaling 
cascade controls the activation of mammalian target of rapamycin (mTOR), 
regulating downstream p70S6 kinase (p70S6K1) activation and the subsequent 
phosphorylation of the S6 ribosomal protein, which in turn regulates mRNA 
translation (Kaur et al, 2008a; Lekmine et al, 2004; Lekmine et al, 2003). 
However, PI3K/AKT pathway activation does not play a role in the activation of 
the ISGF3 complex and transcriptional regulation of genes that contain ISREs in 
their promoters (Uddin et al, 1997). AKT activation is also unrelated to 
regulatory activities on IFN-dependent STATs phosphorylation/activation and 
had no effect on gene transcription (Lekmine et al, 2004; Lekmine et al, 2003). 
The activation of this signaling pathway by IFN may complement the function of 
IFN-activated JAK-STAT pathways, by allowing increased translation of ISG 
mRNAs and, ultimately, increased induction of the biological effects of IFNs. In 
terms of biological relevance, the activation of PI3K/AKT/mTOR signaling has 
been shown to mediate the antiviral effects of IFNα against the hepatitis C virus 
(Matsumoto et al, 2009). It is important to note that PI3K activation events 
reportedly occur very early (30min) in the cells after stimulation with IFNα and 
regulate the induction of early response ISGs such as ISG15, CXCL10 and/or 
IRF7 to mediate IFN antiviral responses, the biological significance of this effect 
remains unclear (Kaur et al, 2008a; Uddin et al, 1997). In contrast to the 
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activation of AKT signal by IFNα, a recent report showed AKT and NF-κB 
signaling were inhibited by IFNβ treatment in human cervical cancer cells, thus 
decreasing the expression of anti-apoptotic protein Bcl-2 (Ethiraj et al, 2016).   
 
The function of the IFN-ERK/AKT axis in virus-infected cells and cancer cells is 
different. This is probably because, when cells require an immediate anti-virus 
function with corresponding short-term IFN release, IFNα may activate 
ERK/AKT signaling, while when cells are exposed constitutively to IFNα 
stimulation, the effect on ERK/AKT signaling is inhibitory, thus inhibiting cell 
proliferation and promoting cell apoptosis. The differing outcomes of IFN 
stimulation on ERK/AKT signaling may also suggest an IFN concentration-
saturation threshold: when IFN concentration is saturating, it more likely to exert 
a pro-apoptosis function thus ERK/AKT signaling is inhibited, while when IFN 
is at non-saturating concentrations, IFNα may conversely activate ERK/AKT 
signaling and thus promotes cell survival.  
 
1.11 IFNα-induced pro-apoptotic proteins  
 
The expression products of pro-apoptotic ISGs are thought to be the primary 
effectors that mediate the IFNα antitumor function. A group of ISGs have been 
identified that are related to this biological response (Chawla-Sarkar et al, 2003; 
de Veer et al, 2001). For example, the increased expression of classical ISG15 
(Zhou et al, 2017), ISG54 and OAS1 (2'-5'-Oligoadenylate synthetase 1) (Reich, 
2013; Stawowczyk et al, 2011) and XAF-1 (XIAP associated factor-1), CD95 
(Fas/APO-1), OAS1, PML and RIDs (regulators of IFN induced death) had been 
reported as one means by which IFNα induces cell apoptosis (Chawla-Sarkar et 
al, 2003). The TRAIL/Apo2L (tumor necrosis factor-related apoptosis-inducing 
ligand) was also demonstrated to be an important effector required for IFNα-
mediated growth inhibition and apoptosis in myeloma and hepatocellular 
carcinoma (Crowder et al, 2005; Herzer et al, 2009). Moreover, the expression 
level of PUMA, a p53-dependent gene, was also increased in response to IFNα 
stimulation in human myeloma cells suggesting a possibility of PUMA being 
related to IFNα-induced apoptosis (Gómez-Benito et al, 2007). In addition to 
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inducing the expression of pro-apoptotic proteins, IFNs also directly induces 
caspase-4 and caspase-8 (Chawla-Sarkar et al, 2003; de Veer et al, 2001). 
Activated caspase-8 cleaves Bid, a pro-apoptotic member of Bcl2 family, 
resulting in disruption of mitochondrial potential and intrinsic apoptotic pathway 
activation.  
 
1.11.1 Fas/CD95 and XAF-1 
 
IFNα has been shown to induce apoptosis by inducing Fas/CD95 expression in 
multiple myeloma cells and leukemia cell lines (Selleri et al, 1997; Spets et al, 
1998). Upregulation of Fas expression, induction of apoptosis and tumor 
regression were observed following injection of IFNα into basal cell carcinomas 
(Buechner et al, 1997). Like other TNF family members, Fas ligation resulted in 
FADD (Fas-associated death domain) activation, thus activating the extrinsic 
apoptosis pathway. However, the induction of Fas alone may not be sufficient to 
cause apoptosis as in vitro most tumor cells were resistant to Fas. However IFN-
γ treatment sensitized melanoma and cholangiocarcinoma cells to Fas-induced 
apoptosis in vitro (Ahn et al, 2002; Ugurel et al, 1999).  
 
XAF-1 (X-linked inhibitor of apoptosis (XIAP) associated factor-1), a candidate 
tumour suppressor ISG gene was identified ubiquitously in all normal adult and 
fetal tissues but was present in very low levels in a variety of cancer cell lines 
(Fong et al, 2000). Over expression of XAF-1 results in neutralization of the 
ability of XIAPto inhibit cell death (Liston et al, 2001).  XIAP is one of the six 
known human inhibitors of apoptosis (IAP), it being shown that it bound directly 
to and inhibited caspase-3, caspase-9 and caspase-7 function (Deveraux et al, 
1998; Deveraux et al, 1997). XIAP levels were high in the majority of cell lines. 
Both IFNα and IFNβ effectively induced XAF-1 transcript in all cells examined 
however, induction of XAF-1 protein expression was observed only in cell lines 
sensitive to apoptotic effects of IFNs. IFNβ may therefore inhibit XIAP function 
(and hence promote apoptosis) by induction of XAF-1. Although constitutive 
expression of XAF-1 in A375 melanoma cells did not induce apoptosis, it did 




1.11.2 TRAIL   
 
The TRAIL/Apo2L (tumor necrosis factor-related apoptosis (TNF)-inducing 
ligand),  is a transmembrane protein that shares homology in its extracellular 
domains with other members of the TNF family (Hymowitz et al, 2000).  Both in 
vitro and in vivo studies have demonstrated that TRAIL is without significant 
toxicity towards normal cells or tissues (Pitti et al, 1996). However, once TRAIL 
was bound to its receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5), it resulted in 
activation of caspase-8 (pro-apoptotic) pathways. 
 
TRAIL has been identified as an ISG (Chawla-Sarkar et al, 2001; Chen et al, 
2001; Kayagaki et al, 1999) and has also been demonstrated to be an important 
effector required for IFNα-mediated growth inhibition and apoptosis in myeloma 
and hepatocellular carcinoma (Crowder et al, 2005; Herzer et al, 2009). In non-
hematopoietic cells, such as melanomas and ovarian carcinoma, IFNβ 
preferentially induced TRAIL in comparison to IFNα (IFN-α2) and resulted in 
induction of apoptosis (Chawla-Sarkar et al, 2001; Morrison et al, 2001); in 
comparison, melanoma cells were resistant to IFN-α2 and showed poor induction 
of TRAIL. However in multiple myeloma, IFN-α2 can effectively induces 
TRAIL (Chawla-Sarkar et al, 2001; Morrison et al, 2001). The inhibitory effect 
of IFNα on myeloma cell growth correlated with PML and TRAIL induction 
(Crowder et al, 2005). The expression of IFNα-induced TRAIL was also greatly 
decreased by the loss of PML in hepatocellular carcinoma cells (Chawla-Sarkar 
et al, 2001) whilst RNAi silencing of PML downregulated TRAIL expression in 
hepatoma cells and correspondingly blocked IFNα-induced apoptosis (Herzer et 
al, 2009).  
 
All these results suggest that TRAIL is essential in IFNα-induced growth 
inhibition or apoptosis and also suggest that PML has an important regulation 




1.11.3 PUMA   
 
PUMA is a member of the Bcl-2 homology 3 (BH3)-only Bcl-2 family of 
proteins. The human PUMA gene contains three coding exons (exons 2–4) and 
two noncoding exons (exons 1a and b) (Nakano & Vousden, 2001). PUMA has 
multiple variants due to mRNA alternative splicing (Nakano & Vousden, 2001). 
PUMAα and PUMAβ are two identified forms of encoded protein which have 
the BH3 domain (Nakano & Vousden, 2001). A BH3 domain is important for 
PUMA interacting with Bcl-2-like proteins such as Bcl-2 and Bcl-XL (Nakano & 
Vousden, 2001; Yu et al, 2001), while the C-terminal hydrophobic domain of 
PUMA directs its mitochondrial localization (Yee & Vousden, 2008; Yu et al, 
2003). The PUMA gene contains several potential binding sites for the binding 
with various transcription factors such as p53 (Kaeser & Iggo, 2002), c-Myc 
(Fernandez et al, 2003) and forkhead box O3A (FoxO3a) (You et al, 2006). 
These transcription factors are rapidly recruited to their respective sites in the 
PUMA promoter and activate transcription by different stimuli.  
 
Normally, the expression level of PUMA is very low in unstressed cells (Yu et 
al, 2001), but it can be rapidly induced by various stimuli including DNA 
damage, IFNα stimulation or virus infection (Gómez-Benito et al, 2007). 
Structure analysis showed that the PUMA promoter, exon 1a and intron 1 are 
enriched with a high ratio of guanine and cytosine nucleotides, which suggests 
secondary structures can be formed to inhibit transcription, and this may also 
account for the low basal levels of PUMA in unstressed cells (Ming et al, 2008; 
Yu et al, 2001). In contrast to other BH3-only proteins, activities of which are 
controlled by multiple mechanisms including posttranslational modification, 
PUMA activity is primarily transcription-dependent. PUMA induces apoptosis 
by interaction with anti-apoptotic Bcl-2 family members, thereby relieving their 
inhibitory effects on the pro-apoptotic proteins Bax and/or Bak, which finally 
results in mitochondrial dysfunction and caspase activation (Nakano & Vousden, 




1.12 Eukaryotic genomes and gene expression 
 
Eukaryotic genomes are packaged into chromatin which is a complex of 
macromolecules found in cells, consisting of DNA, protein and RNA. The 
primary protein components of chromatin are histones that compact the DNA. 
Gene transcription/expression can be initiated/activated by various external 
signals. In eukaryotic cells, gene transcription is complicated and strictly 
regulated process, which involves many factors and cofactors and their 
sequentially or ordered recruitment and assembly at gene promoter/enhancer 
sequences (Agalioti et al, 2000). This process has to occur, for example, during 
activation of genes such as IFNβ and ISGs.  In generally, transcriptional 
activation/initiation involves four key steps: (1) Binding specific transcription 
factors to enhancers and/or regulatory DNA sequences; (2) opening the 
chromatin by chromatin remodeling complex and histone modifiers; (3) Binding 
of mediator complex; (4) assembly of pre initiation complex (Wilson & Roberts, 
2011). 
 
1.13 Histone acetylation  
 
The nucleosome is the basic unit of eukaryotic chromatin, consisting of 146bp 
of DNA wrapped around two molecules each of H2A, H2B, H3 and H4 (known 
as core histones). Histones H3 and H4 have long N-terminal tails which are often 
subjected to a variety of post-translational modifications (PTMs) such as 
acetylation, methylation, phosphorylation, ubiquitination and sumoylation (Li et 
al, 2007). Such modifications within particular sites/promoters create a global 
chromatin environment which affects the association of different factors or 
enzymes with those sites and eventually regulates the expression of the gene. 
 
Histone acetylation is the best-studied histone modification involved 
transcription activation. Typically, transcriptionally active genes possess 
hyperacetylated histones around their promoters, while silent genes have 
hypoacetylated histones. HAT proteins p300/CBP, which were originally 
identified as proteins that bound to the adenoviral E1A and the cAMP-response-
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element binding protein (CREB), respectively (Chrivia et al, 1993; Eckner et al, 
1994), are essential for histone acetylation. Acetylation of lysine residues of 
histone tails helps transcription factors access the DNA in chromatin (Vettese-
Dadey et al, 1996) by weaking internucleosomal interactions and destabilize 
higher-order chromatin structure (Garcia-Ramirez et al, 1995; Luger et al, 1997; 
Tse et al, 1998). Histone acetylation change high order chromatin structure and 
creased a permissive local environment for the subsequent assembly of an active 
preinitiation complex (PIC) at the promoter (Martens et al, 2002; Struhl, 1998). 
For example, the recruitment of HAT CBP is prerequisite for the recruitment of 
Brg-1 – a component of the SWI/SNF chromatin remodeling complex (section 
1.15) – in virus-induced IFNβ promoter activation (Agalioti et al, 2000). 
 
Collectively, these effects facilitate the formation of transcription complexes 
involving RNA pol II and hence the initiation of gene transcription (Nightingale 
et al, 1998). For example, the level of histone H3K9 acetylation is high at active 
gene promoters or the regions surrounding transcription start sites (TSSs) (Barski 
et al, 2007; Bernstein et al, 2005; Roh et al, 2007). 
 
1.14 Histone methylation 
 
Histone methylation occurs at several lysine and arginine residues and is linked 
to either gene induction/activation or gene repression, which depends on the 
residues affected and the number of methylated amino groups. For example, the 
levels of H3K4me1 and H3K4me2 was positively correlated with transcriptional 
levels whilst H3K27me3 levels were higher at silent promoters than at active 
promoters (Barski et al, 2007; Lee et al, 2006). Genome-wide analyses have 
revealed a typical pattern of histone methylation at promoters, enhancers and 
transcribed regions. From these studies, the monomethylation of H3K9, H3K27, 
H4K20, H3K79 and H2BK5 is correlated with gene activation, while on the 
contrary, the trimethylation of H3K9, H3K27, H4K20 and H3K79 is linked to 
gene repression (Barski et al, 2007). Selected histone modifications of relevance 






H3K4 methylation could mark a gene either for the recruitment of protein 
complexes related to transcription activation and/or for the removal of complexes 
involved in transcriptional repression, such as histone deacetylases. H3K4me3 is 
a highly conserved histone modification, and is mainly distributed to gene 
promoters and TSS regions, as well as regions associated with high CpG content 
and GC dense DNA (Calo & Wysocka, 2013; Koch & Andrau, 2011; Pekowska 
et al, 2011). H3K4me3 is always described as a positive histone marker 
associated with active or poised transcription (Barski et al, 2007; Bernstein et al, 
2005; Roh et al, 2007). In mammalian cells, H3K4me3 can be catalyzed by 
methyltransferase MLL1, MLL2 and SETD1 (Katada & Sassone-Corsi, 2010; 
Zhang et al, 2015). The recruitment of these methyltransferases to target genes 
requires cell type-specific transcription factors and coactivators (Narayanan et al, 
2007; Okuda et al, 2014). 
 
H3K4me3 is commonly considered a positive mark in gene activation because it 
is essential for recruitment of other histone-modifying enzymes that are 
important during transcription initiation. For example, H3K4me3 is found to co-
locate at active gene promoters and TSS regions with H3/H4 acetylation, and 
promotes acetylation of downstream H3/H4 through the recruitment of HATs 
(Bian et al, 2011; Hung et al, 2009). However, the role of H3K4me3 in 
transcription is complicated because H3K4me3 seems not always related to 
active transcription: H3K4me3 was also shown to suppress transcription on a 
subset of genes (Howe et al, 2017). Therefore, the ability of H3K4me3 to 
activate or repress transcription must depend on other factors, such as chromatin 
remodeling complex recruitment and the affinity of interaction, the other pre-
existing histone modifications at the site, or the duration of its residency (Howe 
et al, 2017).  
Currently, an important issue in understanding the correlation between gene 
activity and H3K4 trimethylation is whether the deposition of this modification is 
a cause or simply a consequence of the transcription state present at a particular 
gene. A  time-resolved experiment showed that the peak of H3K4me3 deposition 
41 
 
lagged behind mRNA transcription in the majority of yeast genes that were 
involved in metabolic cycles. This observation suggested that the H3K4me3 
deposition is unlikely to regulate transcription initiation on these genes. There 
are also studies that suggest that H3K4me3 might function in a post-initiation 
process, such as the commitment to splicing of nascent pre-mRNA (Mikkelsen et 
al, 2007), transcription termination, or maintaining transcription memory and 
consistency (Martin et al, 2006; Terzi et al, 2011). All these data seem to suggest 
that deposition of H3K4me3 is a consequence of transcription.  However, many 
genes, including developmental regulators such as Hox genes, show reduced the 
recruitment of RNA polymerase II and reduced expression following the loss of 
H3K4 methylation which would indicate that H3K4me3 is a cause of 
transcription rather than a consequence (Wang et al, 2009). Collectively 
however, these findings all indicate that H3K4 methylation has a specific and 
non-redundant role in gene regulation.  
1.14.2 H3K9me3 
 
Histone H3 lysine 9 trimethylation (H3K9me3), also a conserved modification, 
can be catalyzed by multiple methyltransferases (HMTase) including SETD1 (or 
ESET), SUV39H1, SUV39H2, EHMT1(GLP) and EHMT2(G9A) (Kim & Kim, 
2012). Normally, H3K9me3 and its HMTase play an essential role in gene 
silencing. In mammals, H3K9me3 is predominantly enriched in heterochromatin, 
especially in the non-genic regions including the pericentric DNA, long terminal 
repeats of transposons, interspersed repetitive satellite DNA and centromeric and 
plays an important role in heterochromatin compaction, chromatin stability and 
gene repression (Becker et al, 2016; Nizialek et al, 2016). However, 
trimethylated H3K9 is not restricted just to the heterochromatin, this 
modification also occurs at the promoters of some euchromatic genes that are 
related to development and lineage-specific functions (Hawkins et al, 2010; 
Tachibana et al, 2002).  
 
Chromatin that is enriched in H3K9me3 provides a docking site for the 
recruitment and assembly of repressive complexes including heterochromatin 
protein-1(HP1) and HDACs. The removal of acetylation of H3K9, a positive 
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transcriptional activation marker, by HDAC results in further H3K9 methylation 
and enhanced gene repression (Lachner & Jenuwein, 2002; Shilatifard, 2006). 
Unlike the repressive function of H3K27me3, the incorporation of which leaves 
the promoter accessible to general transcription factors, an H3K9me3-marked 
promoter totally precludes the DNA from binding diverse transcription factors 
(Becker et al, 2016).  
 
In apparent contradiction to its role in promoting heterochromatin formation and 
gene silencing, H3K9me3 was also reportedly linked with transcription 
activation because an H3K9me3 signal was detected at active chromatin domains 
in a genome-wide study (Barski et al, 2007). In addition, H3K9me3 and HP1γ 
were found enriched in the coding region of active genes (Vakoc et al, 2006) and 
their deposition relied on RNA polymerase II (pol II) elongation. These findings 
highlight the complexity of the histone modification code for the control of 
transcription.  
 
1.15 Chromatin remodeling complex SWI/SNF  
 
Mammalian DNA is tightly packed into chromatin and this packaging of DNA 
can have a repressive effect on gene expression by preventing the binding of 
specific transcription factors and the general transcription machinery to specific 
DNA binding sites. Therefore, opening chromatin structure to expose the DNA 
sequence for the binding of such factors is a critical step for the activation of 
gene transcription. In addition to changes in histone modification as just 
discussed, this can involve the recruitment of ATP-dependent chromatin 
remodeling complexes such as SWI/SNF.  
 
SWI/SNF is one of the best studied nucleosome remodeling complexes. The 
SWI/SNF complex uses the energy of ATP hydrolysis to alter nucleosome 
structure and then to slide and transfer the nucleosomes to neighbouring DNA, or 
to destabilize and then evict histones from DNA (Peterson & Workman, 2000; 
Wu et al, 2009). In eukaryotic cells, several subunits of SWI/SNF complex were 
encoded by different gene families, which can then assemble to generate diverse 
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combination in different tissues (Wang et al, 1996a; Wang et al, 1996b). Various 
SWI/SNF complexes with different components have been reported in human 
cells and display cell type-specificity (Wang et al, 1996a; Wang et al, 1996b) 
 
In humans, there are major two classes of the SWI/SNF complex: the Brg-1 
(Brahma-related gene 1) based complex and the hBRM (brahma)-based complex 
(Wang et al, 1996a), defined according to the presence of ATPase subunit Brg-1 
or BRM. These two complexes share most of the other core subunits including 
BAF155, BAF170, BAF47 and BAF57, and auxiliary subunits BAF53, BAF60, 





Figure 1.5 SWI/SNF complex 
 
As the subunits of SWI/SNF are heterogeneous, the protein level of each subunit 
is stringently controlled via protein-protein interactions and proteasome-related 
degradation (Chen & Archer, 2005). The protein level of one subunit can affect 
the amount of other subunits. For example, the loss of BAF155 and BAF170 
results in the degradation of BAF57, Brg-1 and BAF47; exogenous expression of 
BAF57 results in the downregulation of endogenous BAF57; and increased BRM 
protein level in HeLa cells by transient transfection results in a decline of 
endogenous Brg-1 (Chen & Archer, 2005).  
Genome-wide studies of SWI/SNF interaction with chromatin have demonstrated 
that the complex prefers to bind transcription start sites (TSSs), enhancers and 
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many regions occupied by Pol II (Euskirchen et al, 2011). Although there was no 
evidence that binding of any particular form of the complex preferred at specific 
sites, increasing data showed that one or more subunits may play leading roles in 
SWI/SNF binding, which is depend on the stage of transcription, nucleosomal 
composition, and promoter architecture (Hogan & Varga-Weisz, 2007; 
Mohrmann & Verrijzer, 2005; Trotter & Archer, 2008). SWI/SNF complexes 
have several subunits that contain motifs that are able to bind DNA without 
sequence specificity, such as the AT-rich interactive domains of BAF250A 
(ARID1A), BAF250B (ARID1B), and BAF200 (ARID2); High Mobility Group 
(HMG) domains of BAF180 and BAF57 are also known to bind DNA without 
sequence specificity.    
Three models of SWI/SNF recruitment to DNA specific sites have been proposed 
(Peterson & Workman, 2000). The first one is SWI/SNF is associated randomly 
on the chromatin templates and becomes targeted to a specific region of the 
chromatin in the presence of a gene-specific transcription factor (Owen-Hughes 
et al, 1996). The second model is the holoenzyme model in which SWI/SNF 
recruitment depends on RNA polymerase II (RNA pol II) holoenzyme, which 
targets SWI/SNF to the gene promoter through association with it (Peterson & 
Workman, 2000). The third ‘Activator Model’ is the most widely accepted. This 
model proposes that many gene-specific activators recruit SWI/SNF to its 
targets. The interaction of SWI/SNF complex with a transcription factor 
facilitates the recruitment of SWI/SNF to specific chromatin sites (Kadam & 
Emerson, 2003).  
The presence of SWI/SNF was previously thought to indicate activation of 
transcription. However, more and more evidence indicates that SWI/SNF 
complexes are also involved in transcription repression and that this function can 
be either ATPase dependent or independent (Dunaief et al, 1994; Stankunas et al, 
2008; Zhan et al, 2011). The ATPase-dependent repression activities may 
involve remodeling chromatin for the recruitment of transcription repressor or 
silencer, or to preclude the binding of activators. The ATPase-independent 
transcription repression is considered to occur through the formation of a 
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complex with DNA methylation enzymes or HDACs (Jani et al, 2008; Zhan et al, 
2011).  
 
1.16 Brg-1 and the IFN response 
1.16.1 Brg-1 
 
Brg-1 protein is one of the two ATPases in the SWI/SNF remodeling complex, 
and is encoded by the SMARCA4 gene in human. Its structure can divided into 
three parts: a conserved C-terminal domain included a bromodomain and AT-
hook motif, a catalytic ATPase region and a less characterized N-terminal region 
that encompasses a glutamine-leucine-glutamine motif (QLQ), as well as 
helicase/SANT-associated (HSA) and KIS (BRK) motifs (Trotter & Archer, 
2008). These motifs have been identified to contribute to the recognition of 
modified histone proteins and/or to recruit the chromatin remodeling activity of 
Brg-1 to genomic targets.  
Brg-1 is capable of providing the ATPase activity needed to remodel the 
chromatin during the transcription process, although most other SWI/SNF 
subunits are also required for the in vivo function of SWI/SNF complexes. In 
vitro studies showed that Brg-1 alone was sufficient to remodel the chromatin. 
However, the addition of core SWI/SNF subunits BAF170, BAF155 and 
BAF147 reconstituted chromatin remodeling activity to near optimal levels 
(Phelan et al, 1999).  
 
As the central enzymatic subunit of SWI/SNF complex, Brg-1 plays important 
roles in transcription regulation. Brg-1 was implicated in various cellular 
activities by regulating the expression of a subset of genes associated with 
controlling related cell activities. For example, Brg-1 positively regulates CD44, 
MMP-2, MMP-9 and p53-dependent gene expression and cooperates with Rb to 
repress E2F1-mediated activation (Trouche et al, 1997), and negatively regulated 




Many previously reports showed that Brg-1 recruitment to its target required 
gene specific transcription factors because Brg-1 lacks gene-specific DNA 
binding regions (Cosma et al, 2001; Cosma et al, 1999). This suggested that the 
Brg-1 recruitment is a secondary event in gene activation. However, in some 
genes such IFITM1, IFITM3 and CIITA (class II transactivator), Brg-1 was 
found bound on those gene promoters before IFN treatment (Cui et al, 2004; Liu 
et al, 2002; Ni et al, 2005), i.e. before the presumed arrival of gene-specific TFs. 
The mechanism for these observations is still not fully understood.  
1.16.2 Brg-1 and IFN 
  
Brg-1 is considered to be a transcription co-regulator essential for SWI/SNF 
chromatin remodeling complex to mediate transcription. In this role, Brg-1 has 
been reported to affect interferon responses. Brg-1 was shown to directly 
regulate expression of IFNβ (Agalioti et al, 2000)and multiple ISGs (Cui et al, 
2004; Huang et al, 2002; Pattenden et al, 2002). Brg-1 is required for the active 
expression of a subset of ISGs such as IFNα-induced transmembrane protein 1 
(IFITM1), IFITM2, IFITM3, IFI27, guanylate-binding protein 1 (GBP1). The 
expression of IFN-γ-induced CIITA, MHCII, TRIM22, and IL-6 expression 
induced by LPS, was also impaired in cells that lacks Brg-1 (Ramirez-Carrozzi et 
al, 2006; Torti, 2012).   
The binding of IFNα-induced ISGF3 complex to the promoters of several ISGs 
such as GBP1, IFI27 and IFITM1 is Brg-1-dependent (Ni et al, 2005). 
Mechanistic studies showed that Brg-1 absence does not impair STAT or IRF1 
activity or expression but influences their binding to target gene promoters (Ni et 
al, 2005). In addition, Brg-1 binds specifically with both STAT1 and STAT2, 
and the binding of Brg-1 with STAT2 is independent of IFNα treatment. Brg-1 is 
also required for the expression of MHC class II and GBP1 in response to IFN-γ 
stimulation, because in a Brg-1/BRM-deficient cell line (SW13), IFN-γ failed to 
induce the expression of MHC class II and GBP1, a defect that was reversed by 
Brg-1 expression (Pattenden et al, 2002). The recruitment of STAT1 and IRF1 to 
the CIITA locus was also blocked upon IFN-γ stimulation in the absence of Brg-




1.17 BRM and BAF 
1.17.1 BRM  
The human BRM (homologue of the Drosophila melanogaster brahma and 
Saccharomyces cerevisiae SNF-2 proteins) is another ATPase core component of 
the SWI/SNF complex. BRM is homologous to Brg-1, with around 74% identity 
in amino-acid sequences. Although Brg-1 and BRM belong to two separate 
forms of SWI/SNF complex, these complexes share most of their other subunits, 
therefore the functions observed for Brg-1 and BRM as they act within these 
complexes are partly similar and redundant. For example, both BRM and Brg-1 
play an important role in ISG expression, and can activate IFITM3 promoter 
activity (Torti, 2012). They are both involved in retinoblastoma (Rb)-mediated 
signaling and BRM can compensate for Brg-1 function if Brg-1 is lost (Strobeck 
et al, 2002). The overall amount of available ATPase subunit is regulated as 
overexpression of BRM by transient transfection results in the decreased 
expression of endogenous Brg-1. 
Despite their sequence similarity and functional interchangeablity, BRM and 
Brg-1 are different in their regulated expression levels. Compared to Brg-1, 
which displays a relatively constant protein level in various cell types, the 
concentration of BRM protein is low at embryonic stem cells (ESCs) while is 
increased in differentiated cells (Kaeser et al, 2008; Muchardt et al, 1998). BRM 
and Brg-1 complexes regulate different gene expression profiles through 
selective association with certain classes of transcription regulator proteins. Zinc 
finger family of proteins interact exclusively with BRG1, while two ankyrin-
repeats proteins CBF-1 and ICD22, that are essential in Notch signal 
transduction, are specifically associated with BRM (Kadam & Emerson, 2003). 
In addition, the requirements for BRM and Brg-1 in some ISGs expression is 
distinct. BRM is required for the basal expression and IFNα-induced IFIT1, 
IFIT3 and OAS1 expression, while Brg-1 is not important for the basal 
expression but important for the IFNα-stimulated expression of these genes 
(Lavigne et al, 2009). Thus BRM and Brg-1 can act synergistic or separately, or 
even antagonize each other, to regulate selective gene expression depending on 




The importance of core SWI/SNF subunits such as BAF170, BAF155 and 
BAF147 for achieving optimal Brg-1 chromatin remodeling activity in vitro 
(Phelan et al, 1999) suggests important roles of at least some BAF subunits in 
promoter-specific targeting or to convey a stabilized nucleosomal conformation 
favorable for SWI/SNF activity (Phelan et al, 1999; Trotter & Archer, 2008). 
BAF155 is one of the core subunits of SWI/SNF remodeling complex, and is 
encoded by the SMARCC gene. BAF155 is highly homologous to BAF170, and 
is likely exist either as heterodimers (BAF155/BAF170) or as homodimers 
(BAF155/155) in the cell (Chen & Archer, 2005; Wang et al, 1996b).  
BAF155 is essential to maintain the integrity of SWI/SNF complex (Chen & 
Archer, 2005; Sohn et al, 2007). Thus, BAF155 is believed to function as a 
scaffold protein to control the assembly and maintain the stability of SWI/SNF 
complex. The downregulation of BAF155 and its homologue BAF170 reduces 
the protein level of other major subunits of SWI/SNF such as Brg-1, BAF57, 
BAF47, and BAF60a, while overexpression of BAF155 increases their level. 
BAF155 directly associates with those subunits and protects them from protease 
degradation. The observation that the deletion of either Brg-1/BRM or BAF47 
does not affect the interaction of remaining subunits with BAF155(Doan et al, 
2004), while the absence of BAF155 impairs the stability of SWI/SNF complex, 
further supports the scaffold role of BAF155. (Trotter & Archer, 2004; Wang et 
al, 1996a). However, there is a study which showed that BAF155 was able to 
function independent from the full SWI/SNF complex, and seems BAF155 can 
bind at some genomic sites independent of Brg-1 (Wang et al, 2016).  
1.18 Aims of this study 
 
Recent work in our laboratory has demonstrated that PML isoform II (PML-II) 
regulates IFN functional responses and ISG gene transcription mainly by 
regulating transcription factors and/or coactivator recruitment at inducible gene 
promoters (Chen et al, 2015). As the distinct function of PML isoforms was 
thought to result from their different C-terminal structures, this suggested PML-
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II C-terminal fragments should play an important role in PML-II transcription 
regulation functions. Therefore, the first aim of this study was to investigate 
PML-II C-terminal functional fragment in gene transcription. 
 
PML protein binds with various TFs and co-activator CBP, and mediates the 
transcriptional complex recruitment at promoters (Chen et al, 2015). These 
findings suggested that PML-II may be a master regulator of gene expression 
having a general regulation function in chromatin remodeling and/or histone 
modification. Chromatin remodeling complex SWI/SNF was reported to regulate 
IFN responses(Agalioti et al, 2000) and ISG expression (Huang et al, 2002; 
Pattenden et al, 2002), so the second aim of this study was to elucidate PML-II 
regulation functions in chromatin remodeling and histone modification.   
 
IFNα has been used to induce cell death/apoptosis in various malignant cancer 
cells (Ferrantini et al, 2007; Rizza et al, 2010). Several studies have shown that 
PML is required for IFNα to effectively inhibit cell growth or to induce apoptosis 
in various cancer cells (Crowder et al, 2005; Quignon et al, 1998; Wang et al, 
1998). However, the exact mechanism remains to be completely understood. 





























































2.1 Materials  
 
This section lists the collections of biochemical reagents, antibodies, plasmids, 
siRNA sequences, qPCR primers, ChIP-qPCR primers that were utilized in this 
study. 
Table 2.1.1 Chemical reagents and suppliers 
Biochemical reagent Supplier 
Anti-FLAG M2 Affinity Gel  Sigma  
Brilliant III Ultra-Fast SYBR Green qPCR Master Mix  Agilent Technologies  
DMEM (41965)  Gibco  
ECL prime (WB substrate)  GE healthcare  
GenElute Mammalian Total RNA Miniprep Kit  Sigma-Aldrich  
Lipofectamine 2000  Invitrogen  
MG132  Sigma-Aldrich  
PageRuler Plus Prestained Protein Ladder  Thermo scientific  
poly(I:C)  Sigma  
Protein A Sepharose CL-4B beads  GE Healthcare  
Proteinase K  Sigma-Aldrich  
PureYield Plasmid Midiprep system  Promega  
QIAprep Spin Miniprep Kit  QIAGEN  
Random Primers  Promoga  
IFNα Pbl interferon source  
siRNA  
Ambion by Life 
Technologies  
SYBR green PCR Master Mix  Agilent Technologies  
TRI reagent  Sigma  
Glycogen Invitrogen  
Brg-1 si RNA(h):sc29827 
Santa Cruz 
Biotechnology  
protease inhibitor cocktail  Sigma-Aldrich 




Table 2.1.2 Antibodies 
 
Antibody Supplier 
NF-κB p65(C-20): sc372 Cruz Biotechnology 
CBP(C-20): sc-583 Santa Cruz Biotechnology  
STAT1 p84/p91(E-23):sc-346  Santa Cruz Biotechnology  
Mouse anti-PML-II  Millipore 
Rabbit anti-Flag epitope  Polyclonal F7425 Sigma-Aldrich  
Goat anti-mouse IgG-HRP  Sigma-Aldrich  
Goat anti-rabbit IgG-HRP (sc-2054)  Santa Cruz Biotechnology  
Rabbit anti-Brg-1 antibody(sc-4227) Santa Cruz Biotechnology  
mono clone mouce anti-Brg-1 antibody Abcam 
Rabbit anti-Brg-1 antibody(sc-10768) Santa Cruz Biotechnology  
Rabbit anti-BAF155 antibody Santa Cruz Biotechnology  
Rabbit anti-H3K4me3 antibody Abcam 
Rabbit anti-H3K9me3 antibody Abcam 
Rabbit normal IgG Santa Cruz Biotechnology  
Mouse normal IgG Santa Cruz Biotechnology  
Mouse anti-GAPDH antibody Santa Cruz Biotechnology 
AKT(s9272) Cell signaling 
p-AKT(Ser473)(s9271) Cell signaling 
Phospho-p70 S6 Kinase (Thr389) (108D2)9234  Cell signaling 
ERK p44/p42 Cell signaling 
p-p44/p42MAPK (Thr202/Tyr204) Cell signaling 
MEK1/2 Cell signaling 
phospho-MEK1/2(Ser217/221)(41G9) Cell signaling 
Phospho-Stat1 (Tyr701) (58D6) Rabbit mAb Cell signaling 
TRAIL (C92B9) Rabbit mAb-3219 Cell signaling 
PUMA Antibody (4976) Cell signaling 
p53 (FL-393) sc-6243 Santa Cruz Biotechnology  















             Table 2.1.4 siRNAs 
 
siRNA Sense 5’3’  Antisense 5’3’  References  
Control siRNA  GAGCCGGACGCCAAAGAAAUU UUUCUUUGGCGUCCGGCUCUU This thesis 




Cell line Phenotype/Origin 
HeLa Supplied by Prof. M.A.McCrae, University or Warwick 
HEK293 
Human embryonic kidney cells expressing adenovirus type 5 E1A and E1B genes, supplied by Dr. K. N. Leppard, 
University of Warwick (Graham et al, 1977). 
DH5α Escherichia coli K12, genotypes: SupE44,ΔlacU169 (φ80lac ZΔM15), hsdR, recA1, endA1, gyr96, thi-1, relA1 
54 
 
       Table 2.1.5 qPCR primers 
 
Gene Forward  5'3' Reverse 5'3' Reference 
IFNβ ATTGCCTCAAGGACAGGATG  GGCCTTCAGGTAATGCAGAA  (Shi et al, 2010)  
ISG15 CCCTCGAAGGTCAGCCAGA GGACAAATGCGACGAACCTCT  (Han et al, 2011) 
ISG54  TGCAACCTACTGGCCTATCTA  CAGGTGACCAGACTTCTGATT  (Shi et al, 2010)  
ISG56 GCCATTTTCTTTGCTTCCCCTA TGCCCTTTTGTAGCCTCCTTG (Yang et al, 2009) 
PML-II-1+2 AGGCAGAGGAACGCGTTGT GGCTCCATGCACGAGTTTTC (Chen et al, 2015) 
PML-II-3+4 GAAAACTCGTGCATGGAGCC GAGGCTCCTTGTGCTCTCAG This study 
GBP1 CAAGCTAAAGCAAACCACCTT TGGTTTCTTCCACCTTCCTC This study 
OAS1 TGCGCTCAGCTTCGTACTGA GGTGGAGTTCTCGCCCTCTT This study 
IFITM3 TTTGTTCCGCCCTCATCTG CTTTTCCTGGCATTTGTCAAATC This study 
IFI27 CAAGTTCATCCTGGGCTCCAT GGGCAGGGAGCTAGTAGAACCT This study 
Brg-1 GTTTGAGGACACCATTGACCATA AATGCCAAGCAAGATGTCGAT This study 
BRM TGGAAATTCTGCAAGAGCGG CCACGGTTGCTTTGGTTCTTAA This study 
BAF155 GCGAGTTCTACATGATCGGCT CACAGTGGCTAGTCGCCTC This study 
BAF47 GGTCGGAGTCAACGGATTT CCAGCATCGCCCCACTTG This study 
c-Fos CCGGGGATAGCCTCTCTTACT CCAGGTCCGTGCAGAAGTC This study 
c-Myc GGCTCCTGGCAAAAGGTCA CTGCGTAGTTGTGCTGATGT This study 
PUMA GACCTCAACGCACAGTACGAG AGGAGTCCCATGATGAGATTGT This study 
TRAIL TGCGTGCTGATCGTGATCTTC GCTCGTTGGTAAAGTACACGTA This study 
p53 GCCCAACAACACCAGCTCCT CCTGGGCATCCTTGAGTTCC This study 
BAK ATGGTCACCTTACCTCTGCAA TCATAGCGTCGGTTGATGTCG This study 




           Table 2.1.5 qPCR primers (continue) 
 
Gene Forward  5'3' Reverse 5'3' Reference 
Bcl-xL GAGCTGGTGGTTGACTTTCTC TCCATCTCCGATTCAGTCCCT This study 
GAPDH GGTCGGAGTCAACGGATTT CCAGCATCGCCCCACTTG (Vestergaard et al, 2011)  
β-actin AAAGACCTGTACGCCAACAC GTCATACTCCTGCTTGCTGAT (Shi et al, 2010)   
 
           Table 2.1.6 ChIP primers 
 
Genes Forward  5'3' Reverse 5'3' reference 
IFNβ TGCTCTGGCACAACAGGTAG CAGGAGAGCAATTTGGAGGA (Chen et al, 2015) 
ISG15 CGCCACTTTTGCTTTTCCCT  ATAAGCCTGAGGCACACACG  (Chen et al, 2015) 
ISG56 TTGGGTTTCTGCAGCACTAGA ACCTAGGGAAACCGAAAGGG (Chen et al, 2015) 
ISG54 GCCGAACAGCTGAGAATTGC CTGGCCCTCTTTGGGAACAT This study  
IFITM3 TCAGGAATTTGTTCCGCCCTC GATTCATGGTGTCCAGCGAAGAC This study 
OAS1 CAGCAGTCCAAGCTCAGTCA GCTACCTCGGAAGCACCTTT This study 
GBP1 TTAAACCCTCCCACTGGCAC GAGCACTGGCTTCTAGCACT This study 
ISG56(promoter downward) CTCTGCCTATCGCCTGGATG CCTGCCTTAGGGGAAGCAAA This study 
ISG15(promoter downward) ATCCTGCCTGTCCTCCATCT AGGACTCACCCCTTACTGCT This study 
ISG15(promoter downward) AGGCAGGCTCTCCATAGGAA GTCTCTACCCCTCCCTAGCC This study 
ISG54(promoter downward) CTGCCACCTGCTACCATTGA GCATTTGGATTGCGTCCAGG This study 




2.2.1 Cell culture  
HeLa cell, a cervical cancer cell line, and HEK293 cell, human embryo kidney 
cells immortalized by a fragment of adenovirus DNA (Graham et al, 1977), were 
grown in 10cm γ-irradiated tissue culture dishes and were maintain in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% (v/v) 
foetal bovine serum (FBS) at 37°C in a 5% CO2 incubator. When the cells were 
confluent, they were passaged by washing the monolayers with 3 ml versene 
(0.02% EDTA in PBS), followed by trypsinizing with 2.5 ml versene containing 
0.02% (v/v) 0.5ml trypsin.  The detached cells were collected into 25 ml tube 
with 0.5 ml FBS and pelleted by centrifugation at 2000 rpm for 3 min. The cell 
pellet was then resuspended with DMEM / 10% FBS and seeded into new dishes 
at the required density for experiments or further passage.  
2.2.2 Cloning/plasmid preparation 
2.2.2.1 Transformation of competent bacterial cells  
Plasmid DNA (typically 50 ng) was added into 50-100 μL of thawed competent 
DH5α and left on ice for 20-30 min. Cells were then placed at 42 °C water bath 
for 30s, followed by immediate incubation on ice for another 2-3 min. 500-800 
μL of pre-warmed liquid LB medium was added and the LB-competent cell 
mixture was incubated at 37 °C in a shaking incubator for 1 h. After that, the 
cells were plated onto LB plates containing 100μg/ml ampicillin to select for 
retention of plasmid and incubated at 37 °C overnight. 
 
2.2.2.2 Extraction of plasmid DNA  
Plasmid DNA was extracted using either the Qiagen MiniprepKitTM, or the 
Promega PureyieldTM Plasmid Midiprep System, using the protocols provided by 
the manufacturers following their instructions. Before DNA was eluted from 
columns with nuclease-free water, the optional Endotoxin Removal Wash step 
was included to enhance removal of any endotoxin, protein, RNA or other 




2.2.2.3 Quantification of nucleic acid  
The concentration of DNA and RNA samples was determined using a Nanodrop-
ND1000 spectrophotometer (Thermo Scientific) by measuring OD260. The purity 
of DNA and RNA was indicated by the absorbance ratio of OD260 to OD280, 
where a ratio of 1.8 indicates pure DNA and a ratio of 2 indicating pure RNA. 
2.2.3 Transfection and stimulation 
2.2.3.1 Plasmid DNA transfection 
A concentration of 2×105 per ml HEK293 cells or 1.0×105 Hela cells were seeded 
in plates, respectively, and transfected after 24 h of culture. This concentration of 
cells were used in all DNA or RNA transfection experiments in this study. Lipid 
reagent LT1 (Mirus) was used for liposome-mediated transfection of plasmid 
DNA, with a ratio of 2 μL LT1 per μg plasmid DNA added. The transfection 
reagent and plasmid DNA was prepared in pre-warmed Opti MEM medium. 
After mixing, the transfection reagent/plasmid DNA complexes were incubation 
for 20 min at room temperature, then pipetted onto the cells in normal growth 
medium and gently mixed. Cells were cultured for various times depending on 
the different requirements of individual experiments.  
 
2.2.3.2 siRNA (short interfering RNA) transfection 
An optimized input of 125 pmol/ml siRNA was used for transfection in this 
study. Lipofectamine 2000 (Invitrogen) was the transfection reagent used and the 
ratio of siRNA to Lipofectamine 2000 was 100 pmol siRNA per microliter of 
Lipofectamine 2000.  The transfection reagent and siRNA was prepared in pre-
warmed Opti MEM medium, mixed and incubated at room temperature for 20 
min, then gently pipetted onto the cells and gently mixed.  
 
2.2.3.3 poly(I:C) and IFNα treatment of the cells 
1.0 μg/ml poly(I:C) or 1000U/ml IFNα was used to stimulate the cells. 
Lipofectamine 2000 (Invitrogen) was the transfection reagent used for poly(I:C) 
stimulation, with 1μg poly(I:C) added to 2μL Lipofectamine 2000. 
Lipofectamine 2000 and poly(I:C) were prepared in pre-warmed Opti MEM 
medium separately. After mixing, the transfection reagent complex was 
incubated for 20 min at room temperature, then pipetted onto the cells in normal 
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growth medium and gently mixed. 
IFNα was diluted with pre-warmed Opti MEM medium and added into the cells 
directly. The length of poly(I:C) or IFNα stimulation varied depending on the 
different requirements of individual experiments.  
2.2.4 RNA extraction and reverse transcription   
 
Cells were harvested and lysed from 24-well-plate cultures, and RNA was 
extracted by using GenElute Mammalian Total RNA Miniprep Kit (Sigma-
Aldrich) following the manufacturer’s instructions. RNA pellets were dissolved 
in 40 µl sterile H2O. 
 
Before reverse transcription, the RNA was treated with DNAase to remove any 
contaminating DNA. Typically, 1µg of RNA was used per reaction and 
incubated with 1unit DNAase and 1µl 10×DNAase Reation Buffer (Promega) 
along with H2O to a volume of 10 µl at 37ºC for 30 min, then 1µl DNAase stop 
buffer was added and incubated at 65ºC for 10 min.  
 
After DNAase treatment, the RNA was subjected to reverse transcription. The 
reactions were performed in a 20 μL volume using GoScript TM reverse 
transcriptase according to the manufacturer’s instructions. 5 μL RNA was 
incubated with 1μL random primer at 70ºC for 5 min then chilled on ice for 5 
min. Then a mixture containing 4 μL GoScriptTM 5×reaction buffer (Promega), 2 
μL MgCl2(25mM) 1 μL PCR nucleotide mix (10mM), 20 units recombinant 
Rnasin ribonuclease inhibitor (Promega), 1 μL GoScriptTM reverse transcriptase 
(Promega)and 6 μL H2O was added to each sample, mixed and placed on the 
PCR machine. The reaction conditions included annealing 25ºC 5 min, extending 
42ºC 1 h and then 70ºC 15 min to inactivate the reverse transcriptase.  
2.2.5 SYBR-Green quantitative PCR 
 
For quantitative PCR (qPCR) reactions a SYBR-Green qPCR Master Mix was 
used according to the manufacturer’s instructions (ABI or Agilent). Briefly, the 
reaction mixture contained 10 µL SYBR green Master Mix, 0.2 µL forward and 
reverse primers (10 µM each primer) and 1 µL (50-100 ng) DNA or cDNA with 
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H2O to a total 20 µL volume was add into the wells of qPCR plates and qPCR 
amplification was carried out using a Stratagene Mx3005P light cycler (Agilent 
Technologies). qPCR primers used in this study are listed in Table 2.1.5.  
 
Reaction conditions were: denaturation at 95ºC for 10 min, then 40-50 cycles of 
denaturation at 95ºC 30 sec, annealing/extension at 60ºC for 60 sec. The results 
were analyzed using Agilent Technologies system software. Quantification was 
based on Ct difference performed according to the “delta–delta Ct method” 
(Livak & Schmittgen, 2001), using the following equation: expression ratio=2-
ΔΔCt, where ΔΔCt = (Ct target−Ct reference). A standard curve was established 
by plotting the C(t) values obtained from the qPCR against the log of plate 
counts on control siRNA and showed good correlation. qPCR efficiency 
calculated from standard curves (E = [10-1/slope]-1). Target gene expression was 
normalized against expression of the housekeeping genes glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) or β-actin. All samples, including the no 
GoScript TM reverse transcriptase negative controls and non-template controls, 
were analysed in triplicate.  
2.2.6 Western-blotting 
 
Protein samples in SDS sample buffer (4% SDS, 20% glycerol and 50mM 
Tris.HCl (PH6.8)) were boiled for 5-10 min before loading onto SDS 
polyacrylamide gels and electrophoresis at 110 V for 1.5 h. Proteins were then 
transferred to a nitrocellulose membrane and the membrane then blocked with 
2% (w/v) milk diluted with PBS containing 0.05% Tween 20 (PBS-T) at room 
temperature for 1 h, or at 4 C overnight. The membranes were then incubated 
with the appropriate concentration of specific primary antibody (Table 2.1.3) 
diluted with blocking solution for 1 h at room temperature on an orbital shaker. 
The dilution of the primary antibody was dependent on the protein under 
investigation. Membranes were then washed with PBS-T 4 times, with the PBS-
T being replaced every 10 min. After washing, the appropriate HRP-conjugated 
secondary antibody was added and incubated and washed as before. Finally, the 
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blot was detected using ECL TM Advance reagent (GE healthcare) according to 
the manufacturer’s instruction by exposure to Fuji Super RX X–Ray film.  
2.2.7 Flow cytometry   
 
Cell death/apoptosis was determined by flow cytometry. Briefly, HeLa cells 
were cultured in 24-well plates. Following transfection and/or stimulation 
treatment, culture medium was removed, and cells were washed once with ice-
cold PBS, released from the well with trypsin. Cells were collected and 
centrifuged at 1,100 rpm for 3 min, then washed twice with cold PBS. Cells were 
resuspended in PBS then stained by incubation with 100 µl PBS containing 0.5–
5μl (0.1-1μg) of Annexin-V FITC and/or 1µl propidium iodide (PI) (50µg/ml) 
and put on ice for 20-30 min in the dark. After twice washing with cold PBS, 
cells were transfected to FACS tubes for flow cytometry. Assays were performed 
in duplicate and data were acquired using a FACSCanto II flow cytometer (BD 
Biosciences). 
2.2.8 Co-immunoprecipitation  
 
Two alternative protocols were followed, either a standard antibody protocol or 
one specifically for Flag epitope tagged proteins.  
Standard antibody protocol: Cells cultured in 10 cm dishes (80-100% confluent, 
about 6×106-1×107 cells) were washed once with 10 ml cold PBS. Then cells 
were scraped, lysed with 0.5-1.0 ml cold NP-40 cell lysis buffer (50 mM 
Tris.HCl pH8.0, 150 mM NaCl, 1% (v/v) NP-40) on ice for 10 min and sonicated 
40 min using the Biorupter (Diagenode). After centrifugation in a microgufe at 
13,000 rpm for 10 min, the sonicated cell lysate was incubated with specific 
antibody, by rotation at 4 °C overnight. Protein A Sepharose beads were then 
added and rotated for 2 h to collect antibody:antigen complexes. After washing 
the protein/antibody/beads complex with 0.5-1.0 ml IP-washing buffer (10 mM 
Tris.HCl pH7.4, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 1 mM 
EGTA and 0.2 mM Na3VO4) five times, the beads were resuspended with 2 × 
SDS sample buffer and boiled for 10 min to release bound proteins. After 
centrifugation, the supernatant was recovered, 10 μL DTT (dithiothreitol) added 




Flag beads fusion protein protocol: Cells cultured in 10 cm dishes (80-100% 
confluent, about 6×106-1×107 cells), were washed three times with 10 ml cold 
PBS and lysed on ice with 0.5 ml cold 25 mM HEPES (pH 7.0), 0.5 M NaCl, 
0.1% NP-40, 1mM sodium butyrate, 1% protease inhibitor cocktail (Sigma-
Aldarich) and 1% phosphatase inhibitor cocktail (Sigma-Aldrich) (Hoppe et al, 
2006). Cell lysates were collected and sonicated on ice by the Biorupter for 20 
min and then diluted with equal volumes of low salt lysis buffer (as above except 
50 mM NaCl). Flag affinity gel was thoroughly resuspended and washed with 
TBS buffer and 0.1 M Glycine (pH3.5) following product instruction. The 
protein complexes were then precipitated with 50 µl Flag affinity gel per sample 
at 4 °C for 3 h or overnight.  After extensive washing with TBS buffer, 40 μL 
2×SDS sample buffer was added into the beads and boiled for 10 min before 
centrifugation at 13,000 rpm for 10 min in a microfuge. The supernatant of the 
mixture was recovered, 10 μL DTT added and stored for western blotting.  
2.2.9 Chromatin immunoprecipitation (ChIP) assay  
 
Cells cultured in 10 cm dishes (80-100% confluent, about 6×106-1×107 cells) 
were cross-linked with formaldehyde to final concentration of 1% for 10 min at 
room temperature, then the reaction was stopped by the addition of glycine to a 
final concentration of 125 mM. After 5 min, fixed cells were washed twice with 
cold PBS, scraped from the dish and resuspended in Buffer C (20 mM HEPES 
pH7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA) on ice for 
20 min. Nuclei were pelleted by centrifugation at 13,000 rpm, 10 min in a 
microfuge, and lysed with 120 µl Breaking Buffer (50 mM Tris-HCl pH8.0, 1 
mM EDTA, 150 mM NaCl, 1% SDS, 2% Triton X-100) on ice for 10 min, then 
sonicated with biorupter for 40 min to shear DNA to lengths between 200 and 
1000 bp. Nuclear lysates were then diluted with 1 ml Triton buffer (50 mM Tris-
HCl pH8.0, 1 mM EDTA, 150 mM NaCl, 0.1% Triton X-100) and stored in 
aliquots at -80 C. Lysates were pre-cleared with 20 µl Protein A Sepharose 
beads at 4 C for 2 h to reduce non-specific binding, then precipitated by 1-2 µg 
specific antibody at 4C overnight. Antibody complexes were collected on 50 µl 
Protein A Sepharose at 4C for 3 h.  The antibody/chromatin/bead complexes 
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were then washed with Triton buffer four times and then once with TE buffer 
(1MTris-HCl pH8.0, EDTA 0.5M), before the crossing-linking was reversed by 
incubation with 400 µl of SDS-NaCl buffer (62.5 mM Tris.HCL pH 6.8, 200 
mM NaCl, 2% SDS, 10mM DTT) at 65C overnight.  
 
ChIP-DNA was then recovered and purified by the following protocol. Samples 
were digested with 0.02 mg Proteinase K, 5 mM EDTA and 20 mM Tris.HCL 
pH 6.5 for 1 hour at 45C. 400 μL phenol-chloroform (1:1) was then added to 
each sample, shaken and centrifuged at 13,000 rpm for 10 min at 4C, collecting 
the upper aqueous phase. Phenol-chloroform (1:1) extraction was repeated, 
followed by chloroform extraction as before. DNA was precipitated by adding 
two volumes of 100% ethanol containing 0.3M Na acetate, 0.3 μL glycogen at -
20C overnight. DNA was pelleted by centrifugation 13,000 rpm for 10 min, 
then the DNA pellets were washed with 70% ethanol, dried for 20-30 min in a 
vacuum dessicator, and finally dissolved in 40 µl of H2O.  
 
ChIP-qPCR assay was carried out using SYBR-Green qPCR Master Mix and 
specific primers as described in Section 2.2.5. CHIP qPCR primers used in this 
study are listed in Table 2.1.6. The relative ChIP signal of each gene target in a 
recovered ChIP DNA sample was expressed as % input specifically precipitated, 
with input DNA being quantified in parallel from DNA purified from a sample of 


























Chapter 3 PML-II C-terminal is essential for its 




















3.1 Introduction  
 
Multiple isoforms of the PML protein are involved in many cellular activities 
including gene transcription regulation (Chen et al, 2015; Zhong et al, 2000b). 
Different isoforms have distinct functions due to various C-terminal functional 
structures which are important for their interaction with partner proteins 
(Bernardi & Pandolfi, 2007; Geng et al, 2012; Nisole et al, 2013). Previous work 
in our laboratory demonstrated that PML isoform II (PML-II) is specifically 
required for efficient induction of IFNβ transcription and of numerous ISGs 
(Chen et al, 2015). PML-II regulates the expression of these genes through 
affecting transcription factor recruitment and transcriptional complexes binding 
at the promoter of these genes (Chen et al, 2015).  Because it is the distinct C-
terminal domain that distinguishes PML-II from other isoforms, it was presumed 
that the distinct function of PML-II resided in that C-terminal structure. This idea 
implies that sequences in the PML-II C-terminal domain may be essential for 
PML-II to bind to transcription factors and to be recruited to target gene 
promoters, thereby exerting a distinct function in transcriptional complex 
assembly at the promoter. This chapter tests this hypothesis. Some of the data in 
this chapter have been published as part of a collaborative paper (Chen et al, 
2015). 
 
3.2 Results  
 
3.2.1 The unique C-terminal domain of PML-II is essential for binding with 
TFs and functions.  
 
Previous work in our laboratory has demonstrated that a 40 aa residue segment 
from the C-terminal domain of PML-II confers an interaction between this 
protein and Ad5 E4 Orf3 (Leppard et al, 2009). It was therefore important to test 
whether these potential protein interaction sites from the unique C-terminal of 





To address this, full length PML-II and three available deletion mutants PML-II-
Δ1, PML-II-Δ2 and PML-II-Δ3 were tested for TF binding by co-
immunoprecipitation assay. These mutants were constructed by deleting specific 
conserved regions within the C-terminal domain of PML-II based on sequences 
alignment, see figure 3.2.1A (Leppard et al, 2009). As expected, full-length 
PML-II could bind with transcription factor NF-κB and STAT1 (Figure 3.2.1 B). 
Deletion of 1 and 2 affected PML-II binding to NF-κB transcription factors 
and slightly affected STAT1, while removal of fragment 3 had no effect on this 
binding ability (Figure 3.1 B). This result suggests that parts of the PML-II C 





Figure 3.2.1 PML-II C-terminal is essential for its binding ability with STAT1 and 
NF-κB (A) Representation of the C-terminal region of PML-II showing the positions of 
deletion mutations. (B) HEK293 cells were transfected with 250 ng/ml Flag-PML-II, 
Flag-PML-II-Δ1, Flag-PML-II-Δ2, Flag-PML-II-Δ3 plasmids or pCI-neo empty vector 
as indicated for 24 h, and then stimulated with poly(I:C) for 16 h, and lysates were 
prepared and immunoprecipitated with anti-Flag beads. Precipitates and total lysates 




3.2.2 PML-II C-terminal binding of TFs independent of N-terminal 
sequences 
 
The N-terminal RBCC domain/structure of PML protein mediates a strong 
homo/ hetero-dimerization with other PML isoforms (Jensen et al, 2001). It is 
likely also to contribute to biochemical functions of the proteins. To determine 
whether the TF binding activity of PML-II required these sequences, and to 
exclude the possibility that PML-II binding with other isoforms, which might 
have an opposite or synergistic function, affected the PML-II contribution to the 
IFNβ response, binding experiments were repeated using ΔRBCC forms of PML.  
 
PML-V has been demonstrated in our laboratory to have no effect on IFN 
induction and downstream signaling, therefore full length PML-II and another 
isoform PML-V as well as their respective ΔRBCC mutant forms, PML-II-
ΔRBCC and PML-V-ΔRBCC plasmids were used to test their interaction with 
STAT1 under IFNα stimulation. The result showed that both full length PML-V 
and PML-II were capable of associating with STAT1. However, the binding 
ability of PML-V with STAT1 was abolished if its N-terminal was deleted, while 
the deletion of N-terminal RBCC domain has less effect on PML-II binding with 
STAT1. These results suggested that PML-II specifically associates with STAT1, 
and that its C-terminal is necessary and sufficient for that association. In contrast, 
the observed interaction of full length PML-V and STAT1 is largely dependent 
on its N-terminal structure. This dependence suggests that the PML-V STAT1 
interaction is indirect, the N-terminal RBCC domain allowing hetero-
dimerization with other PML isoform such as PML-II that interacts directly with 
STAT1.  
 
To further test this interpretation, the TF binding of the PML-II-Δ1, PML-II-Δ2 
and PML-II-Δ3 mutants was tested in a ΔRBCC context. As expect, the deletions 
Δ1 and Δ2 in the ΔRBCC context disrupted the binding of NF-κB and STAT1, as 
was also seen with the full-length constructs, while deletion Δ3 had no effect on 





Figure 3.2.2 PML-II C-terminal binding TF independent of N-terminal. (A) 
HEK293 cells were transfected with 250 ng/ml Flag-PML-II, Flag-PML-V, Flag-PML-
II-ΔRBCC, Flag-PML-V-ΔRBCC and pCI-neo empty vector, respectively, for 48 h and 
then cells were stimulated with IFNα for 10 h. The lysates were prepared and 
immunoprecipitated with anti-Flag beads. Precipitates and total lysates were analyzed 
for Flag-PML and STAT1 by Western blotting. (B) HEK293 cells were transfected with 
250 ng/ml Flag-PML-II-ΔRBCC mutant or further deletion mutant plasmids Flag-PML-
II-ΔRBCC-Δ1, Flag-PML-II-ΔRBCC-Δ2, Flag-PMLII-ΔRBCC-Δ3 or pCI-neo empty 
vector for 48 h and then cells were stimulated with poly(I:C) for 16 h, and lysates were 
prepared and immunoprecipitated with anti-Flag beads. Precipitates and total lysates 
were analyzed for Flag-PML, NF-κB (p65) and STAT1 by Western blotting. 
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3.2.3 Residues of 645-665 are essential for PML-II binding with STAT1 and 
NF-κB 
 
In order to map more precisely the sequences of PML-II required to bind 
transcription factors STAT1 and NF-κB, further plasmid mutants were tested 
which were constructed in the unique C-terminal domain of Flag-PML-II-
ΔRBCC. It can be seen that the Δm1 sequences (residue 645-665), especially 
regions removed in ΔD are essential for the PML-II interaction with NF-κB, with 
almost no NF-κB protein being precipitated by the Flag antibody in cells 
transfected with this plasmid. The ΔB and ΔC region within Δm1 is also 
important for the binding of PML-II with NF-κB. The deletion of both regions 
impaired the binding of PML-II with NF-κB although with less effect compared 
to ΔD.  In contrast to NF-κB, the binding of PML-II with STAT1 was mainly 
focused at the regions deleted in ΔB, ΔC and ΔD. This suggested that different 
transcription factors have different binding sites in the C-terminal of PML-II. 
Taken together, these results suggested that PML-II can specifically associate 




Figure 3.2.3 Residue of 645-665 is essential for PML-II binding with STAT1 and 
NF-κB. (A) The cartoon represents the unique C-terminal domain that defines PML-II 
(residues 571 – 829 of full-length PML-II), with the sequences deleted or altered in 
individual mutants indicated (Leppard et al, 2009). (B) Hela cells were transfected with 
250 ng/ml Flag-PML-II, Flag-PML-II-ΔRBCC, Δm1, Δm2, Δm1Δm2, Δ8, Δ7, M1-1, 
ΔB, ΔC, ΔD plasmids or pCI-neo empty vector for 24 h, then stimulated with poly(I:C) 
for 10 h, lysates prepared, immunoprecipated with anti-FLAG beads and precipitates & 
total lysates analysed for FLAG-PML, STAT1, and NF-κB by western blotting. (C) The 
precipitated NF-κB and (D) STAT1 bands in (B) were quantified and normalized to total 




3.2.4 Deleting the N-terminal RBCC domain of PML-II does not affect 
PML-II regulation function in a type I IFN response.  
 
Having shown that TF binding was an autonomous function of the C-terminal of 
PML-II, it was important to test whether this binding with TFs correlated with 
function in an IFN response. Full length PML-II and its different mutants, PML-
II-ΔRBCC, PML-II-ΔRBCC-Δ1, PML-II-ΔRBCC-Δ2, PML-II-ΔRBCC-Δ3 and 
empty vector pCI-neo, were transfected into HEK293 cells and the effect of their 
overexpression on IFNβ induction and on the downstream response were tested 
by looking at IFNβ, ISG54 and IP-10 mRNA levels.   
 
It can be seen that the overexpression of PML-II-ΔRBCC plasmid promoted 
ISG56 expression (Figure 3.2.4A). Although IFNα stimulation increase the 
expression level of ISG56, the level was further increased by overexpressing 
PML-II ΔRBCC. Similar results were also observed in the other genes including 
IFNβ and IP-10 (Figure 3.2.4B and C).  This suggested that the removal of the 
RBCC domain of PML-II alone did not impair function but actually further 
enhanced PML function in the expression of IFNβ and ISGs in response to 
different stimulations (Figure 3.2.4 B and C). In contrast, overexpression of 
PML-II-ΔRBCC-Δ1 and PML-II-ΔRBCC-Δ2 reduced the expression of ISG56 
compared to that of overexpressing PML-II-ΔRBCC, this suggests the deletion 
of C-terminal fragments in PML-II particular Δ1 and Δ2 may impair the function 
of PML-II in gene expression (Figure 3.2.4A). This is also consistent with the 
co-IP data that Δ1 or Δ2 is important for transcription factor binding with PML-
II, suggesting an important function of Δ1 and Δ2 regions in PML-II-mediated 
transcription (Figure 3.2.4A). It is noticeable that the deletion of Δ3 increased 
ISG56 expression, however the significance of this remains unclear (Figure 
3.2.4A). Collectively, these results indicated that PML-II C-terminal was 
essential for its function, while loss of the N-terminal RBCC domain had no 




Figure 3.2.4 Deleting the N-terminal RBCC domain of PML-II does not affect 
PML-II regulation function in type I IFN response. HEK293 cells were transfected 
with 250 ng/ml Flag-PML-II-ΔRBCC, Flag-PML-II-Δ1, Flag-PML-II-Δ2, Flag-PML-II-
Δ3 plasmids or pCI-neo empty vector for 24 h. Following 1µg/ml 1000 U/ml IFNα or 
poly(I:C) stimulation for 16 h.  Total RNA was analyzed for specific gene (A) ISG56, 
(B) IFNβ (C) IP-10 mRNA levels by RT-qPCR. mRNA level was quantified by ΔΔCt 
method and  is displayed relative to those observed in empty vector pCI-neo transfected 
cells without stimulation. Data shown are the mean ± SD of technique triplicate. Two 
tailed student t-test; * p<0.05, ** p<0.01.   
 
3.2.5 PML-II binds/is recruited to the promoter of inducible genes  
 
PML-II is associated with multiple transcriptional complexes under the condition 
of stimulation, suggesting that PML-II might also be recruited to the promoter of 
the inducible genes and that such recruitment might be necessary for regulating 
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the transcription of inducible genes in response to various stress responses. My 
results had showed that PMLII-ΔRBCC had a stronger ability to bind 
transcription factors compared to full length PML-II. Moreover, using the 
PMLII-ΔRBCC form avoided effects of potential interactions between 
exogenous and endogenous PML via their RBCC domains. So, for this series of 
experiments, PML-II-ΔRBCC rather than the full length PML-II was used to test 
for binding ability of PML-II at the promoters. As demonstrated in Figure 3.2.5 
A and B, more ISG15 and ISG56 promoter DNA was precipitated by FLAG 
antibody from the cells transfected with PML-II-ΔRBCC compared to the empty 
vector pCI-neo. The specific binding ability of PML-II at promoter was further 
demonstrated by using another PML isoform, PML-V-ΔRBCC, which had been 
shown not to bind STAT1. The result showed that PML-V-ΔRBCC did not bind 
to the promoter of ISG56, in contrast to PML-II-ΔRBCC (Figure 3.2.5 B).  
 
Finally another two pairs of primers that were designed to amplify sequences 
from promoter or ‘far from promoter’ regions of a PML target gene were used to 
test the specificity of PML-II binding to gene promoters. The results showed that 
more ISG56 promoter DNA was precipitated by FLAG antibody than non-
promoter DNA (Figure 3.2.5C). This indicated that PML-II is recruited/bound at 
the promoter of inducible genes, the expression of which it up-regulates. Taken 
together, these results provide a further mechanistic understanding of PML-II in 






Figure 3.2.5 PML-II binds/is recruited to the promoter of inducible genes. (A) 
HEK293 cells were transfected with 250 ng/ml Flag-PML-II- Δ RBCC, Flag-PML-V- Δ 
RBCC, or pCI-neo plasmids, and 48 h later, cells were transfected with poly(I·C) for 16 
h. Cell lysates were subjected to ChIP with normal IgG or anti-Flag antibody. 
Precipitated chromatin DNA was assayed by SYBR green qPCR for (A) ISG15, (B) 
ISG56 promoter sequences, (C) for both promoter and non-promoter sequences. Results 
are presented as mean ± SD of technique triplicate.  One tailed student t-test; * p<0.05, 










3.3 Discussion   
3.3.1 PML-II C-terminal binding  
 
PML currently is known to have seven principal isoforms, which contain an 
identical N-terminal region and divergent C termini as a result of different RNA 
splicing. All the principal PML isoforms may have similar function due to the 
RBCC domain that they share, however, increasing evidence suggests that 
different PML isoforms have distinct functions mediated by their unique C-
terminal domains (Nisole et al, 2013). Bioinformatic analysis showed that the C-
terminal region of PML-II was likely to be unstructured but with the propensity 
to become ordered upon interaction with partner proteins (Leppard et al, 2009). 
Mutational analysis revealed that one particular molecular recognition element in 
the C-terminal region of PML-II was required for its interaction with Ad5 E4 
Orf3 protein (Leppard et al, 2009). Recently, based on its chemistry and 
localization properties, the unique C-terminal domain of PML-II has been 
speculated to interact with transcription factors (Geng et al, 2012). In the present 
study, PML-II C-terminal sequences were demonstrated to be essential for PML-
II binding with transcription factors including NF-κB and STAT1. Interestingly, 
the deletion of the PML-II N-terminal RBCC domain did not affect its 
interaction with TFs. However, deletion of particular sequences, residue 645-
684, in the C-terminal of PML-II did reduce its binding ability with these factors. 
The sequence from 645 to 684 is encoded by exon 7b of the PML-II gene, the 
part of the protein that makes PML-II distinct from other PML isoforms.  
 
In the Co-IP experiments, the amount of PML-II-RBCC-1 that was expressed 
and/or precipitated by Flag antibody was reduced compared with other PML-II 
mutants. The amount of PML-II-RBCC-1 was similar to that of other mutants 
when expressed in unstimulated cells but upon stimulation with poly(I:C), the 
amount of PML-II-RBCC-1 was reduced greatly. This instability of the PML-
II-RBCC-1 protein is probably because poly(I:C) stimulation activates the 
expression of other genes such as ISG15, which has the potential to trigger the 
degradation of target proteins (Zhou et al, 2017). This result also suggests that C-
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terminal 1 region of PML-II is not only important for PML-II binding with TFs 
but also is essential for PML-II structure and stability. In contrast to the 1 
protein, the PML-II-RBCC-2 mutant protein was very stable in both cases. 
However, deletion of 2 from PML-II-RBCC impaired PML-II binding ability 
to NF-κB and STAT1, while removal of the regions defined by the RBCC and 
3 deletions had no effect on their binding ability. 
3.3.2 PML-II C-terminal function 
   
It was recently reported that the unique C-terminal domain of PML-II can bind to 
PML-NBs independent of the shared N-terminal region (Geng et al, 2012). This 
finding suggested that C-terminal PML-II might be able to replace full-length 
PML-II for some functions. In this context, it was found that deletion of the N-
terminal 360 amino acids of PML-II further enhanced the expression of IFNβ 
and ISGs while full-length PML-II only modestly increase the expression of 
these genes. This suggested that the N-terminal RBCC region may have negative 
effects on some functions of PML protein, perhaps contributing to keep some 
balance in vivo.  Potentially therefore, some other PML isoforms may also have 
the potential to activate more potently some other classes of gene expression if 
they lost the N-terminal regions. Full length PML-IV is already known to 
activate p53-dependent gene expression (Bischof et al, 2002). Removal of the 
RBCC domain gave a PML-II protein with enhanced activity in the expression of 
IFNβ and ISGs; the biological significance and mechanism of this effect remains 
to be determined, but it could reflect a greater functional availability of the PML-
II C-terminal domain when less tightly tethered to PML-NB. Taken together, 
these results provided further evidence of PML-II, particularly its distinct C-
terminal domain, playing a key role in the regulation of IFN responses.  
 
3.3.3 PML-II binding at promoters  
 
Results from the current study have shown that PML-II can bind at a gene 
promoter in response to stimulation. This provided strong evidence that PML-II 
participates in the gene regulation. PML-II was recruited to the promoter of 
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activated ISGs most likely is because of its association with various transcription 
factors or co-activators that are recruited there, as another isoform, PML-V, 
which does not bind these transcription factors, was not recruited to these 
promoters. However, we cannot exclude the possibility that PML-II associates 
with some other transcription-related factors, such as the general transcription 
factors, which may also contribute to its binding to these promoters.  
 
Collectively, the data in this chapter have shown that specific sequences in the 
unique PML-II C-terminal domain are essential for its interaction with 
transcription factors such as NF-κB and STAT1, while the N-terminal RBCC 
domain is dispensable (Figure 3.3.1). The recruitment of PML-II at active gene 
promoters suggests a possibility that PML-II recruited in this way regulates the 
basal/general transcriptional mechanism, perhaps including histone DNA 
modification and other chromatin remodeling protein such as SWI/SNF complex 



























Chapter 4 PML and chromatin remodeling 
















The modification of chromatin structure is increasingly recognized to be an 
important facet for transcriptional regulation. Upon transcriptional activation, the 
highly ordered structure of the chromatin is modified by the recruitment of 
various histone-modifiers and chromatin remodeling complexes and finally 
forms an opening chromatin structure for the binding of activators and members 
of the general transcription machinery.  
The SWI/SNF enzymatic complexes are large multimeric assemblies which are 
thought to be recruited to specific gene targets through association with DNA-
binding transcription factors, co-regulators, or members of the general 
transcriptional machinery. In addition to ATP-dependent chromatin modifiers, 
various modifications on histone tails also play an important role in regulating 
chromatin structure and gene transcription (Kouzarides, 2007). Histone 
modifications within target gene promoters may serve as an interaction surface 
for the assembly and /or recruitment of co-regulator complexes such as SWI/SNF 
to the DNA and eventually regulate the expression status of these genes.  
SWI/SNF complexes have been shown to regulate expression of multiple 
interferon-responsive genes (Agalioti et al, 2000; Huang et al, 2002). For 
example, Brg-1 is involved in IFNβ transcription (Agalioti et al, 2000). Brg-1 is 
also required for the expression of MHC class II and guanylate-binding protein 1 
(GBP1) as the induction of both genes by IFN-γ is defective in a Brg-1/BRM-
deficient cell line (SW13) (Pattenden et al, 2002). Mechanistically, the absence 
of Brg-1 blocks the recruitment of transcription factor STAT1 to the CIITA locus 
so reducing its expression (Ni et al, 2008; Pattenden et al, 2002). Moreover, 
depletion of Brg-1 impeded ISGF3 (STAT1/STAT2/IRF9) complex binding to 
several ISGs, such as GBP1, IFI27 and IFITM1 promoter in response to IFNα 
stimulation, resulting in impaired gene expression (Ni et al, 2005). 
Recent work in our laboratory had demonstrated that PML-II plays an important 
regulatory function/role in the induced transcription during IFN and 
inflammatory responses (Chen et al, 2015). Depletion of PML-II impaired 
specific transcription factor and coactivator CBP recruitment to the promoters of 
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inducible genes (Chen et al, 2015). This suggested that PML-II may be a master 
regulator with a general regulation function in gene transcription. To address this 
hypothesis, the purpose of this chapter was to dissect PML-II regulation function 
on the basal transcriptional machinery, including chromatin remodelling and 
histone modification, and the link between PML-II and Brg-1 in this process.  
4.2 Results 
4.2.1 Brg-1 can be knocked down by siRNA  
 
To establish an experimental system in which Brg-1 could be studied, the 
knockdown efficiency of Brg-1 by siRNA was tested. As shown in Figure 4.2.1, 
Brg-1 protein levels were decreased by Brg-1 siRNA in a concentration 
dependent pattern, the expression of Brg-1 being greatly inhibited at the 
concentration of 125 pmol/ml siRNA compared to the control siRNA (Figure 
4.2.1A). The efficiency of 125 pmol/ml Brg-1 siRNA knockdown was further 
confirmed by testing Brg-1 mRNA levels (Figure 4.2.1B). 125 pmol/ml siRNA 
therefore was used as the optimized concentration for Brg-1 knockdown in the 






Figure 4.2.1 Brg-1 can be knocked down by siRNA. (A) HEK293 cells were 
transfected with 0, 25, 50, 75, 100, 125 pmol/ml siBrg-1 or siControl and incubated for 
48 h, then the cells were harvested. Cells lysates were separated by 8% SDS-PAGE and 
subjected to western blotting for either Brg-1 or GAPDH (loading control). (B). 
HEK293 cells were transfected 125 pmol/ml control or Brg-1 siRNA for 48 h, and then 
total RNA was extracted and Brg-1 mRNA quantified by SYBR-Green RT-qPCR. The 
data shown are relative to control siRNA and are the mean +/- standard deviation of 
three replicates 
 
4.2.2 Knockdown of Brg-1 or PML-II downregulates the expression of ISGs  
 
Previous studies showed that Brg-1 is required for the expression of a group of 
ISGs (Agalioti et al, 2000; Ni et al, 2005; Pattenden et al, 2002), and recent work 
in our laboratory demonstrated that PML-II is also important for regulating ISGs 
expression (Chen et al, 2015). To study the relationship between PML-II and 
SWI/SNF chromatin remodeling protein Brg-1, the effect of knockdown of either 
Brg-1 or PML-II was tested on the expression of a subset of  ISGs such as GBP1, 
IFI27, ISG54, ISG15 and ISG56 in HeLa cells. The results showed that the 
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mRNA expression of GBP1, IFI27, ISG15 and ISG54 was severely decreased by 
depleting Brg-1, while the knockdown of Brg-1 only modest reduced the 
expression of ISG56. This suggested that the relative dependence on Brg-1 may 
vary between different genes (Figure 4.2.2). Consistent with our previous 
reports, knockdown of PML-II severely affected the expression of all these genes 
tested, confirming that PML-II regulates IFN and ISGs gene transcription (Figure 
4.2.2). This downregulation of induced gene expression by depleting Brg-1 and 
PML-II was also observed in HEK293 cells (Figure 4.2.6). Together, these 
results confirmed the notion that both Brg-1 and PML-II are essential in the 




Figure 4.2.2 Knockdown of Brg-1 or PML-II downregulates the expression of ISGs. 
Hela cells were treated with 125 pmol/ml PML-II, Brg-1 or Control siRNA for 48 h, and 
stimulated with IFNα for 16 h. mRNA expression levels were measured by SYBR Green 
qPCR. The values presented are relative to control siRNA with no-stimulation and are 
the mean +/- standard deviation of three technical replicates. One tailed student t-test; * 






4.2.3 Time course of dynamic chromatin modification at ISG promoters  
 
Histone modifications are thought to cooperate with chromatin remodeling 
complexes to reconfigure chromatin, thereby establishing a local chromatin 
structure and facilitating the subsequent assembly of an active preinitiation 
complex at the promoter (Aaronson & Horvath, 2002; Reith & Mach, 2001). The 
levels of H3K4me3 and H3K9me3 function as marks of gene transcription 
activation and silencing, respectively. Given Brg-1 and PML-II are required for 
gene transcription, and the depletion of PML-II or Brg-1 inhibits gene 
transcription,  it was asked whether knockdown of PML-II and Brg-1 affects 
histone modification at interferon response promoters. The dynamic change of 
H3K9me3 and H3K4me3 histone modification at selected promoters in response 
to gene activation was tested firstly. The relative ChIP signal of each gene target 
in a recovered ChIP DNA sample was expressed as % input specifically 
precipitated, with input DNA being quantified in parallel from DNA purified 
from a sample of chromatin reserved at the nuclear lysate stage. As observed in 
Figure 4.2.3, the basal level of  H3K4me3 at ISG54 and ISG56 promoter was 
significantly higher than that of H3K9me3 in inactive cells. However, upon IFNα 
stimulation, the level of H3K4me3 at the ISG54 gene promoter was increased 
greatly to (7-fold) after 8 hours IFNα treatment. Similarly, in the promoter of 
ISG56, the enrichment of H3K4me3 reached a peak at 8h after stimulation, a 
level nearly three-fold more than basal level (non-stimulation) (Figure 4.2.3).  
 
However, the level of H3K9me3 at ISG54 promoter was decreased immediately 
after IFNα treatment, and the downward trend continued for the initial 6h then 
followed by recovery to the basal level (see Figure 4.2.3). Similarly, over the 
same period the level of H3K9me3 in the ISG56 promoter was suppressed to a 
relatively low level in response to IFNα stimulation, then showed some increase 
at 8 hour, but its levels was still lower than the basal level (Figure 4.2.3). 
 
The time course of CBP binding at these promoters during stimulation was tested 
since it is a very important histone acetyltransferase (HAT) (Bannister & 
Kouzarides, 1996). Interestingly, the temporal pattern of CBP recruitment is very 
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similar to that of H3K4me3 modification although the signals were generally 
weak (Figure 4.2.3).  
 
 
Figure 4.2.3 Time course of dynamic chromatin modification at ISG promoters. 
95% confluent Hela cells were stimulated with IFNα for 0, 2, 4, 6, 8, 10h and then cells 
were collected and equal aliquots of fixed chromatin were subjected to ChIP 
precipitation with normal IgG, H3K4me3, H3K9me3 and CBP antibody respectively. 
Precipitated chromatin DNA was assayed by SYBR green qPCR for ISG54, ISG56 
promoter sequences. Results are presented as mean ± SD of technical triplicate. One 





4.2.4 Depletion of either Brg-1 or PML-II affects histone modification  
 
Having tested the dynamics of H3K9me3 and H3K4me3 enrichment/disposition 
at gene promoter (Figure 4.2.3), the effect of knockdown of PML-II or Brg-1 on 
H3K9me3 and H3K4me3 at gene promoters was tested. As both PML-II and 
Brg-1 are positive regulators for ISG transcription, the depletion of either PML-
II or Brg-1 might increase or maintain level of H3K9me3, and/or decrease 
H3K4me3 level at the promoter. As expected, the level of H3K9me3 was 
decreased in response to IFNα stimulation but the knockdown of either PML-II 
or Brg-1 increased/recovered the level of H3K9me3 at these promoters (Figure 
4.2.4 A). This is consistent with a recent study where silencing of PML enhanced 
the H3K9me3 level at the Oct4 gene promoter in P19 embryonal carcinoma (EC) 
cells (Chuang et al, 2011). Surprisingly, the level of H3K4me3 was not 





Figure 4.2.4 Depletion of either Brg-1 or PML-II affects histone modification at 
ISGs. (A) Hela cells were transfected with 125pmol/ml control, PML-II or Brg-1 siRNA 
for 48 h, then treated with 1000 unit/ml IFNα for 6 h (H3K9me3) or (B) HeLa cells was 
transfected with siRNA as A and stimulated with 1000 unit/ml IFNα for 8 h 
(H3K4me3), and then cells were collected and equal aliquots of fixed chromatin were 
subjected to ChIP precipitation with normal IgG, H3K4me3 orH3K9me3 antibody 
respectively. Precipitated chromatin DNA was assayed by SYBR green qPCR for 
ISG15, ISG54 and ISG56 promoter sequences. Results are presented as mean ± SD of 




4.2.5 Loss of either Brg-1 or PML-II affects transcription factor STAT1 
recruitment at ISG promoters 
 
Other studies and our previous work (Chen et al, 2015; Ni et al, 2005) have 
shown knockdown of Brg-1 or PML-II affects transcription factor STAT1 
binding at ISG promoters. To confirm and extend this, transcription factor 
binding at these promoters was tested. Firstly, the binding time-course of STAT1 
to the ISG15/54/56 genes in response to IFNα stimulation was tested (Figure 
4.2.5A). The result showed that upon stimulation the binding of STAT1 at the 
promoter was gradually increased and reached the highest level at 4-6 hours after 
stimulation. This peak of STAT1 binding was followed by a slow dropdown but 
the level was still higher than basal level. This result showed that the recruitment 
of transcription factor STAT1 to these promoters is an earlier event than the 
recruitment of CBP or the changes in histone modification just described (Figure 
4.2.3).  
 
Next, the effect of depletion of Brg-1 and PML-II on the binding of STAT1 at 
these promoters was detected. The level of STAT1 binding was decreased  in the 
absence of either Brg-1 or PML-II (Figure 4.4B). It is notable that the level of 
STAT1 reduction caused by depleting PML-II or Brg-1 is very similar, 
confirming the function of PML-II in gene transcription and suggesting a 
potential interaction of PML-II with Brg-1 in this process. Together, this result is 
consistent with others’ and our previous reports (Chen et al, 2015; Ni et al, 2005) 
and providing support for the idea that both Brg-1 and PML-II are required for 
STAT1 binding at ISG promoters.    
 
Collectively, the effects of PML-II and Brg-1 removal on histone modification 
and transcription factor STAT1 binding provide a mechanistic hypothesis for 
their regulatory function in gene transcription and also further evidence that Brg-






Figure 4.2.5 Losing either Brg-1 or PML-II affects transcription factor STAT1 
recruitment at ISG promoters. (A) Hela cells were treated with 1000 unit/ml IFNα for 
the times indicated. (B) Hela cells were transfected with 125 pmol/ml control, PML-II or 
Brg-1 si RNA for 48 h, then treated with 1000 unit/ml IFNα for 6 h. Cells were then 
collected and equal aliquots of fixed chromatin were subjected to ChIP precipitation 
with normal IgG and STAT1 antibody. Precipitated chromatin DNA was assayed by 
SYBR green qPCR for ISG54, ISG56 and ISG15 promoter sequences. Results are 
presented as mean ± SD of technical triplicate. STAT1 binding during IFN stimulation 
was significantly (P<0.05) or highly significantly (p<0.01) increased over the t=0 value 
at all time points by Student t-test, panel A. The reduction in binding after specific PML 
or Brg-1 siRNA treatment was highly significant by the same test as indicated in B. 
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4.2.6 PML-II and Brg-1 cooperatively regulate Brg-1-dependent gene 
expression  
 
Having demonstrated that both PML-II and Brg-1 regulate ISGs transcription, it 
was asked next whether double knockdown of PML-II and Brg-1 would further 
enhance the inhibition effect on gene transcription, greater than knockdown of 
either one (Figure 4.5). As before, knockdown of either Brg-1 or PML-II alone 
significantly reduced the mRNA expression of a group of genes including IFNβ, 
ISG54, IFI27, ISG15 and GBP1, while the expression of ISG56 was less affected 
by depleting Brg-1. Depletion of both PML-II and Brg-1 further decreased the 
mRNA level of IFNβ, ISG54, IFI27 and GBP1 genes. This suggested that PML 
may play a role in Brg-1-containing transcriptional complex assembly or 
mediated-modification, or may collaborate with Brg-1 in gene transcription. 
However, an additive effect of double knockdown of Brg-1 and PML-II on the 
expression of ISG15 and ISG56 was not observed (Figure 4.2.6). These data may 
suggest the expression of these genes is less dependent on Brg-1, or the functions 
of PML-II and Brg-1 in this gene transcription are overlapping/redundant so that 




Figure 4.2.6 PML-II and Brg-1 cooperatively regulate Brg-1-dependent gene 
expression. HEK293 cells were treated with 125 pmol/ml PML-II, Brg-1, Control or 
both PML-II and Brg-1 siRNA for 48 h, and stimulated with poly(I:C) or IFNα for 16 h. 
mRNA expression levels were measured by SYBR Green qPCR. The values presented 
are relative to control siRNA with no-stimulation and are the mean +/- standard 
deviation of three technical replicates. Reductions in IFN-induced gene expression 
following specific siRNA treatment were all significant or highly significant by Student 
t-test. 
 
4.2.7 PML-II is physically associated with Brg-1  
To investigate the possible regulation mechanism of PML-II on Brg-1-containing 
SWI/SNF transcription complexes, A co-immunoprecipitation (co-IP) 
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experiments to test the interaction of PML-II and Brg-1 was carried out. To do 
this, Hela cells were transfected with a plasmid expressing Flag-tagged full-
length PML-II, PML-V or pCI-neo (empty vector control) and carried out 
immunoprecipitation experiments with anti-Flag-beads. Full-length PML-II 
could co-precipitate Brg-1 (Figure 4.2.7A). Strikingly though, the full-length 
PML-V isoform could also form a protein complex with Brg-1 (Figure 4.2.7A). 
Potentially, therefore both isoforms might interact with Brg-1 complexes via 
their distinct C-terminal domains. Alternatively, this binding to Brg1 might be 
mediated by the N-terminal RBCC structure found in all PML isoforms, or it 
might be that the binding to Brg-1 by PML-V is an indirect event,  mediated 
through the association of the tagged PML-V with endogenous PML isoforms 
possess direct binding ability for Brg-1 (e.g. PML-II), because all PML isoforms 
can bind to each other through their RBCC structures.  
To rule out/exclude the possibility that PML-V binding to Brg-1 is an indirect 
binding through the association with other PML isoforms, cells were transfected 
with plasmid expressing N-terminal RBCC deleted/truncated PML-II and PML-
V, named PML-II-RBCC and PML-V-RBCC. PML-II-RBCC had a strong 
ability to bind Brg-1 even though its transfection efficiency was lower compared 
to PML-V-RBCC, while PML-V-RBCC only showed a very weak association 
with Brg-1 (Figure 4.2.7 B). Interestingly, PML-II-ΔRBCC also specifically 
bound to transcription coactivator CBP while PML-V-RBCC failed to do this 
(Figure 4.2.7 B). Thus Brg-1 associates specifically with the PML-II C-terminal 
domain. 
The binding of endogenous PML-II with Brg-1 was also tested (Figure 4.2.7 C). 
In this experiment, both Brg-1 and PML-II antibodies were used for precipitation 
to test for interaction in both directions. As expected, Brg-1 antibody could 
precipitate PML-II protein. However, the reciprocal test could not detect this 
interaction as no Brg-1 was detected when PML-II antibody was used for the 
precipitation. This perhaps is because the specific PML-II antibody binding site 
in PML-II protein is occupied by Brg-1 so PML-II antibody could not pull down 
Brg-1; the test with exogenous expressed PML-II works because that used Flag 
antibody to precipitate rather than an internal PML epitope. The association of 
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both Brg-1 and PML-II with STAT1 was also observed, which is consistent with 
previous reports (Chen et al, 2015; Zhang et al, 2010). These results have shown 
that endogenous PML-II as well as ectopically expressed PML-II can physically 
interact with BRG1. Taken together, these data indicate that PML-II can interact 
with Brg-1 suggesting a possibility that the interaction regulates Brg1 functions 
in gene transcription.  
 
 
Figure 4.2.7 PML-II is physically associated with Brg-1.  (A) Hela cells were 
transfected with 250 ng/ml Flag-PML-II, Flag-PML-V plasmids or pCI-neo empty 
vector for 24 h, (B) Hela cells were transfected with 250 ng/ml Flag-PML-II-ΔRBCC, 
Flag-PML-V-ΔRBCC or pCI-neo empty vector for 24 h, then stimulated with poly(I:C) 
for 10 h, lysates prepared, immunoprecipitated with anti-Flag beads and precipitates & 
total lysates analysed for Flag-PML, Brg-1 or CBP or STAT1 by western blotting. (C) 
Confluent Hela cell were stimulated with poly(I:C) for 10 h, lysates prepared and 
aliquots immunoprecipitated with IgG, Brg-1 or PML-II antibody. Precipitates and total 




4.2.8 PML-II C-terminal ΔD fragment is essential for PML-II associated 
with Brg-1 and CBP  
In order to further map the functional fragments of PML-II which are responsible 
for binding to Brg-1, flag-tagged full length PML-II, PML-II ΔRBCC and a pre-
existing set of mutants which are further deleted in specific sequences from the C 
terminal domain (Leppard et al, 2009) were used to test their associate with Brg-
1. As is seen in Figure 4.2.8A, each of the PML mutants tested was efficiently 
expressed and could be precipitated by anti-Flag agarose beads, however the 
amount of Brg-1 co-precipitated with the various Flag-PMLs varied greatly 
indicating that some of the mutations had affected sequences necessary for Brg-1 
binding. PML-II and II ΔRBCC co-precipitated significant amounts of Brg-1 
(Figure 4.2.8B). However, Δm1Δm2 mutant was unable to co-precipitate Brg-1. 
The amount of Brg-1 co-precipitated was also greatly affected by mutation ΔB, 
Δ7 and ΔD. These results therefore show that PML-II residues 645–674, 
comprising the sequence deleted in Δm1 plus Δ7, are required for Brg-1 binding 
(Figure 4.2.8B). The binding of this panel of PML-II mutants with CBP was also 
tested, which can bind to all the PML isoforms through an interaction with 
sequences in the common N terminal domain. Interestingly, it was found that ΔD 
also disrupted sequences essential for PML-II binding with CBP, as very little 
CBP was precipitated from cells transfected by ΔD plasmid (Figure 4.2.8B). The 
CBP binding ability was also impaired with various degrees in the Δm1Δm2, Δ7 
and ΔB PML-II mutants (Figure 4.2.8B). This suggested the PML-II sequence 
required for Brg-1 binding is similar to that required for CBP binding. 
The specific association of PML-II with Brg-1 widens the regulation function of 
gene transcription by PML-II. Based on the results above, it can be hypothesised 
that PML-II regulates Brg-1 function by three possiblities: (1) directly regulating 
Brg-1 expression; (2) affecting Brg-1-containing complex formation; or (3) 






Figure 4.2.8 PML-II C-terminal ΔD fragment is essential for PML-II associated 
with Brg-1 and CBP. (A) The cartoon represents the unique C-terminal domain that 
defines PML-II (residues 571 – 829 of full-length PML-II), with the sequences deleted 
or altered in individual mutants indicated. (B) Hela cells were transfected with 250 
ng/ml Flag-PML-II, Flag-PML-II-ΔRBCC, Δm1, Δm2, Δm1Δm2, Δ8, Δ7, M1-1, ΔB, 
ΔC, ΔD plasmids or pCI-neo empty vector for 24 h, then stimulated with poly(I:C) for 
10 h, lysates prepared, immunoprecipitated with anti-Flag beads and precipitates & total 
lysates analysed for Flag-PML, CBP and Brg-1 by western blotting. (C, D) The 
precipitated protein bands of Brg-1 and CBP in (B) were quantified by image analysis 
using QuantityOne software (Biorad) and normalized to total expressed proteins. 




4.2.9  Knockdown of PML-II affects expression of some SWI/SNF subunits 
  
Firstly, the effect of knockdown of PML-II on Brg-1 expression was tested. As 
shown in Figure 4.2.9, the mRNA expression of Brg-1 was slightly increased by 
PML-II depletion under the conditions tested (Figure 4.2.9A). There was also no 
obvious decrease in Brg-1 expression at the protein level  by depleting PML-II 
(Figure 4.2.9B). Next, the expression of the other core enzymic subunit of 
SWI/SNF complex, BRM was also tested. Surprisingly, the mRNA expression of 
BRM was decreased by knocking down of PML-II (Figure 4.2.9C). This 
suggested a possibility that the expression of BRM-dependent genes can be 
regulated by PML-II via an effect on BRM expression.  
 
Although Brg-1 alone can remodel the chromatin, the addition of other core 
subunits of SWI/SNF complex, such as BAF155 and BAF47, will maximise its 
function (Euskirchen et al, 2011). PML-II might affect the expression of such 
non-enzymic components of SWI/SNF, thus affecting the stability or activity of 
the complex. Therefore, the effect of PML-II knock-down on mRNA levels for 
representive subunit BAF155 and BAF47 was also tested. The depletion of 
PML-II reduced BAF47 (Figure 4.2.9D) and BAF155 expression (Figure 4.2.9E) 
to similar extents. Interestingly, this effect was also similar to the reduction in  
BRM caused by reducing PML-II. These data suggest an effect of PML-II on 





Figure 4.2.9 Knockdown of PML-II affects expression of some SWI/SNF subunits. 
HEK293 cells were treated with 125 pmol/ml PML-II, Brg-1 or Control siRNA for 48 h, 
and stimulated with IFNα for 16 h. (A) Brg-1, (C) BRM, (D) BAF47 and (E) BAF155 
mRNA expression levels were measured by SYBR Green qPCR. The values presented 
are relative to control siRNA and are the mean +/- standard deviation of three technical 
replicates. (B) HEK293 cells were transfected siRNA as A, and stimulated with 
poly(I:C) for 16 h, and cell lysates were separated by 8% SDS-PAGE and subjected to 
western blotting for Brg-1 or GAPDH (loading control). Two tailed student t-test; * 




4.2.10 PML-II, Brg-1 and BAF155 is recruited to the promoter in response 
to IFNα stimulation 
To determine the effect of PML-II on Brg-1 recruitment to promoters, the 
binding of PML-II and Brg-1 itself at selected promoters was firstly tested by 
using IFNα stimulation at different time points. Compared to the level of STAT1 
and H3K4me3, the basal level of Brg-1 binding at the ISG54 promoters (input 
%) was much lower, similar to that of H3K9me3 and CBP (Figure 4.2.3 and 
4.2.5). IFNα stimulation increased Brg-1 binding somewhat but the level was 
still not as high as that of STAT1 and H3K4me3 (Figure 4.2.10A). 6 hours after 
stimulation the level of Brg-1 occupation at ISG54 promoter peaked, which is 2 
hours later than the peak binding of STAT1 and 1-2 hours earlier than other 
factors such as CBP and H3K4me3 (Figure 4.2.10A, 4.2.3 and 4.2.5).  
Given the fact that SWI/SNF remodeling complex can have alternative 
compositions, and BAF155 is one of the most important scaffold/component 
proteins in both Brg-1-containing and BRM-containing complexes, the kinetic 
binding of BAF155 at ISG54 and ISG56 gene promoters were tested. The level 
of BAF155 binding was higher than for Brg-1. The binding pattern of BAF155 
was very similar as that of Brg-1 but reached the highest level at 8 hours after 
stimulation then decreased after that (Figure 4.2.10 B and C). 
Given the interaction of PML-II with Brg-1 demonstrated earlier, the binding of 
PML-II to ISG promoters was also tested. IFNα stimulation increased 
endogenous PML-II recruitment to ISG54 promoter and reached the highest level 
at about 8-10 hours after stimulation, similar to CBP, H3K4me3 and BAF155, 2 
hours later than Brg-1 recruitment and 4 hours later than STAT1 DNA binding. 
As this PML-II signal was weak, the recruitment of exogenously expressed Flag-
PML-II was tested, which showed a similar temporal pattern with a clearer signal 




Figure 4.2.10 PML-II, Brg-1 and BAF155 are recruited to promoters in response to 
IFNα stimulation. Confluent Hela cells were stimulated with IFNα for 0, 2, 4, 6, 8, 10 h 
and then cells were collected and equal aliquots of fixed chromatin were subjected to 
ChIP precipitation with normal IgG, Brg-1, BAF155 and PML-II antibodies or Flag 
antibody, respectively. Precipitated chromatin DNA was assayed by SYBR green qPCR 
for testing (A) Brg-1 binding (B and C) BAF155, (D) PML-II and (E) PML-II-ΔRBCC 
binding at ISG54 or/and ISG56 promoter sequences. Results are presented as mean ± SD 
of technical triplicate. One tailed student t-test; * p<0.05, ** p<0.01.   
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4.2.11 Knockdown of PML-II decreases Brg-1 and BAF155 binding at gene 
promoter 
Next, whether knockdown of PML-II affects Brg-1 and BAF155 binding at gene 
promoters was tested. As shown in Figure 4.2.11, the depletion of PML-II 
decreased Brg-1 and BAF155 binding at ISG54 and IFITM3 promoters (Figure 
4.2.11 A). However, the removal of PML-II did not significantly reduce Brg-1 
recruitment at ISG56 promoter, and also had no effect on BAF155 binding at 
either ISG56 or GBP1 (Figure 4.2.11B). Why did PML-II fail to affect BAF155 
binding at these two promoters? Possibly this is because of individual ISG 




Figure 4.2.11 Knockdown of PML-II decreased Brg-1 and BAF155 binding at ISG 
promoters. Hela cells were transfected with 125 pmol/ml control, PML-II or Brg-1 si 
RNA for 48 h, then treated with 1000 unit/ml INFα for 6 h (Brg-1) or 8 h (BAF155), and 
then cells were collected and equal aliquots of fixed chromatin were subjected to ChIP 
precipitation with normal IgG, Brg-1 and BAF15 antibody respectively. Precipitated 
chromatin DNA was assayed by SYBR green qPCR for (A) ISG54, (B) IFITM3, (C) 
ISG56 and (D) GBP1 promoter sequences as indicated. Results are presented as mean ± 
SD of technical triplicate. One tailed student t-test; * p<0.05, ** p<0.01.   
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4.2.12 Different gene transcription/expression characteristics determines 
Brg-1 and BAF155 different binding pattern 
ISGs generally can be divided into two groups, namely, the immediate & early 
responsive genes, and the later responsive genes (Ramirez-Carrozzi et al, 2009; 
Ramirez-Carrozzi et al, 2006). To test whether the differential effect of PML-II 
depletion correlated with ISG class, the transcription/expression pattern was 
tested on various ISGs including ISG54 and ISG56, together with two additional 
ISGs: ISG15 and GBP1 (Figure 4.2.12). Expression of ISG54 was activated and 
reached the highest expression level 2 hours quicker than that of ISG15, ISG56 
and GBP1. This result confirmed that ISG54 belongs to the immediate & early 
responsive ISG class, while ISG15, ISG56 and GBP1 are from the later 
responsive class. This suggested that PML-II may have different influence on 
BAF155 recruitment patterns at promoters of these genes. As expected, the loss 
of PML-II indeed affected BAF155 binding at IFITM3 and ISG54 promoter and 
has no effect on GBP1 (Figure 4.2.11).  
Accordingly, it can be concluded that PML-II regulates SWI/SNF complex 
chromatin remodeling function by decreasing subunit protein expression (BRM) 











Figure 4.2.12 Different gene transcription/expression characteristics determines 
Brg-1 and BAF155 different binding pattern.  Confluent Hela cells were stimulated 
with IFNα for 0h, 1.5h, 3.5h, 6h, 8h, 10h, 12 and 16h, then total RNA was extracted and 
subject to SYBR-Green RT-qPCR testing for various gene. The data shown are relative 









4.3 Discussion  
4.3.1 ISG gene transcription and regulation by PML-II and Brg-1  
 
In this chapter, the regulation function of PML-II on SWI/SNF Brg-1-containing 
transcription complex and histone post-translation methylation modification was 
studied. Consistent with our and others’ previous reports, knockdown of either 
PML-II or Brg-1 decreased the expression of a large number of ISGs in response 
to IFN, including ISG54, ISG56, IFI27, IFI16 and GBP1 (Figure 4.2.2). 
Importantly, we also found that double-knockdown of PML-II and Brg-1 slightly 
enhanced the inhibition effect on the expression of these genes (Figure 4.2.6). 
This suggested a collaboration between PML-II and Brg-1 in gene transcription 
regulation.  
 
Based on the gene expression timecourse testing, it was found that the mRNA 
expression of ISG54 reached the highest level  at 6 hours after IFNα stimulation, 
then decreased gradually. This is consistent with characterization of primary-
responsive ISG genes (also named immediate-early genes). In contrast, the 
mRNA level of genes such as ISG15, ISG56 and GBP1 reached the highest level 
at 8 hours which is 2 hours later that that of ISG54 6 hours. This may suggest 
that these genes belong to the later gene class (also named secondary-responsive 
gene). This result is quite similar to previous observation that some genes 
responsed quickly while others responsed slowly (Ramirez-Carrozzi et al, 2006). 
The different expression profiles of these genes may suggest a different 
regulation pattern in transcription. This study may imply different regulation 
model for Brg-1 and BRM in early and later ISGs, which may be helpful for 
understanding why different patterns of Brg-1 binding and regulation were 
observed in different genes.  
The SWI/SNF remodeling complex in humans mainly includes the Brg-1-
containing complex and the BRM-containing complex. Brg-1 has about 76% 
identity in amino acids with BRM indicating that functional activity of these two 
complexes may be similar to some extent. Both Brg-1 and BRM are implicated 
in the regulation of ISGs expression, and previous studies have indicated that the 
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requirement for Brg-1 or BRM in ISGs expression is different. For example, a 
IFITM3 gene reporter construct can be activated by both Brg-1 and BRM, this 
suggested this gene needs the overlap function of Brg-1 and BRM (Liu et al, 
2002). In contrast, BRM is required by ISG56, IFITM3 and OAS1 for 
maintaining both basal and IFNα-induced expression (Lavigne et al, 2009), while 
Brg-1 is only partially required for ISG56 induction and unnecessary to maintain 
its basal expression. ISG15 expression is also less Brg-1 dependent (Liu et al, 
2002).  
In this study, the expression of ISG15, ISG56 and GBP1 was found reaching the 
highest level is about 2 hours later than that of the immediate-early genes such as 
ISG54 and IFITM3. This suggest Brg-1 and BRM may be responsible different 
in immediate-early and later ISG gene expression. Brg-1 is largely responsible 
for early/immediate ISG expression, while the later expressed genes are more 
likely regulated by BRM. In fact, biochemical assays have shown that the 
ATPase activity of Brg-1 is stronger than BRM (Kadam & Emerson, 2003). The 
difference of ATPase activity between Brg-1 and BRM might explain why early 
response gene induction, which is more likely regulated by Brg-1, is faster than 
slow response genes.  
Brg-1 and BRM differentially regulate immediate-early and later-responding 
gene transcription, this may suggest a sequential recruitment and synergy 
function between Brg-1 and BRM protein. It therefore can be proposed that Brg-
1 complexes quickly initiate early gene expression and leave the promoter, then 
BRM complexes are recruited after Brg-1 dissociate from the promoter and 
continue the remodeling process in the following time courses. Thus genes such 
as ISG54 and IFITM3 are more dependent on both Brg-1 and BRM, and their 
transcription can be started quicker by Brg-1 and maintained longer by BRM. In 
contrast the transcription of later genes like ISG15, ISG56 and GBP1 reaches the 
highest level later because they are less dependent on Brg-1 but more dependent 
on BRM. This may provide a mechanistic explanation for some cells retaining 
the overlapping function of Brg-1 and BRM-containing chromatin remodeling 
complexes, while others do not require Brg-1 (Kadam & Emerson, 2003; Liu et 
al, 2002; Ryme et al, 2009).  
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4.3.2 Association of PML-II with Brg-1 and TFs  
 
SWI/SNF exists as a multiple protein complex. In this study, PML-II was found 
to associate with Brg-1 of SWI/SNF complex and STAT1 in response to IFNα 
stimulation. Brg-1 was also found to bind STAT1 suggesting PML-II might form 
a complex with SWI/SNF complex and STAT1. However, it is not sure whether 
the association of PML-II with Brg-1 is a direct event or indirect interaction as 
the co-IP technique is a technique that uses target protein-specific antibodies to 
indirectly capture proteins that are bound to a specific target protein. It would be 
of interest to conduct a further test by using GST-pulldown technique, which 
tests specifically for direct interactions, to clarify this outstanding question in the 
future.  
In this study, the full-length PML-V isoform was also found to associate with 
Brg-1 under stimulation.  This was shown to be probably through an indirect 
binding with other PML isoforms via their common RBCC structure because the 
RBCC domain-deleted form of PML-V lost the ability to bind Brg-1 and CBP, 
while the equivalent RBCC-deleted form of PML-II retained binding Brg-1 and 
CBP. This is consistent with previous observations, and also suggested an 
important function of the C-terminal fragment of PML-II in the association with 
Brg-1. Subsequently, a further analysis was conducted on PML-II C-terminal 
functional fragments. PML-II C-terminal 645-695 sequence fragment, especially 
661-664 residue was necessary for this binding with Brg-1. Similarly, residue 
645-695 was also very important for PML-II binding with CBP. The specific 
association of PML-II with Brg-1 and CBP suggested PML-II could have a role 
in chromatin remodeling/modification.   
To further study the effect of PML-II on SWI/SNF complex stability/integrity, 
some co-IP experiments was performed to test whether the knockdown of PML-
II impaired the interaction of Brg-1 with subunit BAF155 or transcription factor 
STAT1. However, the experimental background was always very high, so that it 
was not possible to make a conclusion. The reasons for this may be the 
interaction among SWI/SNF subunits is very tight, making SWI/SNF a very 
large molecular size pre-existing complex, so it is hard to demonstrate impaired 
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association among these proteins during transient knock-down experiments. 
Together, although it could not be concluded the effect of depletion of PML-II 
on the SWI/SNF complex stability, the observation that PML-II physically 
associated with Brg-1, STAT1 and CBP, suggesting PML-II is certainly involved 
in Brg-1-related transcription. This interaction between PML-II and Brg-1 
suggested their collaboration on gene transcription.  
4.3.3 Timing, order and interdependence of protein recruitment and histone 
modification at ISGs  
 
In this study, as expected, STAT1 was not bound to ISG promoters in inactivate 
genes, however its binding was increased greatly by induction of IFNα, this 
supported that STAT1 activation is required for ISG gene expression as has been 
shown previously (Darnell, 1997; Darnell et al, 1994). Importantly, the 
enrichment of STAT1 binding at these promoters was closely associated with the 
mRNA expression from these genes, which was 1-2 hour later to reach the 
highest level than that of STAT1 binding. Similar to STAT1 association, the 
level of H3K4me3 modification at ISG promoters was also greatly increased by 
IFNα induction. Conversely, the level of H3K9me3 at promoters was decreased 
by IFNα. Interestingly, CBP binding was also increased which is very similar as 
that of H3K4me3.  
 
It is notable that the temporal course of H3K4me3 modification was different in 
different genes. In ISG54 (early gene), H3K4me3 increased slowly in the first 6h 
after IFNα treatment and reached the highest level at 8 hours and decreased after 
then, while H3K4me3 in the ISG56 promoter underwent a trend of decrease 
during that period then rebounded to the highest level at 8h then quickly 
decreased. Loss of H3K9me3 was observed in ISG54 and ISG56 promoters upon 
IFNα stimulation that continued for the initial 6 hours after which amounts 
returned to those in unstimulated cells/basal level. The promoter specific 
differences of H3K4me3 disposition most likely is correlated with the 
differences, already discussed, in the way these genes interact with and are 
regulated by different forms of SWI/SNF complex containing the enzymatic core 




Similar to STAT1, CBP and H3K4me3 association with the promoters, the 
binding of PML-II, BAF155 and Brg-1 at ISG promoters was also increased by 
IFNα stimulation, and the maximum level of PML-II and BAF155 present at 
these promoters was at 8 h after stimulation, while the highest enrichment level 
of Brg-1 at the promoters was variable and dependent on the gene identity: for 
example, in ISG54 (early gene), Brg-1 binding reached its highest level at 6 hour 
after stimulation.  
 
Taken together, the time post-stimulation that all these factors are recruited to 
promoter at the highest level is 2 hours late than the time of STAT1 DNA 
binding reaching its peak (4h-6h) and the induction of the highest amount of 
mRNA expression (6h-8h). This indicates that the maximum STAT1 binding is 
two hours earlier than that of the whole transcriptome assembly. The time of 
highest gene transcription level is consistent with the time of the whole 
transcriptional complex assembly, at 6h (early gene) or 8h (later gene) after 
stimulation. This suggested that transcription factor STAT1 activation and DNA 
binding is the most important determinant for transcription initiation of the genes 
tested here. However, the highest level of gene transcription requires full 
transcriptional complex assembly. 
4.3.4 Sources of variation in ChIP signal strength for histone marks and 
proteins bound at ISG promoters  
 
In this study, the occupation level of STAT1 and H3K4me3 at the promoter was 
very high while, in contrast, the binding level of Brg-1 was very low; similar 
phenomena were observed in CBP, BAF155 and PML-II binding. The variation 
of % precipitation at target gene promoters by different antibodies is unlikely to 
be due to variation in the expression of those proteins as the assay effectively 
reports on events at a chosen promoter across a large number of cells, within 
which there is unlikely to be large fluctuations in the expression of any given 
protein. Instead, this might reflect real differences in the proportions of target 
promoters carrying these modifications or bound proteins, or it might reflect 
technical differences such as antibody affinity. We have addressed several 
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possibilities that may contribute to this lower binding signal. For example, to 
discount the possibility that the antibody is not effective for immunoprecipitation 
experiments and to reduce nonspecific pulldown of other proteins, different 
antibodies was tested and the cell lysates was also precleared by salmon sperm 
affiliated beads to reduce the nonspecific binding. The gentle manipulation was 
also tried to avoid any interactions of Brg-1 with chromatin being disrupted by 
harsh washing buffers. Despite these efforts, the background signal in Brg-1 
precipitations was very high but Brg-1 binding signal was very low. Potentially, 
the target epitope on Brg-1 might be masked as a consequence of variation with 
local experimental environments or in some complexes. Also, the affinity of 
SWI/SNF with DNA may also affect the ChIP efficiency. Although Brg-1 
protein has a bromo domain, this motif has nothing to do with binding to 
promoter directly. The binding of SWI/SNF to the promoter requires other 
subunits of the SWI/SNF or DNA-binding proteins such as STAT1. This 
suggests that the binding of Brg-1 to DNA is via it association with other 
proteins.  
Brg-1 might be working at more distant sites and have long-range effects on gene 
transcription. It has been described that Brg-1 has a long-range effect at the 
CIITA locus (Pattenden et al, 2002). One experiment was also carried out and 
found Brg-1 can bind not only at promoters, but also at far-downstream regions 
from the promoter with the same weak level, but the effect on upstream regions 
was not checked. It is possible that Brg-1 binding ability is stronger at the 
upstream region far from promoter.  
In agreement with our observation, Ni (Ni et al, 2005) conducted an experiment 
testing the ChIP efficiency, and showed that histone has the most efficient DNA 
binding, followed by DNA-bound factors such as transcription factor and Pol II, 
the lowest binding efficacy being for cofactors that are recruited via protein-
protein interaction. This is completely consistent with my results that the histone 
H3K4me3 has the highest binding efficiency (input %), next was STAT1, with 
the lowest binding proteins including PML-II, CBP, Brg-1 and BAF155 that 
associate with chromatin by protein: protein interactions.    
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4.3.5 Possible binding and regulation patterns of Brg-1 and PML-II  
 
Various SWI/SNF complex (Brg-1) DNA binding models have been proposed, 
including the constitutive binding of SWI/SNF complex on an inactive ISG 
promoter to make it in a loose configuration, which allows STAT1 rapidly to 
target and bind the promoter upon stimulation, and so to activate transcription. 
That is, without prior chromatin remodeling by SWI/SNF complex, STAT1 may 
not efficiently bind the ISG promoter to induce gene transcription. Thus 
SWI/SNF was thought to be bound to promoter in silent genes independent of 
STAT1 (Ni et al, 2005), and that IFNα stimulation was not required for the BAF 
complex to bind (Cui et al, 2004; Liu et al, 2002). In other cases, specific DNA 
binding factors may be relevant to SWI/SNF recruitment. It was reported that 
SWI/SNF components can be detected in a multiprotein complex that contains 
both histone methyltransferases and HATs (Nakamura et al, 2002). For example, 
SWI/SNF and CBP/p300 interact with some DNA-binding proteins such as c-
MYC, and Pol II in untreated cells, each of these factors is present at CIITA 
promoter IV (pIV) at detectable levels. Thus, these DNA-binding proteins may 
help tether Brg-1 and HATs to the silent pIV (Ni et al, 2005),   
 
Data in this study firmly support the idea that STAT1 complexes play a role in 
constitutive Brg-1 recruitment to promoter and that is required for gene fully 
transcription/expression. One possibility is that the low level of SWI/SNF 
complex can be detectable in some gene promoters, for the maintaining the basal 
expression level of some early-responding gene, however, the gene highly 
activation and product expression must need STAT1 participation. It have been 
observed in the present study that STAT1 activation (30min phosphorylation) 
and recruitment to the promoter (4-6h) occur significantly earlier than the 
recruitment of Brg-1 and BAF155, also some other transcription coactivators. 
From this it can be concluded that the recruitment of Brg-1 to the promoter 
regions of selected ISGs and the activation of Brg-1 activity require additional 
transcription factors. Further studies are required for providing insight into the 




4.3.6 Why does knockdown of PML-II and Brg-1 have less effect on 
H3K4me3 at ISG promoters? 
 
H3K4me3 is often considered to be a positive mark for transcription. The 
enrichment of H3K4me3 at ISG promoters was greatly increased by IFNα 
stimulation and the dynamics of H3K4me3 modification were closely matched to 
those of the other transcription-related factors including BAF155, CBP and 
PML-II (8h highest level). Depletion of PML-II or Brg-1 affected the binding of 
STAT1 and CBP and increased the level of H3K9me3 modification. However, 
the amount of H3K4me3 at these promoters was less affected by depleting PML-
II or Brg-1, whereas it might have been predicted to be reduced. This is probably 
because H3K4me3 is not an essential component of an actively transcribed gene 
(Howe et al, 2017) and PML-II and Brg-1 depletion only have significant effects 
on transcription factor recruitment and of other proteins whose recruitment is 
transcription factor dependent. This may also because other pre-existing histone 
modifications such as acetylation on H3K4 at this site affect H3K4me3 
enrichment/deposition at a promoter (Howe et al, 2017). Collectively, this result 
further emphasized a key role of STAT1, acting as a bridge in PML-II and Brg-1 
recruitment and exerting regulation function on some other transcription-related 
factors. This suggested additional studies are required to clarify this question in 
the future.   
4.3.7 How PML-II and Brg-1 affect the complex through STAT1 recruitment  
 
Our and others’ previous studies have suggested the recruitment of PML-II and 
Brg-1 at a promoter was STAT1 dependent and both proteins exerted functions 
via STAT1. The highest level of Brg-1 and PML-II enrichment at the promoter 
was 6h and 8h, respectively, while STAT1 DNA binding started from 2 hours 
and reached the highest level at 4h or 6h (depending on specific gene 
characteristics), which is 2 h earlier than Brg-1 and PML-II binding. In this case, 
it can be asked how do the later-recruited PML-II and Brg-1 proteins affect the 
earlier-arrived STAT1 binding, since PML-II or Brg-1 reduction clearly reduces 
STAT1 promoter binding. In fact, it can be seen that the formation of the whole 
transcriptional complex including PML-II, Brg-1, CBP and BAF155 was 
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maximal at about 8 hours after stimulation. At this time point, the level of 
STAT1 at the promoter was still very high compared to the basal level, although 
the level had started to decrease from the peak. This means there is a period 
when both Brg-1 and PML-II coexist with STAT1 at the promoter and may 
regulate its binding there.  
 
Although depletion of either Brg-1 or PML-II reduced STAT1 binding at 
promoters, both proteins may function differently in the process. Depletion of 
Brg-1 impaired chromatin structure remodeling which would certainly increase 
the difficulty of STAT1 binding and thus inhibit STAT1-activated transcription. 
However, PML-II may function as scaffold protein for transcription complex 
formation. Therefore the knockdown of PML-II may impair the stability and 
integrity of the whole complex. Moreover, the depletion of PML-II decreased the 
expression of core SWI/SNF subunits such as BRM and BAF47 and could thus 
result in secondary impairment of the whole transcriptional complex through 
reduced SWI/SNF activity. This could then eventually affect STAT1 DNA 
binding. 
4.3.8 The effect of PML-II on SWI/SNF complex and Brg-1/BAF155 
recruitment 
 
In this study, it has been demonstrated PML-II regulate the binding of Brg-1 and 
BAF155 at ISG promoters, however, it is notable that the influence of PML-II on 
these genes is not equal. PML-II has a stronger effect on Brg-1 and BAF155 
binding at promoters of early genes such as ISG54 and IFITM3, while it has 
relative less effect on later genes including ISG56 and GBP1 (Figure 4.9A). 
Consistently, the dual-knockdown of Brg-1 and PML-II also showed the 
difference between earlier gene ISG54, and also IFNβ, and later genes such as 
ISG15 and ISG56. It can be seen that knockdown of PML-II further inhibits the 
expression of IFNβ and ISG54 by depleting Brg-1, while this effect was not 
observed in the later genes ISG15 and ISG56 (Figure 4.5). Considering the 
transcription of early gene is more likely regulated by BRM and Brg-1 (most 
likely in combination), while the expression of later gene is less dependent on 
Brg-1 (probably by BRM alone), it is not surprising that there is a smaller effect 
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of knockdown of PML-II on Brg-1 and BAF155 binding at promoters of these 
later response genes including ISG56 and GBP1 (Figure 4.2.11).  
Collectively, these results suggest that the expression of the less Brg-1- 
dependent later genes may be more likely dependent on BRM activity, and 
therefore BRM may be the main subunit regulating their transcription. On that 
basis, knockdown of PML-II should have a significant effect on BRM binding at 
these promoters and this should be tested in the future.  
Beside the effect of PML-II on Brg-1 and BAF155 binding at promoter, we have 
also observed that the loss of PML-II affected BAF47 and BRM gene expression. 
This suggested an alternative way for PML-II to exert a regulation function on 
SWI/SNF complex, because BAF47 is another important core subunit of the 
SWI/SNF chromatin remodeling complex and BAF47 down-regulation 
influences Brg-1 and BRM stability (Cui et al, 2004). The decreased expression 
of BAF47 and BRM would affect complex stability and integrity thus the 
binding at a promoter. The decreased expression of BRM due to depleting of 
PML-II is likely to impair BRM binding and BRM-containing complex stability. 
Therefore, regulating BAF47 and BRM expression by PML-II may also partly 
contribute to the influence on SWI/SNF complex function. Together, I conclude 
that PML-II regulates SWI/SNF remodeling complex function by affecting core 
subunits expression and/or its promoter binding.  
4.3.9 Summary  
 
In this chapter further evidence have been provided on PML-II functions in gene 
transcription. PML-II can form a complex with various transcription-related 
proteins including chromatin remodeling complex subunit Brg-1, transcription 
factor STAT1 and coactivator CBP, and these interactions are mediated by the 
PML-II C-terminal fragment. Depletion of PML-II impaired the binding of Brg-
1, BAF155, STAT1 and CBP to ISG promoters. The SWI/SNF complex 
chromatin remodeling function was further affected by PML-II through 
downregulated levels of subunits BAF47 and BRM. PML-II and Brg-1 also 
demonstrated regulation function on histone H3K9me3 enrichment/deposition 
but had no effect on H3K4me3 recruitment. This suggested that PML-II is 
required for forming and stabilizing the whole transcriptional complex and hence 
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the depletion of PML-II impaired transcriptional complex stability and hence the 

























Chapter 5 PML-II affects ERK and AKT signal 





















Type I IFNs elicit pleiotropic biological effects including anti-virus, modulating 
immune responses and anti-tumour effects. Type I IFNs have been used for the 
treatment of several types of haematological malignancies and solid tumours 
(Ferrantini et al, 2007; Rizza et al, 2010). The expression products of a group of 
ISGs are thought to be the primary effectors that mediate the IFN antitumor 
function. Many ISGs have been identified that are related to this biological 
response, for example, classical ISG15 (Zhou et al, 2017), ISG54 (Reich, 2013; 
Stawowczyk et al, 2011), OAS1 and XAF-1 (XIAP associated factor-1), CD95 
(Fas/APO-1), PML and RIDs (regulators of IFN induced death) (Chawla-Sarkar 
et al, 2003). The TRAIL/Apo2L (tumor necrosis factor-related apoptosis-
inducing ligand) was also demonstrated to be an important effector required for 
IFNα-mediated growth inhibition and apoptosis in myeloma and hepatocellular 
carcinoma (Crowder et al, 2005; Herzer et al, 2009). Moreover, the expression 
level of PUMA, a p53-dependent gene, was also increased in response to IFNα 
stimulation in human myeloma cells suggesting a possibility of PUMA related to 
IFNα-induced apoptosis (Gómez-Benito et al, 2007).  
 
Besides the increase of pro-apoptotic protein expression by IFNα stimulation, the 
inhibition of pro-survival signaling pathways such as ERK and AKT is also 
regarded as an important mechanism for IFNα-mediated antitumor function. 
IFNα treatment inhibited ERK signaling in transformed T cells and monocytes 
(Romerio et al, 2000). IFNα also transiently diminished the phosphorylation of 
both ERK and MEK in hepatocellular carcinoma (HCC) cell lines suggesting an 
inhibition on this pathway (Inamura et al, 2005). Recently, IFNα inhibition on 
AKT signaling was also observed in human cervical cancer cells (Ethiraj et al, 
2016). PML, a tumour suppressor protein, has also been demonstrated to be 
involved in cell proliferation and apoptosis. The expression level of PML was 
low in various cancer cells compared to normal cells, and the deficiency of PML 
likely leads to tumorigenesis (Gurrieri et al, 2004; Trotman et al, 2006). The loss 
of Pml gene in a mouse model markedly accelerates tumour onset, incidence and 
progression (Trotman et al, 2006). Cells from PML-deficient mice show severe 
apoptotic defects, including a strongly decreased sensitivity to death receptor-
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mediated apoptosis (Wang et al, 1998). It has been suggested that PML prevents 
cancer by inactivating nuclear AKT activity (Trotman et al, 2006).  
 
Several studies have shown that PML is required for the efficient induction of 
apoptosis induced by type I and II IFNs (Quignon et al, 1998; Wang et al, 1998). 
Moreover, growth inhibition effects of IFNα in myeloma cells correlated with the 
presence of PML (Crowder et al, 2005). IFNα-induced apoptosis in 
hepatocellular carcinoma also involves PML (Herzer et al, 2009). However, the 
exact mechanism remains to be completely understood. Recent work in our 
laboratory demonstrated that PML-II regulates the type I IFN response and ISGs 
expression (Chen et al, 2015). This suggested that PML-II may also be involved 
in IFNα-mediated apoptosis. The purpose of this chapter is to dissect the role of 
PML-II in pro-survival ERK and AKT signaling pathway activation and IFNα-
mediated apoptosis. 
 
5.2 Results  
 
5.2.1 Knockdown of PML-II downregulates anti-apoptotic ISGs expression  
 
To investigate the biological role of PML-II in IFNα-induced apoptosis, the 
expression of PML-II itself in response to IFNα stimulation was studied. The 
Pml gene is an ISG because its promoter contains ISRE and GAS element 
sequences that make it possible for activation by IFN stimulation (Lavau et al, 
1995; Stadler et al, 1995). As expected, the expression of PML-II was greatly 
increased and reached the highest level at 4 hours after stimulation (Figure 5.2.1 
A). The expression level of PML protein is closely related to the induction of cell 
death and PML is one of the important ISG proteins that mediates IFN apoptosis 
function (Chawla-Sarkar et al, 2003; Quignon et al, 1998; Wang et al, 1998). The 
elevated expression of PML-II after IFN treatment may suggest a direct 
contribution of PML-II in IFNα-induced cell apoptosis. Importantly, the mRNA 
level of PML-II was reduced to undetectable when cells were treated with PML-
II specific siRNA, and this inhibitory effect was not overcome by IFNα 
stimulation (Figure 5.2.1 A). Next, ISG15, ISG54 and OAS1 mRNA was 
117 
 
detected, expression of which was reportedly related to cell apoptosis (Reich, 
2013; Stawowczyk et al, 2011; Zhou et al, 2017). Similar to PML-II, the 
expression of these genes was greatly increased by IFNα stimulation, and the 
level of ISG15 and ISG54 was greatly decreased by depleting PML-II. The 
expression of OAS1 was not so severely decreased as ISG15 and ISG54 but was 
still significantly decreased due to the loss of PML-II (Figure 5.2.1 B, C and D). 
This suggested that PML-II participates in IFNα-induced apoptosis probably 




Figure 5.2.1 Knockdown of PML-II decreased pro-apoptotic protein 
expression. 1×105 Hela cells were plated at 24-well culture plate and grown to 30-50% 
confluence then transfected with 125 pmol/ml PML-II siRNA or control siRNA for 48 h. 
Cells were stimulated with 1000 U/ml IFNα and samples were collected at described 
time points. The mRNA levels of genes were measured by SYBR Green qPCR. The 
mRNA levels of (A) PML-II, (B) ISG15, (C) ISG54 and (D) OAS1 were quantified 
relative to GAPDH, based on Ct difference performed according to the “ΔΔCt” method, 
and were then normalized to the level in control siRNA-treated, unstimulated cells. 
Results are presented as mean ± SD of technical triplicate experiments. One tailed 




5.2.2 Knockdown of PML-II decreases IFNα-induced TRAIL expression 
  
Besides the expression of classical ISGs, the direct induction of death receptor 
proteins such as TRAIL by IFNα and consequent activation of the extrinsic 
apoptosis pathway was also reported as one of the important means by which 
IFN induced cell apoptosis in melanoma and multiple myeloma (Crowder et al, 
2005). In this study, the expression level of TRAIL was also observed quickly 
induced by IFNα stimulation at both mRNA level and protein level in Hela cells 
(Figure 5.2.2 A-C). The knockdown of PML-II greatly decreased the expression 
of TRAIL at both the mRNA and protein level (Figure 5.2.2 D-F). This result is 
consistent with a previous report that depletion of total PML downregulates 
TRAIL expression in hepatoma cells (Herzer et al, 2009) and suggests that PML-
II is (one of) the most important isoforms that regulates IFNα-induced TRAIL 
expression. The regulation of IFNα-induced TRAIL expression suggests the 





Figure 5.2.2 Knockdown of PML-II decreases IFNα-induced TRAIL expression.  
1×105 HeLa cells were cultured in 24-well-plates and grown to 30-50% confluence then 
stimulated by 1000 U/ml IFNα and collected at different time points. Cell pellets were 
processed for total mRNA and protein, then analysed for TRAIL by qPCR (A) and WB 
(B), respectively. (C) The WB bands in panel B were visualized and quantified with an 
Odyssey system (Pierce). (D-E) Hela cells were transfected with 125 pmol/ml PML-II 
siRNA or control siRNA for 48 hours then stimulated by 1000 U/ml IFNα and collected 
at different time points for testing mRNA (D) and protein (E) expression by SYBR 
Green qPCR or WB, respectively. One tailed student t-test; * p<0.05, ** p<0.01. (F) The 




5.2.3 Knockdown of PML-II reduces IFNα-induced PUMA expression  
 
In addition to the extrinsic apoptosis pathway, the mitochondrial-mediated 
intrinsic apoptosis pathway is also essential for cell apoptosis. PUMA is one of 
the important pro-apoptotic proteins of the mitochondrial pathway. 
Overexpression of PUMA resulted in an extremely rapid and profound apoptosis 
in colorectal cancer cells (Yu et al, 2001). IFNα treatment increased the level of 
PUMA in multiple myeloma (MM) (Gómez-Benito et al, 2007). Therefore, the 
effect of IFNα stimulation on PUMA expression was tested in HeLa cells. It was 
found that the transcripts of pro-apoptotic PUMA and BAK were induced 
following IFNα treatment although this induction was very much less than that of 
ISGs and TRAIL (Figure 5.2.3 A-C). However, IFNα stimulation had no effect 
on the expression of BCL-2 family pro-survival proteins such as Bcl2 and Bcl-
xL (Figure 5.2.3 D and E). Similar to other ISGs, the depletion of PML-II 
significantly decreased the expression of PUMA at the mRNA level (Figure 5.2.3 
B) and protein level (Figure 5.2.3 F and G).  
 
Collectively, the observations that PML-II regulates both IFNα-induced PUMA 
and TRAIL expression suggested that PML-II is an important 
participant/regulator in both mitochondrial-mediated apoptosis (PUMA) and 





Figure 5.2.3 Knockdown of PML-II decreases IFNα-induced PUMA and BAK 
expression. (A) 1×105 HeLa cells were seeded in 24-well-plates and grown to 80% 
confluence then stimulated by 1000 U/ml IFNα at different time points, samples was 
collected, the relative expression of PUMA by SYBR-Green PCR. (B-F). HeLa cells 
were cultured as (A) and when grown to 30-50% confluence, cells were transfected with 
125 pmol/ml PML-II siRNA or control siRNA for 48 hours then stimulated by 1000 
U/ml IFNα. At different time points, the relative mRNA expression of (B) PUMA, (C) 
BAX, (D) BCL2 and (E) BCL-XL was tested by SYBR-Green qPCR. One tailed student 
t-test; * p<0.05, ** p<0.01. (F) PUMA protein level was detected by WB. (G) The 




5.2.4 PML-II regulates transcription factor p53 and STAT1 expression and 
activation  
 
Next, the mechanism of how PML-II regulates the transcription of these pro-
apoptotic genes was investigated. Transcription is strictly regulated by specific 
transcription factors. STAT1/2 is the most important transcription factor for ISGs 
expression by binding to the ISRE element in ISG promoters. PUMA is a well-
known p53-dependent gene but it can also be induced in response to IFNs 
(Gómez-Benito et al, 2007). The TRAIL promoter sequence also contains 
various binding sites for the recruitment of TFs such as p53 and NF-κB, but also 
has both ISRE and GAS element sequences (Wang et al, 2000). Therefore the 
effect of IFNα and PML-II depletion on p53 and STAT1 expression and 
activation was tested. The expression level of STAT1 was gradually increased by 
IFNα which is consistent with previous report that STAT1 is an ISG (Figure 
5.2.4 A-C) (Lehtonen et al, 1997; Matikainen et al, 1999). The phosphorylation 
level of STAT1 was undetectable in unstimulated HeLa cells, however, upon 
stimulation by IFNα the level of p-STAT1 was quickly and greatly increased to 
the highest level at 30 minutes after stimulation (Figure 5.2.6A). It then gradually 
decreased in the following hours but still remained at a relatively higher level 
than the non-stimulated control (Figure 5.2.4 A, B, F and G). Interestingly, the 
total level of STAT1 was slightly decreased by depleting PML-II (Figure 5.2.4 A 
and B) and consequently the level of p-STAT1 was also decreased (Figure 5.2.4 
F and G). This is probably because STAT1 itself is an ISG, and hence its 
expression is regulated by PML-II.  
 
A previous report showed that in mouse embryonic fibroblasts (MEFs), IFNα/β 
stimulation could induce p53 expression but could not induce p53 activity 
(Takaoka et al, 2003). In HeLa cells, p53 expression level is low, because of the 
presence of the human papillomavirus E6 protein, and the phosphorylation level 
of p53 was undetectable in unstimulated HeLa cells (Figure 5.2.4 A and F). IFNα 
stimulation did not apparently increase p53 expression but greatly increased p-
p53 level (Figure 5.2.4 F). This observation is different from the previous report 
of Takaoka (Takaoka et al, 2003), probably because the cell type and IFN 
utilized in the two studies are different. The earlier study used MEF cells and 
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IFN-β stimulation, while in my study, HeLa cancer cell was used and stimulated 
with IFNα.  
 
Knockdown of PML-II decreased the expression of p53 at the mRNA and 
protein levels, while there was no obvious effect of depleting PML-II on p53 
phosphorylation (Figure 5.2.4 E, F and H). In this case, how could the 
transcription and expression of PUMA be significantly affected by depleting 
PML-II? This may be because the phosphorylation of p53 is not essential for 
PUMA gene transcription but rather that other post-translational p53 
modifications such as acetylation determine p53 activation and p53-dependent 
gene transcription. Altogether, these data suggest that regulation of transcription 
factor p53 and STAT1 expression and/or their post-translational modification 
may be one of the mechanisms by which PML-II regulates ISGs, TRAIL and 





Figure 5.2.4 PML-II regulates transcription factor p53 and STAT1 expression and 
phosphorylation. (A) 1×105 Hela cells were seeded into 24-well-plates and grown to 
30-50% confluence, transfected and stimulated as Figure 5.2.3 F, then protein detected 
for p53 and STAT1 by WB. (B) Protein bands of total STAT1 in (A) were quantified 
with an Odyssey system (Pierce), normalized to internal control GAPDH, and the value 
was presented relative to control siRNA without stimulation. (C) HeLa cells were 
treated as Figure 5.2.2B, and the level of phosphorylated STAT1 was tested by WB. (D) 
Protein bands of total p53 in (A) were quantified as in (B). (E) The mRNA level of p53 
in Hela cells treated as in (A) was analyzed by SYBR Green qPCR. (F) 1×105 HeLa 
cells were cultured in 24-well-plates to 80% confluence and stimulated with 1000 U/ml 
IFNα then, at the time points shown, phospho-STAT1 and phospho-p53 were detected 
by WB. (G, H) Protein bands in (F) of phospho-STAT1 (G) and phospho-p53 (H), were 




5.2.5 PML-II affects transcription factor binding at gene promoters  
 
We recently demonstrated that PML-II can bind to various TFs and affect their 
recruitment at gene promoters (Chen et al, 2015). Therefore the effect of PML-II 
on p53 and STAT1 binding at these pro-apoptotic gene promoters was tested. As 
expected, IFNα stimulation increased p53 binding at PUMA, and STAT1 binding 
at ISG54 and OAS1 gene promoters. The knockdown of PML-II considerably 
decreased STAT1 binding at ISG54 and OAS1 gene promoters. This is 
consistent with our previous observation in ISG15 and ISG54 genes (Chen et al, 
2015). Similarly, p53 binding at the PUMA promoter was also significantly 
affected by depletion of PML-II. Taken together, these results indicated that 
PML-II regulates expression of this pro-apoptotic protein probably through 
affecting TFs expression, activation or DNA binding. This provided a 




Figure 5.2.5 Knockdown of PML-II affects p53 and STAT1 binding at gene 
promoters. 1×106 HeLa cells were cultured in 10 cm dishes and grown to 30-50% 
confluence, then transfected with 125 pmol/ml PML-II or control siRNA for 48 h, and 
stimulated with 1000 U/ml IFNα for 8h, ISG54 (A) or OAS1 (B) and for 4 h, PUMA 
(C), then chromatin was subjected to ChIP with STAT1 and p53 antibodies. Precipitated 
DNA was assayed for ISG54, OAS1 and PUMA promoter sequence by SYBR Green 
qPCR. Results shown are the means ± SD of technical triplicate experiments. One tailed 




5.2.6 IFNα inhibits AKT signaling but has no effect on ERK signaling in 
HeLa cells 
 
ERK and AKT signaling pathways are essential for cancer cells acquiring 
proliferation and survival signaling. Inhibiting both pathways accordingly 
promotes cell apoptosis. As discussed in section 5.1, previous studies have 
shown that IFNα can reduce both ERK and AKT signaling, therefore the effect 
of IFNα on these signaling pathways in the context of PML-II depletion was 
tested. Initially, the effect of IFNα on these pathways was characterized in HeLa 
cells. As shown in Figure 5.2.6 A, upon stimulation of Hela cells by IFNα the 
phosphorylation level of STAT1 was quickly increased, suggesting stimulation 
was successfully. However, IFNα stimulation did not transiently alter p-ERK 
level in the first hour (Figure 5.2.6 A). There was no apparent change in ERK 
phosphorylation in the following several hours, and even after 24 or 72 hours 
exposure to IFNα at the concentrations of 1000 U/ml and 5000 U/ml (Figure 
5.2.6 B, C and E). This visual impression was confirmed by band quantitation 
relative to the loading control (Figure 5.2.6 D and F). Similar to p-ERK, the 
phosphorylation level of MEK, the upstream signaling component of the ERK 
pathway was also less affected by IFNα stimulation (Figure 5.2.6 C-F). 
 
Similar to its lack of effect on total ERK, IFNα stimulation did not change the 
total level of AKT. However, IFNα treatment inhibited AKT phosphorylation in 
a dose-dependent pattern after 24 hours IFNα treatment. This inhibitory effect on 
AKT phosphorylation was also observed with a 72 hours IFNα stimulation 
(Figure 5.2.6 E and F). This is consistent with the recent observation that IFNα 
inhibited AKT signaling in human cervical cancer cells (Ethiraj et al, 2016). 
Altogether, these data demonstrated that IFNα inhibits AKT pro-survival 
signaling in HeLa cells and may suggest that inhibition of the AKT pathway by 








Figure 5.2.6 IFNα stimulation decreases AKT but not ERK signaling pathway 
activation. (A-B) 1×105 HeLa cells were cultured in 24-well-plates and grown to 80-
100% confluence, then stimulated with IFNα at 1000 U/ml, cells were collected at the 
described time points and lysed for detecting appropriated proteins by WB. (C) HeLa 
cells were cultured to 30-50% confluence and stimulated with 1000 U/ml or 5000 U/ml 
IFNα or no stimulation, for 24 h, then cells were lysed for WB testing. (D) ] 
he graph shows the quantification of WB bands in (C) by using the Odyssey system 
(Pierce), normalized to GAPDH and expressed relative to non-IFNα stimulation.  (E) 
HeLa cells were cultured as (C) and stimulated with IFNα for 72 h. (F) The graph shows 




5.2.7   Knockdown of PML-II enhances ERK and AKT signaling 
 
Given the biological role of PML in cancer cell proliferation and apoptosis 
(Crowder et al, 2005; Herzer et al, 2009; Wang et al, 1998), the effect of PML-II 
depletion on ERK and AKT signaling pathways was tested.  The knockdown of 
PML-II increased ERK phosphorylation level, suggesting an enhancement of 
ERK signaling (Figure 5.2.7 A). To further confirm this, the expression of ERK-
dependent genes c-Fos and c-Myc was tested. As expected, the depletion of 
PML-II indeed upregulated the expression of these ERK-dependent genes 
(Figure 5.2.7 B). The phosphorylation level of AKT was also increased by 
depleting PML-II (Figure 5.2.7 A); this is consistent with a previous report that 
PML prevents cancer by inactivating p-AKT inside the nucleus (Trotman et al, 
2006). Moreover, the depletion of PML-II also increased the phosphorylation 
level of p70S6K1, a downstream effector of AKT, suggesting PML-II is an 
important isoform in the suppression of AKT signal activation in cancer cells 
(Figure 5.2.7 C). Collectively, these data suggested that PML isoform II 
negatively regulates ERK and AKT signals in HeLa cells, which provides further 







Figure 5.2.7 Knockdown of PML-II promotes ERK and AKT activation. (A) HeLa 
cells were transfected with 125 pmol/ml PML-II siRNA or Control siRNA, and after 48 
h, cells were lysed and the expression of p-ERK and p-AKT proteins was detected by 
WB. β-actin was used as loading control. Two independent experiments were conducted 
and shown here. (B) Cells were treated as (A), and the mRNA expression of c-Fos and 
c-Myc genes tested by SYBR-Green qPCR. (C) HeLa cells were treated as (A), and 
phospho-p70S6K1 was detected by WB as (A). (D) Cells were transfected with siRNA 
as (A), then following a 1000 U/ml IFNα stimulation, cells were collected at various 
time points as described and cell pellets were lysed for detecting p-ERK and p-AKT 
protein by WB; β-actin was used as loading control. Two tailed student t-test; * p<0.05, 
** p<0.01.   
 





In this study, it has been demonstrated that PML-II positively regulates IFNα-
induced anti-apoptotic protein expression and meanwhile negatively modulates 
pro-survival AKT and ERK signaling in HeLa cells. It was of interest therefore 
to assess the biological significance of PML-II in IFNα-induced cancer cell 
apoptosis.  
 
Before testing cell death, the effect of PML-II on IFNα-mediated inhibition of 
AKT signaling was tested. Similar to Figure 5.2.6 C and D, IFNα stimulation 
decreased AKT phosphorylation in a dose-dependent pattern (Figure 5.2.8 A and 
B). As expected, the depletion of PML-II partly recovered/increased the level of 
p-AKT and this was less dependent on IFNα stimulation (Figure 5.2.8 A and B). 
To conduct apoptosis experiments, the efficiency of IFNα induced apoptosis was 
firstly tested in HeLa cells. Dead cells were stained with both Annexin-V and 
propidium iodide (PI) for testing the different types of cell death. The number of 
cells positive for Annexin-V and PI staining was increased in an IFNα-dose 
dependent pattern. This suggested cell death was due to IFNα-mediated 
apoptosis. Notably, the total death rate of HeLa cells exposed to 1000 U/ml IFNα 
for 24 hours was very low, although higher concentration IFNα (5000 U/ml) 
stimulation did induce some HeLa cell death (Figure 5.2.8 C). Next, the effect of 
PML-II on IFNα-induced cell apoptosis was tested. As expected, the knockdown 
of PML-II increased cell resistance to IFNα-induced apoptosis at every 





Figure 5.2.8 Effect of IFNα stimulation on cell apoptosis and p-ERK and p-AKT 
signaling. (A) Hela cells were cultured and transfected with either siPML-II or control 
siRNA for 48 h, and following IFNα stimulation at 2000 U/ml, 5000 U/ml or 15000 
U/ml for 24 h, cells were collected for WB detecting p-AKT. (B) The graph shows the 
quantification of protein bands in (A). (C) Hela cells were cultured as Figure 5.2.6 A, 
and stimulated with 1000 U/ml or 5000 U/ml IFNα for 24 h, then cells were collected 
and stained with Annexin V and PI for testing cell early apoptosis and later stage death. 
(D) HeLa cells were treated with siRNA as (A), treated with 1000 U/ml for 24 h, and 
cells were collected and stained by PI for FACS analysis to determine the proportion of 
cell death in the population.  
 
5.3 Discussion  
 
5.3.1 PML-II regulate IFNα-mediated apoptotic protein expression  
 
In this Chapter, we have confirmed that IFNα stimulation increases the 
expression of many pro-apoptotic proteins including ISG15 (Zhou et al, 2017), 
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ISG54 (Reich, 2013; Stawowczyk et al, 2011), OAS1 (Chawla-Sarkar et al, 
2003). The expression of PUMA and TRAIL was also greatly increased at both 
mRNA and protein levels by IFNα in HeLa cells, which suggested an activation 
of both intrinsic and extrinsic caspase-mediated cell apoptosis pathways. This is 
consistent with the previous observation that the induction of TRAIL by IFNs 
increases cell sensitivity to IFN treatment in melanoma cell lines (Chawla-Sarkar 
et al, 2001). 
 
It is notable that the expression of some pro-apoptotic genes such as ISG54 
(Figure 5.2.1A), PUMA (Figure 5.2.3A) and TRAIL (Figure 5.2.2A) quickly 
reached the highest level at 4 hours after stimulation, while the level of ISG15, 
PML-II and OAS1 reached the highest level later, at 8 hours after exposure to 
IFNα (Figure 5.2.1A). This may be because some genes play roles in the 
immediate/first phase of an IFN response, while others are secondary response 
genes responsible for the later stages. It was also noted that the expression of 
ISG54 and PUMA decreased again very quickly, while other proteins including 
TRAIL remained at a relative high level for a longer time. The mechanism by 
which some proteins are turned over (degraded) more rapidly than others in the 
context of IFNα treatment remains unclear. Together, the greatly increased 
expression of a group of pro-apoptotic ISGs, PML, PUMA and TRAIL by IFNα 
should contribute to IFNα-mediated apoptosis/death or inhibition of cell 
proliferation.  
 
In this study, PML-II was also demonstrated is required for the efficient IFNα-
induced expression of these pro-apoptotic genes, as knockdown of PML-II 
greatly decreased the expression of these genes. The downregulation of TRAIL 
by depleting PML-II is consistent with a previous observation that loss of PML 
decreased TRAIL expression in hepatocellular carcinoma cells (Chawla-Sarkar 
et al, 2001). The inhibition effect of IFNα on myeloma cell growth correlated 
with PML-NBs and TRAIL induction (Crowder et al, 2005). RNAi silencing of 
PML downregulated TRAIL expression in hepatoma cells and correspondingly 
blocked IFNα-induced apoptosis (Herzer et al, 2009). All these results suggest 
that TRAIL is essential in IFNα-induced growth inhibition or apoptosis and also 
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suggest that PML has an important regulation function in IFNα-induced TRAIL 
expression. 
 
Besides its effects on TRAIL, PML-II regulates IFNα-induced PUMA expression 
was also demonstrated for the first time in this study. PUMA is an important 
effector in mitochondria-mediated cell apoptosis. Downregulating PUMA and 
TRAIL expression by depleting PML-II may be essential for mediating caspase 
activation and thus inducing apoptosis. It was notable that in the unstimulated 
situation, PML-II siRNA treated cells had a relatively higher level of PUMA 
than control treated cells. This is similar to the effect of PML knockdown on 
TRAIL in myeloma cells (Crowder et al, 2005) though the mechanism is 
unknown. Together, silencing PML-II greatly downregulated the expression of 
PML-II itself and many other ISG proteins. Decreased PUMA and TRAIL 
expression provides a mechanistic explanation for why PML is required for 
IFNα-induced apoptosis/anti-tumor activity, though the documented involvement 
of PML-IV in p53 activation is also highly relevant (Fogal et al, 2000; Guo et al, 
2000a). 
5.3.2 The effect of IFNα and PML-II on STAT1 and P53, and recruitment at 
promoters 
 
Previous studies have shown that the p53 gene can be transcriptionally induced 
by IFNβ in mouse embryonic fibroblasts (MEFs): IFNβ stimulation activates 
ISGF-3 and promotes its recruitment to the ISRE element sequence in the p53 
gene promoter, leading to an increase in p53 mRNA and protein levels. 
Importantly, IFNα/β treatment itself does not directly activate p53, but 
contributes to boosting p53 responses to other stress signals (Takaoka et al, 
2003). In the present study, a significant increase in p53 expression by IFNα 
stimulation was not observed in Hela cells. However, IFNα stimulation greatly 
increased p53 phosphorylation level although the basal level of phosphorylated 
p53 was extreme low to undetectable in unstimulated HeLa cells. The relatively 
low level of p53 and p-p53 in HeLa cells is because papillomavirus HPV18 E6 
protein causes p53 degradation in Hela cells so p53 protein remains at a low 
level even under conditions of IFNα stimulation. The difference in expression 
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and activation between both studies is probably because the cell types were 
different and IFNs utilized were different, and thus different PAMPs recognition 
receptors (PRR) were involved. In contrast to p53, the total level of STAT1 was 
gradually increased and the phosphorylation level of STAT1 was immediately 
increased after IFNα stimulation to the highest level at about 30 minutes, and 
then followed a gradual decrease in the following several hours although the 
level of p-STAT1 was increased due to the total STAT1 level increasing upon 
prolonged IFNα stimulation.  
 
The depletion of PML-II decreased the expression of total p53 and STAT1 at the 
protein level and the mRNA level, and the phosphorylation level of STAT1 was 
decreased while the level of p-p53 was not significantly affected. Each 
phosphorylation is carried out by a specific kinase that is activated in response to 
a particular stimulus. P-p53 then favors further acetylation modification because 
phosphorylation prevents p53 interaction with MDM2 and hence stabilizes the 
protein (ie prevents its MDM2-dependent degradation). Therefore an IFN-
induced increase in expression is effectively equivalent to phosphorylation in 
providing a greater pool of p53 protein that can then form tetramers and be 
acetylated (the DNA-binding transcription activator form of the protein). IFNα 
stimulation affects the acetylation level of p53 but the effect on the 
phosphorylation level is less clear, actually it is the acetylation level of p53 that 
is essential of p53-dependent gene transcription.  
 
The mechanism of PML-II regulating gene expression was further investigated, 
following the previous observation in our laboratory that knockdown of PML-II 
affects STAT1 binding at ISG54 and OAS1 gene promoters. The binding of p53 
at the PUMA gene promoter was also decreased by depletion of PML-II. This is 
different from our previous work (Chen et al, 2015) which showed that PML-II 
knockdown had no effect on (or slightly increased) p53 binding to the p21 
promoter in response to etoposide (DNA damage) stimulation in HEK293 cells, 
which was consistent with the slight increase in p-p53 due to depleting PML-II 
observed in this study. The reason why PML-II has different effects on p53 
binding at these two p53-dependent genes could be because the genes are distinct 
p53-responsive gene classes (p21, cell cycle arrest class; PUMA, apoptosis 
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class). It may also be because the cell types and mode of stimulation are 
different.  
 
The decreased total STAT1 and p53 expression caused by depleting PML-II may 
also partly have impaired TF binding at promoters and thus possibly activation, 
however, we propose that the direct effect on TF binding by knockdown of 
PML-II contributes the most effect on gene expression. In summary, PML-II can 
regulate gene expression through multiple direct or indirect means, including 
decreased total TF level expression, impaired TF activation and impaired DNA 
binding.   
 
5.3.3 IFNα stimulation has no effect on ERK signaling in HeLa cells 
 
Many previous studies have demonstrated the link between IFNs and ERK 
signaling. Some reports showed that IFNα stimulation transiently activated ERK 
signaling (Arora et al, 1999; David et al, 1995; Stancato et al, 1997), and the 
regulation of MAPK activity is also essential for cytokine-induced expression of 
immediate-early ISG. The reason for the transient activation of ERK signaling by 
IFNα probably is because of the crosstalk between the JAK-STATs pathway and 
the RAF/MEK/ERK pathway. However, some contradictory results have also 
been reported in other studies: IFNα treatment reduces the phosphorylation of 
MEK1 and ERK1/2 in transformed human hepatocellular carcinoma (HCC) cell 
lines (Inamura et al, 2005; Romerio et al, 2000). In the present study, the effect 
of IFNα on ERK and MEK phosphorylation was not observed, although the 
phosphorylation level of both kinases was greatly increased in HeLa cells with 
extended culture time, which probably is because of the acquisition of serum 
growth factor stimuli. However, this p-ERK and p-MEK increase was not 
associated with IFNα stimulation.  
 
Why different effects on ERK signaling by IFNα stimulation have been observed 
is unclear. One reason is probably that the function of the IFN-ERK axis in virus-
infected cells and cancer cells is different. When cells require an immediate anti-
virus function, with short-term IFN release, IFNα may activate ERK signaling, 
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while when cancer cells are exposed constitutively to IFNα, the ERK signaling 
may be inhibited. This may also suggest an IFN concentration-saturation 
threshold: when IFN concentration is saturating, it is more likely to exert a pro-
apoptosis function thus ERK signaling is inhibited, while when IFN is at non-
saturating concentration, it may conversely activate ERK signaling and thus 
promotes cell survival.  
 
Cell type differences may also lead to the different observations. For example, 
some cells are sensitive to IFNα, or IFNs generally (IFNβ, IFNγ or IFNα), whilst 
others have lost this response. If a cell is sensitive to IFNα-induced apoptosis, 
ERK signaling may inhibited by IFNα, whereas ERK signaling may be enhanced 
or unaffected in IFNα resistant cells. Finally, it is necessary to avoid false 
positive observations, because ERK kinase activity (ERK phosphorylation) is 
easily influenced by experimental conditions including temperature, culture 
stress/pressure and serum growth factor stimuli.  
 
In this study, why does IFNα have no effect on MAPK activation/inhibition in 
HeLa cells? Previously, one study has shown that MAPK activity can be induced 
by IFNα in T cells, but only in cells containing the Src-family kinase Lck (Lund 
et al, 1999). The expression level of Lck is not required for, and is not associated 
with, IFNα-stimulated STAT1 phosphorylation, activation and binding to DNA 
(Lund et al, 1999). These data indicate that Lck and active MAPK do not affect 
IFNα-induced growth arrest or induction of STAT1s DNA binding ability. 
Possibly in the HeLa cancer cell line, the Lck gene is less expressed or not 
expressed, thus IFNα did not activate ERK signaling, but could still activate 
STATs and induce ISGs expression, thus mediating some pro-apoptotic function.  
 
5.3.4 IFNα stimulation decreased AKT signaling   
 
In contrast to having no effect on ERK signaling, the data in this study showed 
that IFNα treatment inhibited AKT signaling and the downstream p70S6K1 
kinase activity in HeLa cells. This is consistent with the recent report that AKT 
signaling was inhibited by IFNα in human cervical cancer progression (Ethiraj et 
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al, 2016). Given the fundamental importance of the AKT pathway in regulating 
cell proliferation and survival, this reduction in the activity of AKT may 
constitute a molecular mechanism for the anti-proliferative, pro-apoptosis 
activity of IFNα. Targeting the AKT pathway certainly strengthens the IFN-
mediated anti-tumor effect. The mechanism of IFNα-inhibited AKT signaling 
probably is via IFNα-induced activation of protein phosphatase 2A (PP2A), a 
family of mammalian serine/threonine phosphatases that accounts for most of the 
regulation of serine/threonine kinase activity in cells (Janssens & Goris, 2001) 
and which directly dephosphorylates PI3K or AKT activating phosphorylation 
sites thus inhibiting AKT signaling (Trotman et al, 2006).  
 
However, there are also some reports showing that IFNα can directly activate 
phosphatidylinositol 3-kinase (PI3K) (Uddin et al, 1997). The PI3K pathway has 
an important role in mediating gene transcription in response to both type I and 
type II IFNs and is essential for mediating their antiviral effects through the 
regulation of IFN-sensitive genes such as ISG15, IP-10 (also known as CXCL10) 
and IRF7 genes (Kaur et al, 2008a; Kaur et al, 2008b; Uddin et al, 1997). 
However, it is important to note that PI3K activation events reportedly occur 
very early (30 min) in the cells after stimulation with IFNα (Kaur et al, 2008b; 
Uddin et al, 1995). The biological significance of this effect remains unclear. In 
this current study, IFNα inhibiting AKT signaling was observed at a relative late 
stage, about 24 hours after IFNα treatment. A biochemical and functional 
characterization of the long-term events occurring upon treatment with IFNα is 
needed to better comprehend the mechanisms of action of this multifunctional 
cytokine.  
 
5.3.5 PML-II regulation of ERK signaling  
 
This study has, for the first time, demonstrated that ERK signaling was enhanced 
by depleting PML-II, which suggests an inhibition function of PML-II on this 
signaling pathway. The ERK pathway is strictly regulated by various factors at 
each step, for example by the expression of negative regulators such as Dual-
specificity phosphatases (DUSPs) [also termed MAPK phosphatases (MKPs)] 
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(Jeffrey et al, 2007) and SPROUTY (SPRY) family member proteins (Cabrita & 
Christofori, 2008; Mason et al, 2006; Murphy et al, 2010). Particularly, DUSP5 
(hVH3) acts as both a phosphatase and nuclear anchor for ERKs (Mandl et al, 
2005) and DUSP6 (MKP-3) functions in cytoplasmic retention of 
dephosphorylated ERK2 (Karlsson et al, 2004). In most cases, DUSPs directly 
inactivate ERK by dephosphorylating threonine and tyrosine regulatory residues 
at the MAPKs catalytic loop (Caunt & Keyse, 2013). Therefore, if the expression 
of any of these proteins was dependent on PML-II, its depletion would impair the 
inhibitory effect on this pathway and result in ERK activation, as was observed. 
It would be interesting to carry out some experiments to investigate the effect of 
PML-II on the expression of these genes. Together, the impairment of these 
negative regulators’ expression may contribute to ERK signaling enhancement. 
In conclusion, our results indicate that PML-II regulates the activity of the 
MEK/ERK pathway and consequently modulates cellular proliferation. 
 
5.3.6 PML-II regulation of AKT signaling  
 
In this study, knockdown of PML-II increased AKT activation, this is consistent 
with previous report that unspecified isoform(s) of PML inhibited AKT signaling 
(Trotman et al, 2006). Similar to the RAF/MEK/ERK pathway, the PI3K/AKT 
signaling pathway is also regulated by some feedback regulation mechanisms 
including PTEN (phosphatase and tensin homolog)-mediated negative regulation 
on PI3K/AKT pathway as PTEN deficiency closely correlates with AKT 
activation (Ito et al, 2009; Trotman et al, 2003). The expression of IRS1 (insulin 
receptor substrate 1) (Harrington et al, 2004) and RICTOR (rapamycin-
insensitive companion of mTOR (mammalian target of rapamycin)) also 
positively regulates this pathway activation (Laugier et al, 2015; Sarbassov et al, 
2005). PML-II may regulate the expression of these proteins, and thus affect 
AKT activation in HeLa cells. Phosphorylation plays an important role in the 
regulation of many diverse cellular processes and a delicate balance between 
protein kinases and protein phosphatases regulates these responses. Another 
possibility is that PML-II affects the activity of PP2A. Previous studies have 
demonstrated that PML binds to PP2A, and that loss of PML (in total, not a 
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specific isoform) impairs PP2A activity (Trotman et al, 2006), so knockdown of 
PML-II alone may also affect PP2A activity thus impairing the 
dephosphorylation of AKT and resulting in increased AKT activation. The idea 
that PML isoform II inhibits AKT and ERK is consistent with the PML protein’s 
general function as a tumor suppressor.   
 
5.3.7 Reason potential for IFNα less effectively inducing HeLa cell apoptosis  
 
Although previous studies have implicated a variety of ISGs in mediating cell 
apoptosis, there are still many types of cancer cells that are less responsive to 
IFNα-induced apoptosis. In HeLa cells, IFNα increased the expression of several 
pro-apoptotic proteins, however IFNα only induced very limited amounts of 
apoptosis even at concentration reaching 10,000 U/ml, which is very high 
compared to pharmaceutical dose. We considered increasing the IFNα 
stimulation time to increase the cell death rate, however, it was impractical in 
this siRNA transient knockdown system, because after 48 hours siRNA 
transfection, the cells had already reached or were nearly confluent, making it 
impossible to continue another 3 days IFNα stimulation. Similarly, in human 
hepatocellular carcinoma cell lines, IFNα retarded G1/S transition and inhibited 
cell proliferation with no evidence of apoptosis (Inamura et al, 2005; Romerio et 
al, 2000). There are several factors that may contribute to HeLa cells’ resistance 
to IFNα-induced apoptosis.  
 
a. ISG induction is not strong and sustained 
The expression of ISGs, including PUMA and TRAIL, may not be sufficient for 
inducing a large amount of cell apoptosis in HeLa cells. Because different cancer 
cells require different patterns of gene expression to achieve apoptosis, for 
example in melanomas, TRAIL and XAF1 are required for IFNα-inducted cell 
apoptosis, and defects in induction of either TRAIL or XAF1 rendered cells 
resistant to apoptotic effects of IFNs (Chawla-Sarkar et al, 2001; Leaman et al, 
2002), while in an ovarian carcinoma cell line, the induction of RIDs correlated 
with IFN-induced apoptosis (Morrison et al, 2001). In HeLa cell, there may be 
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some other unknown pro-apoptotic proteins which determine HeLa cells fate and 
that were not overexpressed in response to IFNα stimulation.   
 
Based on the in vitro studies in melanomas and multiple myeloma (Crowder et 
al, 2005), strong and sustained induction of death receptor proteins such as 
TRAIL by IFNs has been reported as one means inducing cell apoptosis. In the 
work reported here in HeLa cells, IFN quickly increased the expression of these 
protein, but then the level decreased and was maintained at a relative low level 
rather than being sustained at high level. Probably this is one of the reasons why 
IFN could not induce a greater amount of cell apoptosis in HeLa cells.  
 
This decrease in pro-apoptotic protein expression with longer induction may be 
due to a natural self-protection or self-renewal mechanism in cells. It is known 
that the interferon response is the first line of immune defense for cells to defeat 
virus infection. Rapid production of a large amount of cytokines is an essential 
mechanism for cells to defend against virus invasion. However, the continued 
production of cytokine would bring negative consequences for the cells. 
Therefore it is necessary for the cells to have a mechanism to re-regulate the 
expression of interferon or ISGs. The quickly decreased expression in specific 
cells such as HeLa cells may reduce the pro-apoptosis function and thus recover 
the resistance of the cell to IFNα-induced apoptosis. 
 
b. Other anti-apoptotic protein expression may also contribute cell 
resistance to IFNα induced apoptosis  
The overexpression of inhibitors of apoptosis, such as XIAP (Liston et al, 2001), 
CIAP-1 or-2 (cellular IAPs) or FLIP (Flice inhibitory protein), has been 
implicated in resistance to apoptosis or chemotherapies in cancer (LaCasse et al, 
1998; Schimmer & Dalili, 2005). For example, in melanoma cells, the expressed 
high levels of XIAP has been implicated in conferring resistance to TRAIL in 
melanoma cells. TRAIL functions in cell apoptosis are largely regulated by the 
expression of XIAP and cFLIP. Therefore, the final fate of cancer cells is 
dependent on the balance between anti-apoptotic and pro-apoptotic protein level.  
 
c. Cell sensitivity to IFNα may also determine IFNα efficacy 
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Cancer cell lines from different histologies respond variably to IFNα or IFNβ or 
IFNγ induced apoptosis. For example, IFNβ was more potent compared to IFNα2 
or IFNγ in inducing apoptosis in melanoma (Chawla-Sarkar et al, 2001), ovarian 
carcinoma (Morrison et al, 2001) and multiple myeloma cell lines (Chen et al, 
2001), which correlated with stronger induction of TRAIL by IFNβ Thus 
melanoma cell lines, where both TRAIL and XAF1 were induced, were sensitive 
to IFNβ induced apoptosis. To examine the relevance of differential activity of 
IFNs to HeLa cell apoptosis, it would be necessary to repeat these experiments 
using IFNβ or poly(I:C), a synthetic analog of double- stranded RNA (dsRNA), 
stimulation in place of IFNα. Carrying out some experiments using a more IFNα-
sensitive cancer cell line may also need to be considered. 
 
d. ERK signaling pathway enhancement may also promote cell survival   
The increased activation of ERK signaling by culture medium, probably through 
the growth factors contained in serum, may also be one of the reasons that cells 
showed resistance to IFNα-induced apoptosis. The enhanced pro-proliferation 
and pro-survival ERK signaling may also compensate for the inhibition on AKT 
signaling by IFNα. Together, the mechanisms that are responsible for a lack of 
response to IFNα are still not fully understood. Thus a better understanding of 
the mechanisms that underlie IFNs anti-tumor effect and the factors that are 
responsible for a lack of response to IFNs is desirable.  
 
5.3.8 PML-II collaborates with IFNα to induce apoptosis  
 
The function of PML in tumor suppression suggests that inactivation or 
downregulation of PML would provide an advantage for tumor development and 
progression. Indeed, the expression of PML protein is frequently downregulated 
in diverse types of human tumors and this downregulation often correlates with 
tumor progression (Gurrieri et al, 2004). In this study, depletion of PML-II 
increased cell survival in HeLa cells, a cervical cancer cell line. Mechanistically, 
depletion of PML-II results in downregulated expression of many anti-apoptotic 
proteins such as ISG15/54, OAS1, TRAIL and PUMA, through a mechanism of 
regulating the determinant transcription factor p53 or STAT1 expression and 
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recruitment at gene promoter. Moreover, the loss of PML-II increases pro-
survival AKT and ERK signals and thus partly recovered ATK signal inhibited 
by IFNα and consequently increased cell resistance to IFNs-induced apoptosis. 
Taken together, PML-II positively regulates IFNα-induced pro-apoptotic protein 
expression and negatively regulates AKT and ERK signals activation thus 
provides a molecular basis for the involvement of PML-II in IFNα-mediated 





























































































6.1 The unique C-terminal fragment of PML-II determines its 
distinct function in gene transcription 
 
Multiple isoforms of tumour suppressor protein PML have been demonstrated to 
participate in various cellular activities (Bernardi & Pandolfi, 2007). The C-
terminal of PML is thought to be associated with the specific biological 
properties of each isoform. In this study, the functional fragments of the C-
terminal domain in PML-II was firstly investigated. The C-terminal fragments, 
particularly the regions covering 7b exon (645-758) defined by deletions 1 and 
2, are essential for the PML-II regulation function in a type I IFN response, 
while the N-terminal RBCC structure is dispensable. The loss of the RBCC 
domains has no effect either on PML-II association with other transcription-
related proteins or on PML-II binding at relevant promoters. However, the 
removal of C-terminal 1 and 2 sequences greatly impaired PML-II binding 
with transcription factors and consequently decreased gene transcription.  
 
PML protein has been reported to interact with coactivator CBP via the N-
terminal coil-coil motif that is found in all the main isoforms (Doucas et al, 
1999). Consistently, both full-length PML-II and PML-V indeed interacted with 
CBP. However, the deletion of the N-terminal RBCC domain changed the 
binding characterization of both isoforms: PML-II-ΔRBCC could still interact 
with CBP while PML-V-ΔRBCC could not do so. Similarly, the full-length 
PML-II and PML-V were found to bind to chromatin remodelling complex 
subunit Brg-1, while PML-II-ΔRBCC and PML-V-ΔRBCC performed 
differently. While PML-II-ΔRBCC could form a complex with Brg-1, 
transcription factor STAT1 and coactivator CBP, suggesting an interaction can 
be mediated by the PML-II C-terminal fragment, PML-V-ΔRBCC failed to 
interact with Brg-1 or CBP.  
Subsequently, a further testing was performed to determine the exact binding 
sites that are responsible for PML-II binding with transcription factor STAT1 
and NF-κB, coactivator CBP and chromatin remodelling subunit Brg-1. It can be 
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found that the key sequences for interaction with these proteins are at different 
sites in the C-terminal part of PML-II.  STAT1 binding to PML-II was most 
affected by loss of residues 653-665, defined by mutations ΔB, ΔC and ΔD 
within Δm1, while NF-κB binding was mainly affected by mutation ΔD at 
residue 661 to 665, although NF-κB binding was also somewhat affected by ΔB 
or ΔC mutations. CBP binding was also preferentially affected by removing 
residues 661-665 of PML-II: this deletion sequence greatly disrupting PML-II 
binding with CBP. CBP binding ability to PML-II was also impaired by the 
Δm1Δm2, Δ7 and ΔB mutations to various degrees. Similarly, the ΔD mutation 
also disrupted Brg-1 binding with PML-II, because very little Brg-1 was 
precipitated from the cells transfected by ΔD mutant plasmid. It is interesting to 
note that the PML-II sequences required for Brg-1 binding are similar to those 
required for CBP and NF-κB binding. This suggests that one or more of these 
factors might be a direct interactor with PML-II whilst others interact indirectly 
via that primary interactor. It is also consistent with the idea that PML-II may 
function as a scaffold protein to recruit various transcription-related proteins and 
form a transcriptional complex.  
It was recently reported that the unique C-terminal domain of PML-II can bind to 
PML-NBs independent of the shared N-terminal region (Geng et al, 2012). This 
is consistent with our observation and, taken together, it can be suggested that the 
C-terminal part of PML-II might replace full-length PML-II for some functions if 
it were to be expressed independently. In this context, we found that 
overexpressing PML-II deleted of its N-terminal RBCC domain further enhanced 
the expression of IFNβ and ISGs while full-length PML-II only modestly 
increased the expression of these genes. This may suggest that removal of the 
RBCC domain actually gives a protein with enhanced activity in the expression 
of genes. The biological significance and mechanism of this effect remains to be 
determined, but it could reflect a greater functional availability of the PML-II C-
terminal domain when less tightly tethered to PML-NB. Taken together, these 
results provided further evidence of PML-II, particularly its distinct C-terminal 
domain, playing a key role in the regulation of gene transcription.  
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6.2 PML functions in post-translational modification 
(phosphorylation and acetylation)  
 
Many proteins that are resident in PML-NBs are subject to various post-
translational modifications including SUMOylation (Fogal et al, 2000; Zhong et 
al, 2000a), ubiquitination , phosphorylation and acetylation (Cheng & Kao, 2012; 
Hofmann & Will, 2003). PML protein participates in diverse modifications to 
activate or suppress the function of these proteins. In this study, the knockdown 
of PML-II decreased transcription factor STAT1 phosphorylation in response to 
IFN stimulation, suggesting PML-II may facilitate IFNα-induced STAT1 
activation. Similarly, overexpression of PML isoforms (I-VI) in human cells 
increased IFNγ-induced STAT1 phosphorylation, conversely, downregulation of 
PML by RNA interference was accompanied by a decrease in IFNγ-induced 
STAT1 phosphorylation (El Bougrini et al, 2011). Mechanistically, PML 
localization within the NBs and its SUMOylation at some/all of the specific 
lysines at 65, 160 and 490 are required for increased STAT1 phosphorylation in 
response to IFNγ stimulation, while the mutation of these lysines in PML-III 
abrogated its positive regulation of IFNγ-induced STAT1 phosphorylation (El 
Bougrini et al, 2011). Given the PML gene encodes PML-III from an mRNA that 
is very similar to PML-II mRNA, this may suggest PML-II SUMOylation is 
required for STAT1 phosphorylation in response to IFNα stimulation. In 
addition, the possibility cannot be excluded that PML-II directly regulates 
STAT1 upstream kinases JAK1 and TYK2. Further studies are required to 
determine the mechanism of PML-II regulating STAT1 phosphorylation. In fact, 
PML protein has previously been reported to regulate the activity of other 
kinases and activate transcription factors. For example, PML-IV promotes the 
phosphorylation of p53 by regulating homeodomain-interacting protein kinase-2 
(HIPK2) kinase, which increases the rate of acetylation of p53 and consequently 
its transcriptional activation (Hofmann et al, 2002).  
PML was also reported to modulate the activity of phosphatases. For example, 
the loss of PML delocalized PP1A and reduced its activity towards pRb, 
resulting in increased proliferation and reduced differentiation of neural 
progenitors (Regad et al, 2009). PML also positively regulates the activity of 
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phosphatase PP2A towards AKT in PML-NBs, and, as a result, losing PML leads 
to a more aggressive form of cancer (Trotman et al, 2006). In this study, 
knockdown of just PML-II alone also promoted AKT and ERK phosphorylation, 
and hence activation, in HeLa cells suggesting a negative regulation of PML-II 
on the activities of these kinases. This is probably because the loss of PML-II 
reduces the suppression/inhibition on AKT and ERK signals or on activation of 
the upstream kinase PI3K and CRAF/C-RAF, respectively. It could also be that 
depletion of PML-II disrupts AKT and ERK signaling pathway negative 
feedback loops that are mediated by DUSPs and PP2A phosphatase. Further 
studies are needed to elucidate the mechanism of PML-II negative regulation on 
ERK and AKT signals.  
The function of PML-NBs/PML in the regulation of protein acetylation has been 
extensively demonstrated. For example, PML activates p53-dependent gene 
expression by promoting its acetylation by CBP in the PML-NBs (Pearson et al, 
2000). In this study, the association of specific isoform PML-II with histone 
acetyltransferase CBP/p300 was demonstrated, and that the depletion of PML-II 
affects CBP/p300 recruitment at gene promoters (Chen et al, 2015). This 
suggested the possibility that PML-II positively regulates CBP-mediated 
acetylation of transcription factors or histones. However, PML was also reported 
to form complexes with multiple corepressors (c-Ski, N-CoR, and mSin3A) and 
histone deacetylase 1 (HDAC1), and to mediate tumour suppressor protein Mad 
transcriptional repression (Khan et al, 2001). This distinct function involving 
PML is most likely because of the individual functional differences among PML 
isoforms. Together, these data provide support for the idea that PML regulates 
protein acetylation by affecting acetyltransferase or deacetylase activity.  
 
6.3 PML functions on histone methylation  
 
Gene transcription activation is dynamic process which is accompanied by the 
presence or loss of some special histone modifications from the vicinity of the 
promoter and/or the gene. In this study, deletion of PML-II resulted in the 
enhancement of H3K9me3 at ISG promoters. This result is consistent with a 
recent study where silencing of PML enhanced the H3K9me3 level at the Oct4 
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gene promoter in P19 embryonal carcinoma (EC) cells (Chuang et al, 2011). Our 
study suggests that isoform PML-II may be one of the most important isoforms 
that participates in this process of methylated-histone enrichment/disposition, 
thus regulating gene transcription activation or repression. To further confirm 
this function, it will be necessary to test more repressive markers including 
HP1c, H3K27me3 and RIP140. It would be predicted that the knockdown of 
PML may enhance the recruitment of these repressive markers at IFN-responsive 
promoters. The H3K9me3 modification can be catalysed/mediated by multiple 
methyltransferases (HMTase) including SETD1 (or ESET), SUV39H1, 
SUV39H2, EHMT1(GLP) and EHMT2(G9A) (Kim & Kim, 2012). Particularly 
relevant may be the methyltransferases SETDB1 and SUV39H1, which 
reportedly interact with PML and regulate gene expression (Carbone et al, 2006; 
Cho et al, 2011). Therefore, it will be interesting to test whether loss of PML-II 
also affects the corecruitment of these HMTase to the promoters and thus their 
functions/activities. 
 
A decrease of the supposed activating H3K4 trimethylation mark at promoters 
due to the depletion of Brg-1 or PML-II was not observed in this study, despite 
the reduction in their activity. The exact reasons for this remain unclear. 
However, recent studies showed that CBP/p300-mediated H3K27ac antagonizes 
with PRC2-mediated H3K27me2/3 in regulating polycomb target gene 
expression (Tie et al, 2009; Wang et al, 2010). Moreover, H3K4ac was found 
enriched at promoters of actively transcribed genes and located just upstream of 
H3K4me3, and the Set1-containing complex (COMPASS), which promotes 
H3K4me2 and -me3, also serves to limit the abundance of H3K4ac at gene 
promoters. This may suggest that the histone residue modifications H3K4ac and 
H3K4me2/3 are mutually exclusive (Guillemette et al, 2011). It is also reported 
that H3K4me3 enrichment/deposition at a promoter can be affected by other pre-
existing histone modifications at this site, or by the duration of its residency 
(Howe et al, 2017). This suggests a possibility that the enrichment of H3K4me3 
at promoter may be negatively affected by H3K4ac, the level of which was 




In order to further confirm the importance of PML-II for H3K4me3 
enrichment/deposition, it would be interesting to test co-recruitment of 
H3K4me3 methyltransferases such as MLL1, MLL2 and SETD1 (Yokoyama et 
al, 2004; Zhang et al, 2015). Given that the recruitment of these 
methyltransferases requires specific transcription factors and coactivators 
(Katada & Sassone-Corsi, 2010; Narayanan et al, 2007; Okuda et al, 2014), it  
therefore can be postulated that the recruitment of methyltransferases to target 
gene promoters is most likely affected by depleting PML-II or Brg-1. To extend 
study of the function of PML-II positive regulation on gene transcription, it 
would be better to test the effect of PML-II on the recruitment of more activating 
markers, such as AcH3 and RNA Pol II. Knockdown of PML-II should 
drastically reduce AcH3 and RNA Pol II recruitment at a gene promoter.  
 
PML protein can physically associate with many histone modifying enzymes and 
enzymatic components of chromatin remodeling complexes, such as protein 
acetyltransferase CBP/(p300), deacetylase (HDAC1/2/3/7, SIRT1 and SIRT5) 
(Guan et al, 2014; Morey et al, 2008; Wu et al, 2001), methyltransferases 
(SETDB1 and SUV39H1) (Carbone et al, 2006; Cho et al, 2011), component of 
polycomb repressive complex, EZH2 (Villa et al, 2007), and epigenetic regulator 
UHRF1 (Guan et al, 2013). This suggests that investigating the role of PML in 
epigenetics and chromatin organization will be a key direction for future study. 
The function of PML-II in gene transcription makes it one of the ideal isoforms 
on which to conduct these interesting studies. 
6.4 PML-II affects chromatin remodeling SWI/SNF complex  
As one of two possible core catalytic subunits of SWI/SNF complex, Brg-1 plays 
an important role in transcription. Brg-1 has been reported directly to regulate the 
expression of IFNβ and also multiple ISGs (Agalioti et al, 2000; Cui et al, 2004; 
Huang et al, 2002; Pattenden et al, 2002). Similarly, in this study the expression 
of IFNβ and many ISGs was also decreased by depleting Brg-1. Importantly, this 
decrease was further enhanced by double knockdown of PML-II and Brg-1, this 
may suggest PML-II collaborates with Brg-1 to regulate gene transcription.  
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Several models of SWI/SNF complex (Brg-1) binding to chromatin have been 
proposed. The data in this study supported the idea that Brg-1 recruitment to its 
target required gene specific transcription factors, because as has been observed, 
over a time course, transcription factor STAT1 was first activated and recruited 
to a gene promoter after stimulation and that this occurred significantly earlier 
than the recruitment of Brg-1 and BAF155, and some other transcription 
coactivators.  
Similar to Brg-1, BRM also plays an important role in the expression of some 
ISGs (Torti, 2012). Although the functions of Brg-1 and BRM are partly similar 
or redundant, BRM and Brg-1 complexes regulate different gene expression 
profiles. In this study, PML-II has a stronger effect on Brg-1 and BAF155 
binding at promoters of some genes such as ISG54 and IFITM3 (named as an 
early gene with the IFN response), while it has a relatively smaller effect on 
genes like ISG56 and GBP1, although the expression of all of these gene was 
similarly downregulated by depletion of PML-II. This may suggest the 
expression of some ISGs is Brg-1-dependent, while expression of others is not. 
Considering the previous expression characterization of these genes, it seems the 
expression of some early response ISGs is more likely regulated by Brg-1 and/or 
BRM (maybe in combination), while the expression of later response genes is 
less dependent on Brg-1 (and may depend on BRM alone). Also, it is possible 
that a switch occurs between Brg-1 and BRM during the process of gene 
transcription, namely Brg-1 participates in transcription initiation first, while 
BRM plays a role at later stage. Therefore it would be interesting to identify 
genes that are more BRM dependent by knockdown of BRM and to test the 
dynamic recruitment/binding pattern of BRM at different gene promoters. 
In this study, PML-II bound to Brg-1, CBP and other transcription factors to 
form a transcription complex (Figure 4.2.7 and 4.2.8), and .the depletion of 
PML-II affected the binding of such transcription-related proteins at promoters. 
In addition, the depletion of PML-II down-regulated the expression of the 
SWI/SNF ATPase subunit BRM as well as core subunit BAF47, down-regulation 
of which influences Brg-1 and BRM stability. Accordingly, it can be concluded 
that the regulation by PML-II of chromatin remodeling SWI/SNF complex 
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activity occurs via two distinct methods, including decreasing subunit protein 
expression (BRM and BAF47), and regulating subunit protein (Brg-1 and 
BAF155) binding/recruitment at the promoter.  
Besides SWI/SNF, there are at least four families of chromatin remodelers in 
eukaryotes such as ISWI, NuRD/Mi-2/CHD, INO80 and SWR1 (Wang et al, 
2007). Each remodeler complex has unique protein domains (helicase, 
bromodomain) in their catalytic ATPase region and also has different recruited 
subunits; their functional characteristics thus are different. The ISWI-family 
remodelers have been shown to play central roles in chromatin assembly after 
DNA replication and in the maintenance of higher-order chromatin structures, 
which is completely different to the role of SWI/SNF remodelers in disordering 
nucleosomes. NuRD/Mi-2/CHD remodeling complexes primarily mediate 
transcriptional repression in the nucleus and are required for the maintenance of 
pluripotency of embryonic stem cells (Wang et al, 2007).  SWI/SNF and ISWI 
remodelers are very well studied so far. To further expand the study of PML-II 
transcriptional regulation function on chromatin remodeling, it may be necessary 
to test the effect of PML-II depletion on ISWI or NuRD/Mi-2/CHD remodeling 
complexes activity.  
6.5 Proposed model of gene transcription and PML-II functions 
in this process  
 
In this study, the dynamic changes in the binding of STAT1, CBP, PML-II, Brg-
1 and BAF155, and the enrichment/deposition of H3K4me3 and H3K9me3, at 
gene promoter in response to IFNα stimulation were tested (Figure 6.1). The 
binding of STAT1 at a promoter was first to reach the highest level and this then 
decreased, which was closely associated in time with significant new mRNA 
expression, however the highest level of gene expression was 1-2 hours later than 
that of STAT1 recruitment at the promoter. Similar to STAT1, the level of 
H3K4me3 modification at ISG promoters was also greatly increased by IFNα 
induction. Conversely, the level of H3K9me3 at promoters was immediately 
decreased by IFNα. The timing of CBP binding at the promoter was very similar 
to that of H3K4me3. The binding of PML-II, BAF155 and Brg-1 at ISG 
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promoters was also increased by IFNα stimulation, and the maximum level of 
PML-II and BAF155 present at a promoter was at 8 h after stimulation, while the 
highest enrichment level of Brg-1 at a promoter was at 6 h after stimulation 
which is about 2 hours earlier than PML-II and BAF155 binding. The time 
difference of Brg-1 and BAF155 recruitment at a promoter is consistent with the 
previous observations that the recruitment/assembly of components of chromatin 
remodeling complexes was sequentially within condensed chromatin, Brg-1 
having earlier recruitment kinetics than BAF155 (Memedula & Belmont, 2003; 
Ryme et al, 2009). In order to acquire the complete picture of gene transcription 
initiation dynamics, it will be necessary to test other transcription-related 
mechanisms including the recruitment of RNA pol II, the general transcription 






Figure 6.1 Upper: The recruitment pattern of transcriptional components in 
ISG54 gene during induction by IFNα. Lower: Expression of ISG54 mRNA 
following IFNα induction. 
 
Altogether, based on the DNA binding time course of various proteins to ISG 
promoters and the dynamic changes to histone modifications in those promoters, 
a model of gene transcription at ISGs and the regulation by PML-II on the 
process was proposed. Firstly, gene transcription is initiated by transcription 
factor STAT1 phosphorylation (within 1h), meanwhile the level of H3K9me3 at 
promoter is decreased immediately (probably earlier than the time point tested at 
2h after stimulation). Then STAT1 moves into nucleus and binds to promoter 
DNA (4-6h), followed by chromatin remodeling core enzymatic subunit Brg-
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1/BRM enrichment (6-8h), and scaffold protein PML-II, and co-activator CBP 
and SWI/SNF scaffold protein BAF155 (8h) recruitment and by 8h, when 
H3K4me3 enrichment is observed, the whole transcription complex is assembled 
at the promoter. Meanwhile, mRNA transcription reaches the highest level (6-
8h). This is very consistent with the generally accepted concept that induction of 
gene transcription involves sequential/ordered recruitment of various activators, 
coactivators, regulators/mediators and the general transcription machinery.  
 
Based on the data in this study, it can be concluded that PML-II regulates 
SWI/SNF complex functions in gene transcription. PML-II is required for 
forming and stabilizing the whole transcriptional complex which contains 
various factors including transcription factors (STAT1), coactivator (CBP), and 
chromatin remodeling complex (Brg-1 and BAF155) (Figure 6.2). Depletion of 
PML-II impaired transcriptional complex stability and component protein 
binding at a promoter. According to this model, PML-II mainly functions as a 





Figure 6.2 A model of PML-II function as a scaffold protein in gene transcription 
 
However it is also possible PML-II may function as modifier/mediator through 
its association (direct or indirect) with SWI/SNF complex and transcriptional 
components by regulating their PTMs, hence facilitating their recruitment and 
assembly at promoters. Principal among the PTMs known to be positively 
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regulated by PML are phosphorylation and sumoylation. The loss of PML-II 
would impair the PTMs of these factors and transcriptional complex assembly 
and gene transcription (Figure 6.3). Collectively, this study establishes the 
relationship between PML-II with SWI/SNF chromatin remodeling complex, and 
provides evidence of PML-II’s role in regulation of chromatin remodeling and 




Figure 6.3 A model of PML-II functions as modifier of factors involved in gene 
transcription 
 
6.6 PML functions in tumour suppression 
 
A number of cellular activities of PML protein are related to anti-tumour activity. 
For example, PML activates p53 and recruits it into the PML-NBs where PML 
binds to and inhibits the negative regulator MDM2 by sequestering MDM2 to the 
nucleolus thus enhances p53 stability and mediates p53 pro-apoptotic function 
(Bernardi & Pandolfi, 2003; Takahashi et al, 2004). In this study, the PML-II 
isoform was found to have an effect of regulating p53 expression and the 
expression of a pro-apoptotic p53-dependent gene, PUMA, in response to IFNα 
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stimulation. These results suggested that PML-II is an essential isoform to 
regulate p53-mediated pro-apoptosis function. 
 
Overexpression of PML in gastric cancer cells recently was reported to 
significantly increase cell apoptosis, resulting in decreases in cell growth; this 
effect of PML appeared to be conducted through p73-mediated modulation of 
apoptosis-associated genes, Bcl-2, Bak and caspase-9 (Xu et al, 2015). PML also 
negatively regulates the AKT-mTOR pathway, so inhibiting cancer cells 
angiogenesis (Bernardi et al, 2006). PML was also found to exert proapoptotic 
activity through the regulation of a large complex involving PP2a, AKT, and the 
inositol triphosphate receptor (IP3R), which ultimately controls calcium flux to 
the mitochondria (Giorgi et al, 2010). 
 
Similar to previous observation with total PML, PML-II in this study negatively 
regulated AKT activity as its depletion increased the phosphorylation level of 
AKT and the downstream kinase p70S6K1. Interestingly, PML-II also 
demonstrated a negative regulation function on ERK signaling and the 
expression of ERK-dependent genes, c-Fos and c-Myc. PML was reported to 
regulate AKT activity by recruiting PP2a to PML-NBs, thereby 
dephosphorylating and inactivating AKT (Trotman et al, 2006). It is not sure 
whether PML-II regulates AKT signaling through the regulation on PP2a or by 
another means. Further study is required to investigate this remaining question. 
Collectively, the data do indicate that PML-II negatively regulates ERK and 
AKT signaling pathways, suggesting an important role for PML-II in the 
inhibition of cancer cell proliferation and in promoting cell apoptosis. The data 
also provide a molecular basis for the PML tumour suppression function, and 
suggest that this function resides, in part at least, in the PML-II isoform 
specifically.  
 
6.7 PML regulates IFN-induced apoptosis   
 
The products of a group of ISGs are thought to be the primary effectors that 
mediate the IFN-anti-tumour function. For example, in myeloma and 
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hepatocellular carcinoma cells, the growth inhibition and pro-apoptosis function 
induced by IFNα is mainly dependent on PML and TRAIL induction (Crowder et 
al, 2005; Herzer et al, 2009). Moreover, the expression level of PUMA, a p53-
dependent gene, was also increased in response to IFNα stimulation in human 
myeloma cells suggesting the possibility that PUMA is related to IFNα-induced 
apoptosis (Gómez-Benito et al, 2007).  
 
Similarly, in this study, IFNα stimulation greatly induced the expression of pro-
apoptotic proteins including ISG15, ISG54, OAS1 and TRAIL and PUMA in 
HeLa cells. In addition, IFNα treatment also inhibited AKT signal activation 
which will likely contribute to IFNα-induced apoptosis. IFN-induced cell 
apoptosis is complex: the eventually cell death may be a result of collaboration 
of multiple IFNα-regulated mechanisms. This study has shown IFNα not only 
increases antiapoptotic protein expression but also inhibits pro-survival AKT 
signaling. This suggests the function of IFNα to promote cancer cell apoptosis is 
most likely a cumulative effect of expressing many pro-apoptotic proteins and 
the inhibition of multiple pro-survival signaling pathways.  
 
In this study, depletion of PML-II reduced the death of cells in response to IFNα 
stimulation. This provides further support to the idea that PML is required for the 
efficient induction of apoptosis by IFNs (Quignon et al, 1998; Wang et al, 1998) 
and also suggests that PML-II is one of the important isoforms involved in IFNα-
mediated apoptosis. Mechanistically, knockdown of PML-II greatly decreased 
the expression of genes including TRAIL, which is consistent with a previous 
observation that loss of all PML decreased TRAIL expression in hepatocellular 
carcinoma cells (Crowder et al, 2005). Also, the expression of many pro-
apoptotic ISG proteins and PUMA was also decreased by PML-II depletion. This 
is consistent with a previous observation that the growth inhibition effects of 
IFNα correlated with the presence of PML in myeloma cells (Crowder et al, 
2005). IFNα-induced apoptosis in hepatocellular carcinoma also involves PML 
(Herzer et al, 2009). Taken together, PML-II regulation of IFNα-induced pro-
apoptotic protein expression, and inhibition of pro-survival AKT and ERK 
signaling pathways provides a molecular basis for the involvement of PML-II in 




6.8 Loss of PML-II may contribute cell resistance to IFN-
mediated apoptosis  
 
Type I IFNs have been used for the treatment of several types of haematological 
malignancies and solid tumours (Ferrantini et al, 2007; Rizza et al, 2010). 
However, there are many type of cancer cells that are less responsive to IFNα-
induced apoptosis. Clinically, a substantial proportion of patients fail to respond 
to IFN treatment, although beneficial effects of IFNs in some malignant disease 
patients was observed. In HeLa cells, IFNα induced a very limited amount of 
apoptosis although IFNα considerably/significantly induced the expression of a 
group of pro-apoptotic proteins including ISG15/54, OAS1, TRAIL and PUMA. 
The factors that may contribute to HeLa cells resistance to IFNα-induced 
apoptosis have been discussed in Chapter 5. Here the focus will be on the 
resistance probably due to the loss of PML/PML-II protein.  
 
The expression of PML tumour suppressor protein is frequently downregulated 
in diverse types of human tumour and this downregulation often correlates with 
tumour progression (Gurrieri et al, 2004; Trotman et al, 2006). In a mouse 
model, loss of the Pml gene markedly accelerates tumour onset, incidence and 
progression (Trotman et al, 2006). Cells from PML-deficient mice show severe 
apoptotic defects, including a strongly decreased sensitivity to death receptor-
mediated apoptosis (Wang et al, 1998).  
 
Our and others’ previous studies have confirmed that PML protein is required for 
IFN-induced apoptosis. It therefore can be proposed that the basis of resistance to 
IFNα-induced apoptosis in HeLa cells and other resistant tumour cells is that the 
protein level of PML-II is lower compared to IFNα-sensitive cancer cells, 
although the mRNA level may be still detectable. Full length PML-II is very 
hard to detect in Hela cells and in other tumour cell lines (Wright, PhD thesis, 
University of Warwick, 2010). A reduced amount of functional or active PML-II 
will affect IFNα-induced pro-apoptotic protein expression and thus should 
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increase cell resistance to IFNα-induced apoptosis. The inactivation or 
downregulation of PML would provide an advantage for tumour development 
and progression. 
 
The low level of PML-II may arise by the protein undergoing post-translation 
modification which eventually results in PML-II degradation via the 
ubiquitination-proteasome pathway. Alternatively, its expression might be 
affected by changes in alternative RNA splicing patterns. Collectively, the 
downregulation or inactivation of PML-II may be a critical factor leading to 
cancer cells becoming less responsiveness to IFNα-mediated apoptosis. Thus a 
better understanding of how PML protein (particular PML-II) is involved in the 
response to IFNs may ultimately lead to better utilization of IFNs in the 
treatment of cancer.  
6.9 Preventing PML-II degradation sensitizes IFNα-induced 
apoptosis  
 
To overcome the possible resistance of cancer cells to IFNα-induced apoptosis, 
many strategies have been reported which include inhibiting the expression of 
natural inhibitors of apoptosis, for example targeting XIAP to sensitize cancer 
cells to IFN-mediated apoptosis (LaCasse et al, 1998; Leaman et al, 2002), or 
overexpression of XAF-1 (X-linked inhibitor of apoptosis-associated factor-1) to 
sensitize melanoma cells to TRAIL-induced apoptosis by modulating cleavage of 
XIAP (Leaman et al, 2002). Also, the concept of combination therapy including 
IFN has been accepted, for example, the combination of IFNα and imatinib (an 
inhibitor of Bcr-Abl tyrosine-kinase) significantly increased the 
synergistic/additive effects to inhibit chronic myeloid leukemia (CML) cell 
growth compared to single treatment (Kano et al, 2001; Simonsson et al, 2011; 
Talpaz et al, 2013). Pre-treating TRAIL-resistant melanoma cells with IFNβ for 
12–24 h also increased the sensitivity of cells to TRAIL-induced apoptosis and 
cleavage of XIAP (Chawla-Sarkar et al, 2001; Kumar-Sinha et al, 2002).  
 
In view of the important role of PML/PML-II in the regulation of IFNα-mediated 
apoptosis, the partial or complete loss of PML/PML-II protein certainly affects 
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the efficacy of IFNα-mediated apoptosis. Recently, it was reported that 
overexpression of PML in gastric cancer cells significantly increased cell 
apoptosis (Xu et al, 2015). Therefore it can be proposed that the overexpression 
of PML/PML-II/PML-II-ΔRBCC protein may be a possible approach to improve 
PML tumour suppression function and/or to increase the sensitivity of cells to 
IFNα/β-induced apoptosis.  
 
In recent years, targeting the PML ubiquitination pathway, thus preventing its 
degradation, has become an attractive approach for anti-cancer therapy. Aberrant 
PML protein degradation has been observed in human cancers from multiple 
origins including prostate adenocarcinoma, colon adenocarcinoma, lung 
carcinoma, breast carcinoma, lymphoma, central nervous system (CNS) tumours 
and germ cell tumours (Chen et al, 2012). Proteasome-dependent degradation is 
proposed to be a mechanism by which tumour cells restrict the expression of 
PML protein. Since ubiquitination is the major posttranslational modification 
that controls protein degradation through the proteasome, targeting the PML 
ubiquitination pathway therefore becomes an attractive strategy for anti-cancer 
therapy.  
 
The approaches that can be utilized to prevent PML degradation include 
ubiquitin E3 ligase inhibitors, inhibitors that disrupt the interaction of PML with 
its E3 ligases, or targeting PML phosphorylation and SUMOylation by 
introducing kinase inhibitors, because both these posttranslational modifications 
are often required for the subsequent ubiquitination events, e.g. the action of 
SUMO-dependent ubiquitin ligases. Accordingly, targeting ubiquitination 
mechanisms to prevent PML degradation may provide an opportunity to recover 
PML tumour suppressive functions and to improve the activity of various death 
receptors, IFNα-induced or other drug-induced cell apoptosis. The data in this 
study have shown that PML-II is one of the important isoforms that mediate 
IFNα-induced anti-tumour activity and thus preventing PML-II degradation may 




6.10 Model of PML-II regulation of IFNα-mediated apoptosis  
 
According to the results in this study, a model of PML-II tumour suppressor 
function was proposed (Figure 6.4). According to this model, IFNα stimulation 
increases the expression of PML-II which in turn positively regulates IFNα-
induced pro-apoptotic protein expression, contributing to IFNα-mediated anti-
tumour activity. The intrinsic inhibitory effect of PML-II on AKT and ERK 
signaling also contributes to IFNα exerting this function. This study thus 
provides a mechanism to explain IFNα induced cancer cell apoptosis and the 
important regulatory role of PML-II in this biological process. This study may 
also suggest a novel strategy in cancer therapy by combining IFNα with 
PML/PML-II protein expression/accumulation. Taken together, understanding 
the mechanisms by which PML-II functions in these pathways is important for 
our comprehension of the proper function of PML/PML-II and possibly to 
develop novel targets to improve IFNs-mediated anti-cancer activity.  
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